Document:

Exhibit 10.6

 

EXECUTION VERSION

 

SECURITIES PURCHASE AGREEMENT

 

SECURITIES PURCHASE
AGREEMENT (this “Agreement”), dated as of March 24, 2021 by and among Quoin Pharmaceuticals, Inc., a Delaware
corporation, with headquarters located at 42127 Pleasant Forest Ct, Ashburn, VA 20148 (the “Company”), and the
investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).

 

WHEREAS:

 

A. The
Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Rule 506(b) of Regulation
D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the 1933 Act.

 

B. The
Company has authorized a new series of senior secured notes of the Company, in substantially the form attached hereto as Exhibit
A (the “Notes”).

 

C. Each
Buyer wishes to purchase, and the Company wishes to sell at the First Closing (as defined below), upon the terms and conditions
stated in this Agreement, (i) that aggregate principal amount of Notes set forth opposite such Buyer’s name in column (3)
on the Schedule of Buyers attached hereto (which aggregate principal amount of Notes for all Buyers shall be $2,000,000.00) and
(ii) warrants, in the form attached hereto as Exhibit B (the “Warrants”), representing the right to acquire
the Company’s common stock, par value $0.01 per share (the “Common Stock”) set forth opposite such Buyer’s
name in column (4) on the Schedule of Buyers (such shares of Common Stock issuable upon exercise of the Warrants, collectively,
the “Warrant Shares”).

 

D. Each
Buyer wishes to purchase, and the Company wishes to sell at the Second Closing (as defined below), upon the terms and conditions
stated in this Agreement, (i) that aggregate principal amount of Notes set forth opposite such Buyer’s name in column (5)
on the Schedule of Buyers attached hereto (which aggregate principal amount of Notes for all Buyers shall be $1,666,666.67) and
(ii) Warrants representing the right to acquire Warrant Shares set forth opposite such Buyer’s name in column (6) on the
Schedule of Buyers.

 

E. Each
Buyer wishes to purchase, and the Company wishes to sell at the Third Closing (as defined below), upon the terms and conditions
stated in this Agreement, (i) that aggregate principal amount of Notes set forth opposite such Buyer’s name in column (7)
on the Schedule of Buyers attached hereto (which aggregate principal amount of Notes for all Buyers shall be $1,333,333.34) and
(ii) representing the right to acquire Warrant Shares set forth opposite such Buyer’s name in column (8) on the Schedule
of Buyers.

 

     

     

    

 

F. The
Notes will rank senior to all outstanding and future indebtedness of the Company and its Subsidiaries (as defined below), will
be guaranteed by all direct and indirect Subsidiaries of the Company, currently formed or formed in the future, as evidenced by
a guarantee agreement, in the form attached hereto as Exhibit C (as amended or modified from time to time in accordance
with its terms, the “Guarantee Agreement”), and will be secured by a first priority perfected security interest
(subject to Permitted Liens under and as defined in the Notes) in all of the current and future assets (other than certain Excluded
Assets (as defined in the Security Agreement (as defined below)) of the Company and all direct and indirect Subsidiaries of the
Company, created or acquired in the future and subject to certain exclusions and limitations, as evidenced by a pledge and security
agreement, in the form attached hereto as Exhibit D (as amended or modified from time to time in accordance with its terms,
the “Security Agreement”).

 

G. The
Notes, the Warrants and the Warrant Shares collectively are referred to herein as the “Securities.”

 

NOW, THEREFORE,
the Company and each Buyer hereby agree as follows:

 

1. PURCHASE AND SALE OF NOTES.

 

(a) Purchase
of Notes.

 

(i) First
Closing. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue
and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the First Closing Date
(as defined below), (x) a principal amount of Notes as is set forth opposite such Buyer’s name in column (3) on the Schedule
of Buyers and (y) Warrants to acquire an initial amount of shares of Common Stock as is set forth opposite such Buyer’s name
in column (4) on the Schedule of Buyers (the “First Closing”).

 

(ii) Second
Closing. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue
and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the Second Closing Date
(as defined below), (x) a principal amount of Notes as is set forth opposite such Buyer’s name in column (5) on the Schedule
of Buyers and (y) Warrants to acquire an initial amount of shares of Common Stock as is set forth opposite such Buyer’s name
in column (6) on the Schedule of Buyers (the “Second Closing”).

 

(iii) Third
Closing. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below, the Company shall issue
and sell to each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the Company on the Third Closing Date
(as defined below), (x) a principal amount of Notes as is set forth opposite such Buyer’s name in column (7) on the Schedule
of Buyers and (y) Warrants to acquire an initial amount of shares of Common Stock as is set forth opposite such Buyer’s name
in column (8) on the Schedule of Buyers (the “Third Closing”, and together with the First Closing and the Second
Closing, each a “Closing”).

 

(b) Closing
Date.

 

(i) First
Closing Date. The date and time of the First Closing (the “First Closing Date”) shall be 10:00 a.m., New
York City time, on the date hereof (or such other date and time as is mutually agreed to by the Company and each Buyer) after notification
of satisfaction (or waiver) of the conditions to the First Closing set forth in Sections 6 and 7 below, at the offices of Schulte
Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022. The location of the First
Closing may be undertaken remotely by electronic transfer of First Closing documentation upon mutual agreement among the Company
and the Buyers.

 

    -2-

     

    

 

(ii) Second
Closing Date. The date and time of the Second Closing (the “Second Closing Date”) shall be 10:00 a.m., New
York City time, on April 23, 2021 (or such other date and time as is mutually agreed to by the Company and each Buyer) after notification
of satisfaction (or waiver) of the conditions to the Second Closing set forth in Sections 6 and 7 below, at the offices of Schulte
Roth & Zabel LLP, 919 Third Avenue, New York, New York 10022. The location of the Second
Closing may be undertaken remotely by electronic transfer of Second Closing
documentation upon mutual agreement among the Company and the Buyers.

 

(iii) Third
Closing Date. The date and time of the Third Closing (the “Third Closing Date”, and together with the First
Closing Date and the Second Closing Date, each a “Closing Date”) shall be 10:00 a.m., New York City time, on
May 24, 2021 (or such other date and time as is mutually agreed to by the Company and each Buyer) after notification of satisfaction
(or waiver) of the conditions to the Third Closing set forth in Sections 6 and 7 below, at the offices of Schulte Roth & Zabel
LLP, 919 Third Avenue, New York, New York 10022. The location of the Third Closing
may be undertaken remotely by electronic transfer of Third Closing documentation upon
mutual agreement among the Company and the Buyers.

 

(c) Purchase
Price. The aggregate purchase price for the Notes and the related Warrants to be purchased by each Buyer at the First Closing
(the “First Purchase Price”) shall be the amount set forth opposite each Buyer’s name in column (9) of
the Schedule of Buyers. The aggregate purchase price for the Notes to be purchased by each Buyer at the Second Closing (the “Second
Purchase Price”) shall be the amount set forth opposite each Buyer’s name in column (10) of the Schedule of Buyers.
The aggregate purchase price for the Notes to be purchased by each Buyer at the Third Closing (the “Third Purchase Price”,
and together with the First Purchase Price and the Second Purchase Price, the “Purchase Price”) shall be the
amount set forth opposite each Buyer’s name in column (11) of the Schedule of Buyers. Each Buyer shall pay $750.00 for each
$1,000 of principal amount of Notes and related Warrants to be purchased by such Buyer at each Closing. The Buyers and the Company
agree that the Notes and the Warrants constitute an “investment unit” for purposes of Section 1273(c)(2) of the Internal
Revenue Code of 1986, as amended (the “Code”). The Buyers and the Company mutually agree that the allocation
of the issue price of such investment unit between the Notes and the Warrants in accordance with Section 1273(c)(2) of the Code
and Treasury Regulation Section 1.1273-2(h) shall be an aggregate amount of $0.01 per $750 of Purchase Price to be allocated to
the Warrants and the balance of the Purchase Price allocated to the Notes, and neither the Buyers nor the Company shall take any
position inconsistent with such allocation in any tax return or in any judicial or administrative proceeding in respect of taxes.

 

    -3-

     

    

 

(d) Form
of Payment. On the applicable Closing Date, (i) each Buyer shall pay its applicable Purchase Price to the Company for the Notes
and the related Warrants to be issued and sold to such Buyer at such applicable Closing (less, in the case of the Altium Growth
Fund, LP (the “Lead Investor”), the amounts withheld pursuant to Section 4(d)), by wire transfer of immediately
available funds in accordance with the Company’s written wire instructions and (ii) the Company shall deliver to each
Buyer (x) the applicable Notes (allocated in the principal amounts as such Buyer shall request) which such Buyer is then purchasing
hereunder and (y) a Warrant pursuant to which such Buyer shall have the right to acquire the applicable number of Warrant Shares,
in each case, duly executed on behalf of the Company and registered in the name of such Buyer or its designee.

 

2. BUYER’S
REPRESENTATIONS AND WARRANTIES. Each Buyer, severally and not jointly, represents and warrants with respect to only itself
that, as of the date hereof and as of each applicable Closing Date:

 

(a) No
Public Sale or Distribution. Such Buyer is (i) acquiring the Notes and the Warrants and (ii) upon exercise of the Warrants
(other than pursuant to a Cashless Exercise (as defined in the Warrants)) will acquire the Warrant Shares issuable upon exercise
of the Warrants, for its own account and not with a view towards, or for resale in connection with, the public sale or distribution
thereof, except pursuant to sales registered or exempted under the 1933 Act; provided, however, that by making the
representations herein, such Buyer does not agree to hold any of the Securities for any minimum or other specific term and reserves
the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under
the 1933 Act. Such Buyer is acquiring the Securities hereunder in the ordinary course of its business. Such Buyer does not presently
have any agreement or understanding, directly or indirectly, with any Person (as defined below) to distribute any of the Securities.
For purposes of this Agreement, “Person” means an individual, a limited liability company, a partnership, a
joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof.

 

(b) Accredited
Investor Status. Such Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

(c) Reliance
on Exemptions. Such Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and such Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of such Buyer set forth herein in order to determine the availability of such exemptions and the eligibility
of such Buyer to acquire the Securities.

 

(d) Information.
Such Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of
the Company and materials relating to the offer and sale of the Securities that have been requested by such Buyer. Such Buyer and
its advisors, if any, have been afforded the opportunity to ask questions of the Company. Neither such inquiries nor any other
due diligence investigations conducted by such Buyer or its advisors, if any, or its representatives shall modify, amend or affect
such Buyer’s right to rely on the Company’s representations and warranties contained herein. Such Buyer understands
that its investment in the Securities involves a high degree of risk. Such Buyer has sought such accounting, legal and tax advice
as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.

 

    -4-

     

    

 

(e) No
Governmental Review. Such Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(f) Transfer
or Resale. Such Buyer understands that: (i) the Securities have not been and are not being registered under the 1933 Act or
any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder,
(B) such Buyer shall have delivered to the Company an opinion of counsel, in a form reasonably acceptable to the Company, to the
effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from
such registration, or (C) such Buyer provides the Company with reasonable assurance that such Securities can be sold, assigned
or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act, as amended, (or a successor rule thereto) (collectively,
“Rule 144”) or to an accredited investor in a private transaction exempt from the registration requirements
of the 1933 Act; (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of
Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the
Person) through whom the sale is made may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require
compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the
Company nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities laws
or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged
in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge
of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge
of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant
to this Agreement or any other Transaction Document (as defined in Section 3(b)), including, without limitation, this Section 2(f).

 

(g) Legends.
Such Buyer understands that the certificates or other instruments representing the Notes and the Warrants and, until such time
as the exchange of the Warrant Shares are freely tradable or have been registered under the 1933 Act as contemplated by the Registration
Rights Agreement (as defined in the Primary Financing SPA (as defined in Section 3(c)), the stock certificates representing the
Securities, except as set forth below, shall bear a restrictive legend in the following form (and a stop-transfer order may be
placed against transfer of such stock certificates:

 

    -5-

     

    

 

[NEITHER THE ISSUANCE AND SALE
OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN] [THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED BY
THE HOLDER, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD
OR ELIGIBLE TO BE SOLD (X) PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR (Y) TO AN ACCREDITED INVESTOR IN A PRIVATE
TRANSACTION. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

The legend set forth above shall be removed
and the Company shall issue a certificate without such legend to the holder of the Securities upon which it is stamped, if, unless
otherwise required by state securities laws, (i) such Securities are registered for resale under the 1933 Act, (ii) in connection
with a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel, in a form reasonably acceptable
to the Company, to the effect that such sale, assignment or transfer of the Securities may be made without registration under the
applicable requirements of the 1933 Act, or (iii) the Securities can be sold, assigned or transferred pursuant to Rule 144 or to
an accredited investor in a private transaction exempt from the registration requirements of the 1933 Act. The Company shall be
responsible for the fees of its transfer agent and all DTC fees associated with such issuance, if any.

 

(h) Validity;
Enforcement. This Agreement and the other Transaction Documents to which such Buyer is a party have been duly and validly authorized,
executed and delivered on behalf of such Buyer and shall constitute the legal, valid and binding obligations of such Buyer enforceable
against such Buyer in accordance with their respective terms, except as such enforceability may be limited by general principles
of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to,
or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(i) No
Conflicts. The execution, delivery and performance by such Buyer of this Agreement and the other Transaction Documents to which
such Buyer is a party and the consummation by such Buyer of the transactions contemplated hereby and thereby will not (i) result
in a violation of the organizational documents of such Buyer, or (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which such Buyer is a party, or (iii) result in
a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to
such Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would
not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Buyer to
perform its obligations hereunder.

 

    -6-

     

    

 

3. REPRESENTATIONS
AND WARRANTIES OF THE COMPANY.

 

The Company represents
and warrants to each of the Buyers that, as of the date hereof and as of each applicable Closing Date:

 

(a) Organization
and Qualification. Each of the Company and its “Subsidiaries” (which for purposes of this Agreement means
any entity in which the Company, directly or indirectly, owns any of the capital stock or holds an equity or similar interest)
are entities duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed,
and have the requisite power and authorization to own their properties and to carry on their business as now being conducted and
as presently proposed to be conducted. Each of the Company and its Subsidiaries is duly qualified as a foreign entity to do business
and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it
makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably
be expected to have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means any
material adverse effect on the business, properties, assets, liabilities, operations, results of operations, condition (financial
or otherwise) or prospects of the Company and its Subsidiaries, individually or taken as a whole, or on the transactions contemplated
hereby or on the other Transaction Documents (as defined below) or by the agreements and instruments to be entered into in connection
herewith or therewith, or on the authority or ability of the Company to perform any of its obligations under any of the Transaction
Documents. The Company has no Subsidiaries except as set forth in Schedule 3(a). The outstanding shares of capital stock
of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and non-assessable and are owned by the
Company or another Subsidiary free and clear of all liens, encumbrances and equities and claims; and no options, warrants or other
rights to purchase, agreements or other obligations to issue or other rights to convert any obligations into shares of capital
stock or ownership interests in the Subsidiaries are outstanding.

 

(b) Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, the Notes, the Warrants, the Security Documents (as defined below), and each of the other agreements entered
into by the parties hereto in connection with the transactions contemplated by this Agreement (collectively, the “Transaction
Documents”) and to issue the Securities in accordance with the terms hereof and thereof. The execution and delivery of
the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Notes and the Warrants and the reservation for issuance and the issuance of
the Warrant Shares issuable upon exercise of the Warrants have been duly authorized by the Company’s Board of Directors and
(other than the filing of a Form D with the SEC and any other filings as may be required by any state securities agencies), except
as disclosed in Schedule 3(b), no further filing, consent or authorization is required by the Company, its Board of Directors
or its stockholders. This Agreement and the other Transaction Documents have been duly executed and delivered by the Company, and
constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective
terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights
and remedies. Each of the Subsidiaries party to any of the Transaction Documents has the requisite power and authority to enter
into and perform its obligations under such Transaction Documents. The execution and delivery by the Subsidiaries party to any
of the Transaction Documents of such Transaction Documents and the consummation by such Subsidiaries of the transactions contemplated
thereby have been duly authorized by such Subsidiaries’ respective boards of directors (or other applicable governing body)
and (other than filings as may be required by state securities agencies) no further filing, consent, or authorization is required
by such Subsidiaries, their respective boards of directors (or other applicable governing body) or stockholders (or other applicable
owners of equity of such Subsidiaries). The Transaction Documents to which any of the Subsidiaries are parties have been duly executed
and delivered by such Subsidiaries, and constitute the legal, valid and binding obligations of such Subsidiaries, enforceable against
them in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or
applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally,
the enforcement of applicable creditors’ rights and remedies. For purposes of this Agreement, the term “Security
Documents” means the Guarantee Agreement, Security Agreement, the Perfection Certificate (as defined in the Security
Agreement), any account control agreement, any and all financing statements, fixture filings, security agreements, pledges, assignments,
mortgages, deeds of trust, opinions of counsel, and all other documents requested by the Collateral Agent (as defined below) to
create, perfect, and continue perfected or to better perfect the Collateral Agent’s security interest in and liens on all
of the assets of the Company and each of its Subsidiaries (whether now owned or hereafter arising or acquired, tangible or intangible,
real or personal), and in order to fully consummate all of the transactions contemplated hereby and under the other Transaction
Documents.

 

    -7-

     

    

 

(c) Issuance
of Securities. The issuance of the Notes is duly authorized and, upon issuance, shall be validly issued and free from all preemptive
or similar rights (except for those which have been validly waived prior to the date hereof), taxes, liens, charges and other encumbrances
with respect to the issue thereof. The issuance of the Warrants are duly authorized and, upon issuance in accordance with the terms
of the Transaction Documents, the Warrants shall be validly issued and free from all preemptive or similar rights (except for those
which have been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances with respect to the issue
thereof. As of the applicable Closing Date, a number of shares of Common Stock shall have been duly authorized and reserved for
issuance which equals (i) until the date of the consummation of the transactions contemplated by the Primary Financing SPA (the
“Primary Financing Closing Date”), the quotient obtained by dividing (x) the Principal (as defined in the Notes)
amounts of all Notes issued and issuable pursuant to section 1(a), by (y) the Initial Exercise Price (as defined in the Warrants)
(as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock
splits or other similar events occurring after the date hereof), (ii) from and after the Primary Financing Closing Date until the
Final Reset Date (as defined in the Warrants), the quotient obtained by dividing (x) the Principal amounts of all Notes issued
and issuable pursuant to section 1(a), by (y) the lower of (1) the Initial Exercise Price (as defined in the Warrants) (as adjusted
for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or
other similar events occurring after the Subscription Date) and (2)  25% of the Closing Per Share Price (as defined below)
and (iii) from and after the Final Reset Date, the maximum number of shares of Common Stock as shall from time to time be necessary
to effect the exercise in full of all of the Warrants then outstanding without regard to any limitation on exercise set forth therein
(as applicable, the “Required Reserve Amount”) (as adjusted for stock splits, stock dividends, recapitalizations,
reorganizations, reclassification, combinations, reverse stock splits or other similar events occurring after the date hereof).
Upon exercise of the Warrants in accordance with the Warrants, the Warrant Shares when issued will be validly issued, fully paid
and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to
the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. Assuming the accuracy of
each of the representations and warranties set forth in Section 2 of this Agreement, the offer and issuance by the Company of the
Securities is exempt from registration under the 1933 Act. As used herein, (i) “Primary Financing SPA” means
that certain Securities Purchase Agreement anticipated to be entered into after the date hereof by and among the Company, Cellect
Biotechnology Ltd., an Israeli company limited by shares (“PublicCo”), the Buyer (or an affiliate of the Buyer)
and certain other investors pursuant to which, among other transactions, the Company is expected to issue shares of Common Stock
and PublicCo is expected to issue certain warrants to purchase shares of its common stock, all in accordance with the Primary Financing
Term Sheet, as may be amended, amended and restated, supplemented or otherwise modified from time to time in accordance with its
terms; (ii) ”Primary Financing Term Sheet” means that certain term sheet dated as of September 3, 2020,
by and between the Company and Altium Capital Management, LP, as such term sheet may be amended on or after the date hereof by
the parties thereto; and (iii) “Closing Per Share Price” shall have the meaning ascribed to such term, or similar
term, in the Primary Financing SPA.

 

(d) No
Conflicts. Except as disclosed in Schedule 3(d), the execution, delivery and performance of the Transaction Documents
by the Company and any of its Subsidiaries parties to any of the Transaction Documents and the consummation by the Company and
any of its Subsidiaries of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the
Notes and the Warrants and reservation for issuance and issuance of the Warrant Shares) will not (i) result in a violation of the
Company’s Certificate of Incorporation, as amended and as in effect on the date hereof (the “Certificate of Incorporation”),
and its Bylaws, as amended and as in effect on the date hereof (the “Bylaws”), any memorandum of association,
certificate of incorporation, certificate of formation, bylaws, any certificate of designations or other constituent documents
of the Company or any of its Subsidiaries, any capital stock of the Company or any of its Subsidiaries or the articles of association
or bylaws of the Company or any of its Subsidiaries or (ii) conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) in any respect under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party,
or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities
laws, rules and regulations) and including all applicable foreign, federal and state laws, rules and regulations applicable to
the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or
affected, except, in the case of clauses (ii) and (iii) above, as would not have or reasonably be expected to result in a Material
Adverse Effect. The Company has furnished or made available to the Buyers true, correct and complete copies of its Certificate
of Incorporation and its Bylaws, and the terms of all securities convertible into, or exercisable or exchangeable for shares of
the Company’s common stock, par value $0.001 per share (the “Common Stock”) and the material rights of
the holders thereof in respect thereto.

 

    -8-

     

    

 

(e) Consents.
Except as disclosed in Schedule 3(e), neither the Company nor any of its Subsidiaries is required to obtain any consent
from, authorization or order of, or make any filing or registration with (other than the filing of a Form D with the SEC and any
other filings as may be required by any state securities agencies), any court, governmental agency or any regulatory or self-regulatory
agency or any other Person in order for it to execute, deliver or perform any of its obligations under or contemplated by the Transaction
Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations
which the Company or any of its Subsidiaries is required to obtain pursuant to the preceding sentence have been obtained or effected
on or prior to the applicable Closing Date (or in the case of filings detailed above, will be made timely after the applicable
Closing Date).

 

(f) Acknowledgment
Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that each Buyer is acting solely in the
capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby
and thereby and that no Buyer is (i) an officer or director of the Company or any of its Subsidiaries, (ii) an “affiliate”
of the Company or any of its Subsidiaries (as defined in Rule 144) or (iii) to the knowledge of the Company, a “beneficial
owner” of more than 10% of the Common Stock (as defined for purposes of Rule 13d-3 of the Securities Exchange Act of 1934,
as amended). The Company further acknowledges that no Buyer is acting as a financial advisor or fiduciary of the Company or any
of its Subsidiaries (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby
and thereby, and any advice given by a Buyer or any of its representatives or agents in connection with the Transaction Documents
and the transactions contemplated hereby and thereby is merely incidental to such Buyer’s purchase of the Securities. The
Company further represents to each Buyer that the Company’s decision to enter into the Transaction Documents has been based
solely on the independent evaluation by the Company and its representatives.

 

(g) No
General Solicitation; Placement Agent’s Fees. Neither the Company, nor any of its Subsidiaries or affiliates, nor any
Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning
of Regulation D) in connection with the offer or sale of the Securities. The Company shall be responsible for the payment of any
placement agent’s fees, financial advisory fees, or brokers’ commissions (other than for Persons engaged by any Buyer
or its investment advisor) relating to or arising out of the transactions contemplated hereby, including, without limitation, any
placement agent fees payable to JMP Securities LLC (the “Placement Agent”) in connection with the sale of the
Securities. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including, without limitation,
attorney’s fees and out-of-pocket expenses) arising in connection with any such claim. The Company acknowledges that it has
engaged the Placement Agent in connection with the sale of the Securities. Other than the Placement Agent, neither the Company
nor any of its Subsidiaries has engaged any placement agent or other agent in connection with the offer or sale of the Securities.

 

(h) No
Integrated Offering. None of the Company, its Subsidiaries, any of their affiliates, and any Person acting on their behalf
has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances
that would require registration of the issuance of any of the Securities under the 1933 Act, whether through integration with prior
offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of the Company for purposes
of the 1933 Act or any applicable stockholder approval provisions, including, without limitation, under the rules and regulations
of any exchange or automated quotation system on which any of the securities of the Company are listed or designated for quotation.
None of the Company, its Subsidiaries, their affiliates and any Person acting on their behalf will take any action or steps that
would require registration of the issuance of any of the Securities under the 1933 Act or cause the offering of any of the Notes
to be integrated with other offerings for purposes of any such applicable stockholder approval provisions.

 

    -9-

     

    

 

(i) Private
Placement Memorandum; Financial Statements. The Company’s private placement memorandum, attached hereto as Exhibit
E (the “PPM”) does not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. Except as set forth on Schedule 3(i), each of the Company and its Subsidiaries has no liabilities
or obligations, absolute or contingent (individually or in the aggregate), except (i) liabilities and obligations incurred after
December 31, 2019, in the ordinary course of business that are not material and (ii) obligations under contracts made in the ordinary
course of business that would not be required to be reflected in financial statements prepared in accordance with U.S. generally
accepted accounting principles, consistently applied during the periods involved (“GAAP”). The audited financial
statements included in the PPM complied as to form in all material respects with applicable accounting requirements and the published
rules and regulations of the SEC with respect thereto. Such financial statements fairly present in all material respects the financial
position of each of the Company and its Subsidiaries, on a consolidated basis, at the respective dates thereof and the results
of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements will be subject
to normal adjustments which will not be material, either individually or in the aggregate. No other information provided by or
on behalf of the Company to any of the Buyers which is not included in the PPM (including, without limitation, information referred
to in Section 2(d) of this Agreement or in the disclosure schedules to this Agreement) contains any untrue statement of a material
fact or omits to state any material fact necessary in order to make the statements therein, in the light of the circumstance under
which they are or were made, not misleading.

 

(j) Absence
of Certain Changes. Except as disclosed in Schedule 3(j)(i), since December 31, 2019, there has been no material adverse
change and no material adverse development in the business, assets, liabilities, properties, operations, condition (financial or
otherwise), results of operations or prospects of the Company or its Subsidiaries. Except as disclosed in Schedule 3(j)(ii),
since December 31, 2019, neither the Company nor any of its Subsidiaries has (i) declared or paid any dividends, (ii) sold any
assets, individually or in the aggregate, in excess of $100,000 outside of the ordinary course of business or (iii) had capital
expenditures, individually or in the aggregate, in excess of $100,000. Neither the Company nor any of its Subsidiaries has taken
any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation
or winding up, nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that any of its creditors
intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor
to do so. The Company and its Subsidiaries, individually and on a consolidated basis, are not as of the date hereof, and after
giving effect to the transactions contemplated hereby to occur at the applicable Closing, will not be Insolvent (as defined below).
For purposes of this Agreement, “Insolvent” means, with respect to any Person, (i) the present fair saleable
value of such Person’s assets is less than the amount required to pay such Person’s total Indebtedness (as defined
below), (ii) such Person is unable to pay its debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities
become absolute and matured, (iii) such Person intends to incur or believes that it will incur debts that would be beyond its ability
to pay as such debts mature or (iv) such Person has unreasonably small capital with which to conduct the business in which it is
engaged as such business is now conducted and is proposed to be conducted.

 

    -10-

     

    

 

(k) Conduct
of Business; Regulatory Permits. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default
under any certificate of designations, preferences or rights of any outstanding series of preferred stock of the Company (if any),
its Certificate of Incorporation, its Bylaws or their organizational charter or memorandum of association or certificate of incorporation
or articles of association or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment,
decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither
the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for
possible violations which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
The Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate foreign, federal
or state regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates,
authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company
nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit.

 

(l) Sarbanes-Oxley
Act. The Company is in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that
are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the SEC thereunder that are
effective as of the date hereof.

 

(m) Transactions
With Affiliates. Except as set forth in Schedule 3(m), none of the officers, directors or employees of the Company
or any of its Subsidiaries is presently a party to any transaction with the Company or any of its Subsidiaries (other than
for ordinary course services as employees, officers or directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any such officer, director or employee or, to the knowledge of the Company or any of its
Subsidiaries, any corporation, partnership, trust or other Person in which any such officer, director, or employee has a
substantial interest or is an employee, officer, director, trustee or partner.

 

    -11-

     

    

 

(n) Indebtedness
and Other Contracts. Neither the Company nor any of its Subsidiaries, (i) except as disclosed in Schedule 3(n)(i), has
any outstanding Indebtedness (as defined below), (ii) except as disclosed in Schedule 3(n)(ii), is a party to any contract,
agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract, agreement or
instrument would reasonably be expected to result in a Material Adverse Effect, (iii) except as disclosed in Schedule 3(n)(iii),
is in violation of any term of or in default under any contract, agreement or instrument relating to any Indebtedness, except where
such violations and defaults would not result, individually or in the aggregate, in a Material Adverse Effect, or (iv) except as
disclosed in Schedule 3(n)(iv), is a party to any contract, agreement or instrument relating to any Indebtedness, the performance
of which, in the judgment of the Company’s officers, has or is expected to have a Material Adverse Effect. Schedule 3(n)
provides a detailed description of the material terms of such outstanding Indebtedness. Schedule 3(n)(v) provides a list
of all material contracts, agreements and instruments of the Company that would be required to be filed as exhibits to a Registration
Statement on Form S-1 assuming the Company were to file such a registration statement on the date hereof or the Closing Date, as
applicable. For purposes of this Agreement: (x) “Indebtedness” of any Person means, without duplication (A)
all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property
or services (including, without limitation, “finance leases” in accordance with GAAP (other than trade payables entered
into in the ordinary course of business consistent with past practice), (C) all reimbursement or payment obligations with respect
to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or
similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses,
(E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing,
in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even though the rights and
remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property),
(F) all monetary obligations under any leasing or similar arrangement which, in connection with GAAP, is classified as a finance
lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness
has an existing right, contingent or otherwise, to be secured by) any mortgage, claim, lien, tax, right of first refusal, pledge,
charge, security interest or other encumbrance upon or in any property or assets (including accounts and contract rights) owned
by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such
indebtedness, and (H) all Contingent Obligations in respect of indebtedness or obligations of others of the kinds referred to in
clauses (A) through (G) above; and (y) “Contingent Obligation” means, as to any Person, any direct or indirect
liability, contingent or otherwise, of that Person with respect to any indebtedness, finance lease, dividend or other obligation
of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to
provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating
thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with
respect thereto.

 

(o) Absence
of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened against or affecting the Company
or any of its Subsidiaries, the Company’s or its Subsidiaries capital stock or any of the Company’s Subsidiaries or
any of the Company’s or its Subsidiaries’ officers or directors, whether of a civil or criminal nature or otherwise,
in their capacities as such, except as set forth in Schedule 3(o). The matters set forth in Schedule 3(o) would not
reasonably be expected to have a Material Adverse Effect.

 

    -12-

     

    

 

(p) Insurance.
The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company
and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or
applied for and neither the Company nor any such Subsidiary has any reason to believe that it will be unable to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
continue its business at a cost that would not have a Material Adverse Effect.

 

(q) Employee
Benefits. Schedule 3(q) sets forth a complete and accurate list of each Benefit Plan that is an “employee pension
benefit plan” within the meaning of Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended, including
the regulations and published interpretations thereunder (“ERISA”), whether or not such plan is subject to ERISA
(each, a “Pension Plan”). For purposes of this Section 3(q), a “Benefit Plan” means any “employee
benefit plan” within the meaning of Section 3(3) of ERISA and any other employee benefit plan, program, policy, practices,
or other arrangement providing compensation or benefits to any current or former employee, officer or director of the Company,
its Subsidiaries or their ERISA Affiliates or any beneficiary or dependent thereof, whether written or unwritten, that is sponsored,
maintained or contributed to (or has contributed to), by Company, its Subsidiaries or any of their ERISA Affiliates. For purposes
of this Section 3(q), an entity is an “ERISA Affiliate” of the Company or any Subsidiary if it would have ever been
considered a single employer with the Company or a Subsidiary under ERISA Section 4001(b) or Section 414(b), (c) or (m) of the
Code. Each Benefit Plan has been administered in all material respects in accordance with its terms all applicable laws and each
of the Company, its Subsidiaries and their ERISA Affiliates is in compliance in all material respects with all applicable provisions
of ERISA and the terms of any Benefit Plan. No “reportable event” (as defined in Section 4043 of ERISA (other than
a “reportable event” as to which the PBGC has regulation or otherwise waived the requirement of Section 4043(a) of
ERISA that it be notified within thirty (30) days of the occurrence of such event)) has occurred with respect to any Pension Plan;
none of the Company, its Subsidiaries or any of their ERISA Affiliates has incurred or expects to incur material liability under
(i) Title IV of ERISA with respect to the termination of, or withdrawal from, any Pension Plan or any other “pension plan”
(as defined in ERISA) or (ii) Sections 412 or 4971 of Code; and each Pension Plan that is intended to be qualified under Section
401(a) of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which would cause the loss
of such qualification. Except for liabilities that arise solely out of, or relate solely to, a Benefit Plan, none of the Company,
its Subsidiaries or their ERISA Affiliates has any current or contingent liabilities (i) to any “employee benefit plan”
(as defined in ERISA); (ii) under Title IV of ERISA, (iii) under Section 302 of ERISA, (iv) under Sections 412 and 4971 of the
Code, (v) as a result of a failure to comply with the continuation coverage requirements of Section 601 et seq. of ERISA and Section
4980B of the Code, or (vi) under corresponding or similar provisions of foreign Laws or regulations. Each stock option, if any,
granted by the Company, its Subsidiaries or any of their ERISA Affiliates was granted (i) in accordance with the terms of the applicable
stock option plan of such entity and (ii) with an exercise price at least equal
to the fair market value of such capital stock on the date such stock option would be considered granted under GAAP and applicable
law. The amount by which the actuarial present value of all accrued benefits under any Benefit Plan (whether or not vested) exceeds
the fair market value of the assets of such Benefit Plan is properly accrued and reflected, in all material respects, in the PPM.

 

    -13-

     

    

 

(r) Employee
Relations. Neither the Company nor any of its Subsidiaries is a party to any collective bargaining agreement or employs any
member of a union. The Company and its Subsidiaries believe that their relations with their respective employees are good. No executive
officer of the Company or any of its Subsidiaries (as defined in Rule 501(f) promulgated under the 1933 Act) or other key employee
the Company or any of its Subsidiaries has notified the Company or any such Subsidiary that such officer intends to leave the Company
or any such Subsidiary or otherwise terminate such officer’s employment with the Company or any such Subsidiary. No executive
officer or other key employee of the Company or any of its Subsidiaries, to the knowledge of the Company or any of its Subsidiaries,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement, non-competition agreement, or any other contract or agreement or any restrictive covenant, and the continued
employment of each such executive officer or other key employee (as the case may be) does not subject the Company or any of its
Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits,
terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect. To the knowledge of the Company and its Subsidiaries,
(i) no allegations of sexual harassment have been made against any employee of the Company or any of its Subsidiaries, and (ii)
none of the Company or its Subsidiaries has entered into any settlement agreements related to allegations of sexual harassment
or misconduct by an employee of the Company or any of its Subsidiaries.

 

(s) Real
Property.

 

(i) Schedule
3(s)(i) sets forth a complete and accurate list of all real property owned in fee (or the equivalent interest in the applicable
jurisdiction) by the Company and its Subsidiaries (the “Owned Real Property”). Each of the Company and its Subsidiaries
has good, valid and marketable title in fee simple to the Owned Real Property and to all personal property owned by it which is
material to the business of the Company and its Subsidiaries, in each case, free and clear of all liens, encumbrances and defects
except for Permitted Liens.

 

(ii) Schedule
3(s)(ii) sets forth a complete and accurate list of all leases, subleases, licenses, occupancy and other agreements (including
all amendments, modifications and supplements thereof and assignments and subleases thereof) (the “Company Leases”;
and each, a “Company Lease”) under which the Company or its Subsidiaries leases, subleases, licenses, uses or
occupies (in each case whether as landlord, tenant, sublandlord, subtenant or by other occupancy arrangement), or has the right
to use or occupy, now or in the future, any real property (the “Leased Real Property”, and together with the
Owned Real Property, collectively, the “Real Property”). Each of the Company and its Subsidiaries has a valid
and enforceable leasehold estate in all Leased Real Property free and clear of all liens, encumbrances and defects except for Permitted
Liens, and (ii) no default or breach by the Company or its Subsidiaries, nor any event with respect to the Company or its Subsidiaries
that with notice or the passage of time would result in a default or breach, has occurred under any Company Lease, nor does the
Company or its Subsidiaries have knowledge of the existence of, any default, event or circumstance that, with notice or lapse of
time, or both, would constitute a default by any other contracting parties under any such Leased Real Property.

 

    -14-

     

    

 

(iii) None
of the Company or its Subsidiaries has granted or entered into any sublease, license, option, right of first refusal or other contractual
right or similar agreement to purchase, assign or dispose of the Real Property or to allow or grant to any third party the right
to use or occupy the Real Property. None of the Company or its Subsidiaries has received any written notice of assessments for
public improvements against the Real Property or written notice or law, rule, regulation, order, judgment or decree by any governmental
authority, insurance company or board of fire underwriters or other body exercising similar functions that relates to violations
of building, safety or fire ordinances or regulations that would have, or would reasonably be expected to have, a Material Adverse
Effect on the value of such Real Property or its use in connection with the business of the Company or its Subsidiaries.

 

(t) Intellectual
Property Rights. The Company and its Subsidiaries owns (free and clear of all liens, encumbrances and defects except for Permitted
Liens) or possesses a valid license or other lawful right to use all Intellectual Property Rights (as defined below) necessary,
used or held for use, to conduct its business as presently conducted and as presently proposed to be conducted. Each of the registrations
or applications for registration of Intellectual Property Rights (including issued patents and applications for patent) owned or
licensed to the Company and its Subsidiaries is listed on Schedule 3(t)(i), and each item of such Intellectual Property
Rights is (A) not invalid and (B) enforceable. Each of the licenses (in-bound or out-bound) of Intellectual Property Rights or
other contracts (including settlement agreements) with respect to the use, ownership or enforcement of Intellectual Property Rights
to which any of the Company or any its Subsidiaries is a party is listed on Schedule 3(t)(ii), each such contract is valid
and enforceable against the Company and its Subsidiaries and, to the knowledge of the Company and its Subsidiaries, the counterparty(ies),
and none of the Company or its Subsidiaries and, to the knowledge of the Company and its Subsidiaries, none of the counterparties
to any such contract, is in default or breach thereunder or thereof. Except as set forth in Schedule 3(t)(iii), none of
the Company nor its Subsidiaries Intellectual Property Rights listed or required to be listed on Schedule 3(t)(i) has expired
or terminated, has been abandoned or canceled, or adjudged invalid or unenforceable or are scheduled or expected to expire or terminate
or are scheduled or expected to be abandoned or canceled, or adjudged invalid or unenforceable, within three (3) calendar months
from the date of mutual execution of this Agreement. The conduct of the business of the Company and its Subsidiaries as presently
conducted does not infringe, misappropriate or otherwise violate or conflict with the Intellectual Property Rights of others, and
in the past six (6) calendar years, no claim, action or proceeding (including in the U.S. Patent and Trademark Office, or any corresponding
non-U.S. authority, or before any other governmental authority) has been made or brought alleging the foregoing. There is no claim,
action or proceeding that has been made or brought in the past six (6) calendar years by or against, being threatened by or, to
the knowledge of the Company and its Subsidiaries, being threatened against, the Company and its Subsidiaries regarding Intellectual
Property Rights of the Company and its Subsidiaries, including any challenging the validity, enforceability, ownership, enforcement,
patentability or registrability of such Intellectual Property Rights. To the knowledge of Company and its Subsidiaries, no third
party is infringing, misappropriating or otherwise conflicting with its Intellectual Property Rights. None of the Company or its
Subsidiaries are aware of any facts or circumstances which would reasonably be expected to give rise to any of the foregoing infringements,
misappropriations or other conflicts, or claims, actions or proceedings. Each of the Company
and its Subsidiaries has taken commercially reasonable security measures to protect the secrecy, confidentiality and value of all
of its material Intellectual Property Rights, as applicable, and, to its knowledge, no unauthorized disclosure of any information
comprising any Intellectual Property Rights has occurred, as applicable. All present and former employees, consultants and independent
contractors of each of the Company and its Subsidiaries that have been involved in the development of any material Intellectual
Property Rights have entered into written agreements under which such Persons (A) agree to protect the trade secrets, know-how
and other confidential information of the Company and its Subsidiaries, as applicable, and (B) assign to one of the Company or
its Subsidiaries, as applicable, all right, title and interest in and to all Intellectual Property Rights created by such Person
in the course of his, her or its employment or other engagement by one of the Company or its Subsidiaries. Except as set forth
on Schedule 3(t)(iv), no United States federal or state agency or any other government or governmental agency, university,
research institute or other similar organization has sponsored any research by Company and its Subsidiaries or been involved with
or otherwise sponsored any development of any Intellectual Property Rights claimed by the Company or its Subsidiaries and that
are material to the business of the Company and its Subsidiaries as presently conducted. For purposes of this Agreement, “Intellectual
Property Rights” means all intellectual property and proprietary rights, including all (i) trademarks, trade names,
service marks, service names, domain names, and other designation of origin, together with all goodwill associated therewith, (ii) original
works of authorship and copyrights, (iii) patents and patent applications, together with all divisionals, continuations, continuations-in-part,
reissues and reexaminations thereof, including all rights to file applications for patent, (iv) trade secrets, know-how and other
confidential information and (v) inventions, licenses, approvals and governmental authorizations.

 

    -15-

     

    

 

(u) IT
Systems; Data Privacy and Security. The information technology and computer systems, including the software, firmware, hardware,
equipment, networks, data communication lines, interfaces, databases, storage media, websites, platforms and related systems owned,
licensed or leased by the Company and its Subsidiaries (collectively, “IT Systems”) are sufficient for the conduct
of each of the businesses of the Company and its Subsidiaries, in all material respects, and to the knowledge of each of the Company
and its Subsidiaries, do not contain any “viruses”, “worms”, “time-bombs”, “key-locks”,
or any other devices intentionally designed to disrupt or interfere with the operation of the IT Systems or equipment upon which
the IT Systems operate, or the integrity of the data, information or signals the IT Systems produce; and during the last two (2)
years, there have been no material failures, breakdowns, continued substandard performance or other adverse events affecting any
of the IT Systems. Each of the Company and its Subsidiaries has and maintains commercially reasonable business continuity and disaster
recovery plans, procedures and facilities appropriate for its business and has taken commercially reasonable steps to safeguard
the integrity and security of the IT Systems, and to the knowledge of each of the Company and its Subsidiaries, there has been
no unauthorized access, or any intrusions or breaches, of the IT Systems during the last two (2) years. Each of the Company and
its Subsidiaries is, and during the last three (3) years has been, in compliance in all material respects with all Data Privacy
and Security Laws applicable to it. Each of the Company and its Subsidiaries has maintained and posted all requisite privacy notices
pursuant to Data Privacy and Security Laws. Each of the Company and its Subsidiaries has commercially reasonable security measures
in place designed to protect all Personal Data under its control or in its possession from unauthorized use, access, modification
or destruction. During the last three (3) years, none of the Company nor its Subsidiaries has suffered any breach in security or
other incident that has permitted any unauthorized access to the Personal Data under its control or possession. Each of the Company
and its Subsidiaries maintains, and has remained in compliance, in all material respects, with, a comprehensive written information
security program that includes commercially reasonable administrative, physical and technical measures intended to protect the
confidentiality, integrity, availability and security of Personal Data in is possession or under its control and the IT Systems
against any unauthorized control, use, access, interruption, modification or corruption and to ensure the continued, uninterrupted
and error-free operation of the IT Systems. There are no material claims, actions or proceedings against or affecting any of the
Company or its Subsidiaries pending or threatened in writing, relating to or arising under Data Privacy and Security Laws. None
of the Company nor its Subsidiaries has received any written notices from the Department of Justice, U.S. Department of Education,
Federal Trade Commission, or the Attorney General of any state, or any equivalent foreign governmental authority, relating to possible
violations of Data Privacy and Security Laws. For purposes of this Agreement, (i) “Data Privacy and Security Laws”
shall mean (a) all applicable laws relating to the Processing of Personal Data or otherwise relating to privacy, data protection,
data security, cyber security, breach notification or data localization, and (b) all published policies of the Company and its
Subsidiaries relating to the Processing of Personal Data or otherwise relating to privacy, data protection, data security, cyber
security, breach notification or data localization; (ii) “Process” or “Processing” shall
mean the collection, use, storage, processing, recording, distribution, transfer, import, export, protection, disposal or disclosure
or other activity regarding or operations performed on data or information (whether electronically or in any other form or medium);
and (iii) “Personal Data” shall mean any information that, alone or in combination with other information held
by the Company and its Subsidiaries, allows the identification of an individual, including name, street address, telephone number,
e-mail address, photograph, social security number, driver’s license number, passport number, customer or account number,
biometrics, IP address, geolocation data or persistent device identifier, or any other information that is otherwise considered
personal information, personal data, protected health information and is regulated by applicable Data Privacy and Security Laws.

 

    -16-

     

    

 

(v) Environmental
Laws. Each of the Company and its Subsidiaries (i) is in compliance with any and all applicable Environmental Laws (as hereinafter
defined), (ii) has received all permits, licenses or other approvals required of it under applicable Environmental Laws to conduct
its respective business and (iii) is in compliance, in all material respects, with all terms and conditions of any such permit,
license or approval. Neither the Company nor its Subsidiaries has received from any Person or governmental authority any written
claim, demand, notice of violation, citation or notice of potential liability under any Environmental Law that remains pending
or unresolved and, to the knowledge of each of the Company and its Subsidiaries, no such claims, demands, citations or notices
have been threatened in writing. Except as would not reasonably be expected, individually or in the aggregate, to have a material
effect on the operations of the business or result in material liability of the Company or its Subsidiaries, (i) there has been
no Release (as hereinafter defined) of Hazardous Materials (as hereinafter defined) that could reasonably be expected to result
in a claim or liability under any Environmental Law in, at, on or under or migrating from any real property currently or formerly
owned, leased or operated by the Company or its Subsidiaries or in, at, on or under any other property to which of the Company
or its Subsidiaries sent Hazardous Materials for treatment or disposal; (ii) neither the Company nor its Subsidiaries is a party
to any agreement or the subject of any law, rule, regulation, order, judgment or decree that requires the Company or its Subsidiaries
to conduct a remedial action with respect to Hazardous Materials or requires the Company or its Subsidiaries to indemnify, defend
or hold harmless any governmental authority or Person from or against any claim or liability under Environmental Laws; and (iii)
to the knowledge of the Company and its Subsidiaries, there are no underground storage tanks at any real property currently owned,
leased or operated by the Company or its Subsidiaries. The Company and its Subsidiaries have made available to Buyers (i) true
and correct copies of all permits, licenses and approvals maintained by the Company or its Subsidiaries in compliance with Environmental
Laws; and (ii) all material environmental reports, audits, site assessments and studies related to the Company and its Subsidiaries,
its operations and currently and formerly owned, leased and operated real property. The term “Environmental Laws”
means all laws relating to pollution or protection of human health and safety, natural resources or the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation,
laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous
substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all laws, rules, orders, judgments, decrees, authorizations, codes, demands or demand letters, injunctions, judgments, licenses,
notices or notice letters, permits, plans or regulations issued, entered, promulgated or approved thereunder. The term “Release”
means any depositing, spilling, leaking, pumping, pouring, placing, emitting, discarding, abandoning, emptying, discharging, dispersal,
migrating, injecting, escaping, leaching, dumping, or disposing on or into the indoor or outdoor environment.

 

(w) Subsidiary
Rights. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable
law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or such Subsidiary.

 

    -17-

     

    

 

(x) Taxes.

 

(i) The
Company and each of its Subsidiaries (A) has timely made or filed all foreign, federal and state income and all other tax returns,
reports and declarations required by any jurisdiction to which it is subject and all such tax returns and deliverables are true,
correct and complete in all material respects, (B) has timely paid all taxes which are due and payable (regardless of whether shown
on a tax return) and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith, (C) has set aside on its books provisions reasonably
adequate for the payment of all taxes or periods subsequent to the periods to which such returns, reports or declarations apply
and (D) has complied in all material respects with all applicable legal requirements relating to the withholding and remittance
of all material amounts of taxes, and all such taxes have been withheld and paid over to the appropriate governmental authority.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company know of no basis for any such claim. As used herein, (x) “tax” or “taxes”
means any and all United States federal, state, local, or foreign income, gross receipts, payroll, employment, excise, severance,
stamp, occupation, premium, windfall profits, capital stock, capital gains, franchise, profits, withholding, social security (or
similar, including FICA), unemployment, disability, real property, personal property, sales, use, transfer, registration, value
added, alternative or add-on minimum, or other tax imposed by any governmental authority, including any interest, penalty, indexation
differentials or addition thereto and (y) ”tax return” or “tax returns” means any return,
declaration, report, claim for refund or information return or statement relating to Taxes filed or required to be filed with a
governmental authority, including any schedule or attachment thereto, and including any amendment thereof.

 

(ii) No
deficiency for any material amount of taxes has been asserted or assessed by any governmental authority in writing against the
Company or any of its Subsidiaries, which deficiency has not been paid or resolved. No material audit or other proceeding by any
governmental authority is currently in progress, pending or threatened in writing against the Company or any of its Subsidiaries
with respect to any taxes due from such entities. Neither the Company nor any of its Subsidiaries are currently contesting any
material tax liability before any governmental authority.

 

(iii) There
are no claims in writing by any governmental authority in a jurisdiction in which the Company or any of its Subsidiaries does not
file tax returns that such entity is or may be subject to tax or required to file tax returns in that jurisdiction which claim
has not been dismissed, closed or otherwise resolved.

 

(y) Internal
Accounting. The Company and each of its Subsidiaries maintains a system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and applicable
law, and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only
in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities
is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any
difference. Except as set forth in Schedule 3(y), during the twelve months prior to the date hereof neither the Company
nor any of its Subsidiaries has received any notice or correspondence from any accountant relating to any material weakness in
any part of the system of internal accounting controls of the Company or any of its Subsidiaries.

 

(z) Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company and an unconsolidated
or other off balance sheet entity that would be reasonably likely to have a Material Adverse Effect.

 

(aa) Investment
Company Status. The Company is not, and upon consummation of the sale of the Securities, will not be, an “investment
company,” an affiliate of an “investment company,” a company controlled by an “investment company”
or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment
company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

    -18-

     

    

 

(bb) Ranking
of Notes. No Indebtedness of the Company or any of its Subsidiaries is senior to the Notes in right of payment, whether with
respect of payment of redemptions, interest, damages or upon liquidation or dissolution or otherwise.

 

(cc) Manipulation
of Price. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any
action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) other than the Placement
Agent, sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) other than
the Placement Agent, paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company.

 

(dd) FDA. As
to each product subject to the jurisdiction of the U.S. Food and Drug Administration (the “FDA”) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical
Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company’s
knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge,
complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries
has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests
the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests
the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating
to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent
decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have
a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA.  Except as set forth on Schedule 3(dd)
or as disclosed in the PPM, the Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the Company been
informed by the FDA that the FDA will not approve for marketing any product being developed or proposed to be developed by the
Company.

 

    -19-

     

    

 

(ee) U.S.
Real Property Holding Corporation. The Company is not, and has never been, a U.S. real property holding corporation within
the meaning of Section 897 of the Code, and the Company shall so certify upon any Buyer’s request.

 

(ff) Transfer
Taxes. On the applicable Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required
to be paid in connection with the issuance, sale and transfer of the Securities to be sold to each Buyer hereunder will be, or
will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied
with.

 

(gg) Bank
Holding Company Act. Neither the Company nor any of its Subsidiaries or affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%)
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

(hh) Compliance
with Anti-Money Laundering Laws. The operations of the Company and its Subsidiaries and
their affiliates are and has been conducted at all times in compliance with all applicable U.S. and non-U.S. Laws, rules and regulations
relating to terrorism or money laundering, including, without limitation, the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the U.S. Bank Secrecy Act, as amended by the USA PATRIOT Act
of 2001, and the U. S. Money Laundering Control Act of 1986 (18 U.S.C. §§1956 and 1957), as amended, and any applicable
law prohibiting or directed against the financing or support of terrorist activities (e.g., 18 U.S.C. §§ 2339A
and 2339B), and the rules and regulations promulgated thereunder, and any related or similar
rules, regulations or guidelines, issued, administered or enforced by any governmental agency or self-regulatory body (collectively,
the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or its Subsidiaries or
any of their affiliates with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, its
Subsidiaries or any of their affiliates, threatened.

 

    -20-

     

    

 

(ii) No
Conflicts with Sanctions Laws. Neither the Company nor any of its Subsidiaries, nor any owner or shareholder, director, officer,
employee, agent, affiliate or other Person associated with or acting on behalf of the Company, its Subsidiaries or
their affiliates is, or is directly or indirectly, individually or in the aggregate, owned or controlled by any Person that is
currently the subject or the target of any sanctions administered or enforced by the U.S. government including, without limitation,
the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Departments
of State or Commerce and including, without limitation, the designation as a “Specially Designated National” or on
the “Sectoral Sanctions Identifications List” (collectively, “Blocked Persons”), the United Nations
Security Council, the European Union, Her Majesty’s Treasury of the United Kingdom or any other relevant sanctions authority
(collectively, “Sanctions Laws”), or any Person with whom or with which a U.S. Person is prohibited from
dealing under any of the Sanctions Laws; Neither the Company nor any of its Subsidiaries,
nor any director, officer, employee, agent, affiliate or other Person associated with or acting on behalf of the Company,
its Subsidiaries or their affiliates, is located, organized, resident or doing business in
a country or territory that is the subject or target of a comprehensive embargo or Sanctions Laws prohibiting dealings with the
country or territory, which as of the date hereof, include, without limitation, Crimea, Cuba, Iran, North Korea, and Syria (each,
a “Sanctioned Country”); the Company and its Subsidiaries are in compliance with all Sanctions Laws; the Company
and its Subsidiaries maintain in effect and enforces policies and procedures designed to ensure compliance by the
Company and its Subsidiaries with applicable Sanctions Laws; none of the Company
nor its Subsidiaries, nor any director, officer, employee, agent, affiliate or other Person
associated with or acting on behalf of the Company, its Subsidiaries or their affiliates, acting in any capacity in connection
with the operations of the Company, its Subsidiaries or their affiliates, conducts any business with or for the benefit
of any Blocked Person or engages in making or receiving any contribution of funds, goods or services to, from or for the benefit
of any Blocked Person, or deals in, or otherwise engages in any transaction relating to, any property or interests in property
blocked or subject to blocking pursuant to any applicable Sanctions Laws; no action of the
Company, its Subsidiaries or their affiliates in connection with (i) the execution, delivery and performance of this Agreement
and the other Transaction Documents, (ii) the issuance and sale of the Securities,
or (iii) the direct or indirect use of proceeds from the Securities or the consummation
of any other transaction contemplated hereby or by the other Transaction Documents or the fulfillment of the terms hereof or thereof,
will result in the proceeds of the transactions contemplated hereby and by the other Transaction Documents being used, or loaned,
contributed or otherwise made available, directly or indirectly, to any Subsidiary, joint venture partner or other Person, for
the purpose of (i) unlawfully funding or facilitating any activities of or business with any Person that, at the time of such funding
or facilitation, is the subject or target of Sanctions Laws, (ii) unlawfully funding or facilitating any activities of or business
in any Sanctioned Country or (iii) in any other manner that will result in a violation by any Person (including any Person participating
in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions Laws. For the past five (5) years, each
of the Company, its Subsidiaries and their affiliates has not knowingly engaged in and is not now knowingly engaged in any dealings
or transactions with any Person that at the time of the dealing or transaction is or was the subject or the target of Sanctions
Laws or with any Sanctioned Country.

 

(jj) Anti-Bribery.
None of the Company, its Subsidiaries or their affiliates nor anyone acting
on their behalf have made any contribution or other payment to any official of, or candidate for, any federal, state or foreign
office in violation of any law. None of the Company, its Subsidiaries or their affiliates,
nor any owner or shareholder, director, officer, agent, employee or other Person associated with or acting on behalf of the Company,
its Subsidiaries or their affiliates, has (i) used any funds for any unlawful contribution, gift, entertainment or other unlawful
expense, (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee, to any employee
or agent of a private entity with which any of the Company, its Subsidiaries or their
affiliates does or seeks to do business or to foreign or domestic political parties or campaigns, (iii) violated or is in violation
of any provision of any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials
in International Business Transactions or any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended
(the “FCPA”), the U.K. Bribery Act 2010, or any other similar law of any other jurisdiction in which any of
the Company, its Subsidiaries or their affiliates operates its business, including, in each
case, the rules and regulations thereunder (collectively, the “Anti-Bribery Laws”), (iv) taken, is currently
taking or will take any action in furtherance of an offer, payment, gift or anything else of value, directly or indirectly, to
any Person while knowing that all or some portion of the money or value will be offered, given or promised to anyone to improperly
influence official action, to obtain or retain business or otherwise to secure any improper advantage or (v) otherwise made any
offer, bribe, rebate, payoff, influence payment, unlawful kickback or other unlawful payment; Each of the
Company, its Subsidiaries and their affiliates has instituted and has maintained, and will continue to maintain, policies and procedures
reasonably designed to promote and achieve compliance with the Anti-Bribery Laws and with this representation and warranty; none
of the Company, its Subsidiaries or their affiliates will directly or indirectly use
the proceeds of the convertible securities or lend, contribute or otherwise make available such proceeds to any subsidiary, affiliate,
joint venture partner or other Person for the purpose of financing or facilitating any activity that would violate the Anti-Bribery
Laws; there are, and have been, no allegations, investigations or inquiries with regard to a potential violation of any Anti-Bribery
Laws by the Company, its Subsidiaries or their affiliates, or any of their respective current or former directors, officers,
employees, owners, shareholders, stockholders, representatives, agents or other Persons
acting or purporting to act on their behalf.

 

    -21-

     

    

 

(kk) No
Additional Agreements. Neither the Company nor any of its Subsidiaries have any agreement or understanding with any Buyer with
respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

(ll) Disclosure.
Except for discussions specifically regarding the offer and sale of the Notes and the transactions contemplated by the Primary
Financing SPA and the Merger Agreement (as defined below), the Company confirms that neither it nor any other Person acting on
its behalf has provided any of the Buyers or their agents or counsel with any information that constitutes or could reasonably
be expected to constitute material, non-public information concerning the Company or any its Subsidiaries, other than the existence
of the transactions contemplated by this Agreement and the other Transaction Documents. The Company understands and confirms that
each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company. All disclosure
provided to the Buyers regarding the Company, or any of its Subsidiaries, their business and the transactions contemplated hereby,
including the disclosure schedules to this Agreement, furnished by or on behalf of the Company is true and correct and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not misleading. All of the written information furnished
after the date hereof by or on behalf of the Company to Buyers pursuant to or in connection with this Agreement and the other Transaction
Documents, taken as a whole, will be true and correct in all material respects as of the date on which such information is so provided
and will not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they are made, not misleading. Each press release, if any,
issued by the Company or any of its Subsidiaries during the twelve (12) months preceding the date of this Agreement did not, at
the time of release, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
Except for the transactions contemplated herein and in the Merger Agreement, no event or circumstance has occurred or information
exists with respect to the Company or any of its Subsidiaries or its or their business, properties, liabilities, prospects, operations
(including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public
disclosure at or before the date hereof or announcement by the Company but which has not been so publicly disclosed. The Company
acknowledges and agrees that no Buyer makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 2.

 

    -22-

     

    

 

(mm) Stock
Option Plans. Each stock option, if any, granted by the Company was granted (i) in accordance with the terms of the applicable
stock option plan of the Company and (ii) with an exercise price at least equal to the fair market value of Common Stock on the
date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company’s
stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no policy or practice
of the Company to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.

 

(nn) No
Disagreements with Accountants and Lawyers. There are no material disagreements of any kind presently existing, or reasonably
anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the
Company and the Company is current with respect to any fees owed to its accountants and lawyers which could affect the Company’s
ability to perform any of its obligations under any of the Transaction Documents.

 

(oo) No
Disqualification Events. With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the 1933
Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated issuer, any director,
executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of
the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term
is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer
Covered Person” and, together, “Issuer Covered Persons”) is subject to any of the “Bad Actor”
disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification Event”),
except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine
whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with
its disclosure obligations under Rule 506(e), and has furnished to the Buyers a copy of any disclosures provided thereunder.

 

(pp) Other
Covered Persons. The Company is not aware of any Person (other than the Placement Agent) that has been or will be paid (directly
or indirectly) remuneration for solicitation of Buyers or potential purchasers in connection with the sale of any Regulation D
Securities.

 

(qq) Notice
of Disqualification Events. The Company will notify the Buyers and the Placement Agent in writing, prior to each Closing Date
of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time,
become a Disqualification Event relating to any Issuer Covered Person.

 

    -23-

     

    

 

(rr) Merger Agreement.
The Company has delivered to such Buyer a duly executed copy of the Agreement and Plan of Merger by and among the Company, PublicCo
and CellMSC, Inc., a Delaware corporation and wholly owned subsidiary of PublicCo, dated March 24, 2021 (the “Merger Agreement”).
The representations and warranties of the Company included in the Merger Agreement are true and correct as of the date hereof (except
for representations and warranties that speak as of a specific date which are true and correct as of such specified date), and
the Company has no reason to believe that the Closing (as defined in the Merger Agreement) will not occur.

 

(ss) Dilutive
Effect. The Company understands and acknowledges that the number of Warrant
Shares issuable pursuant to the terms of the Warrants will increase in certain circumstances. The Company further acknowledges
that its obligation to issue Warrant Shares pursuant to the terms of the Warrants in accordance with this Agreement and with the
Warrants are absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests
of other members or stockholders of the Company.

 

(tt) Application
of Takeover Protections; Rights Agreement. The Company and its board of directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, interested shareholder, business combination (including, without
limitation, under Section 203 of the Delaware General Corporation Law), poison pill (including, without limitation, any distribution
under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws or other organizational
documents or the laws of the jurisdiction of its formation which is or could become applicable to any Buyer as a result of the
transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and
any Buyer’s ownership of the Securities. The Company has not adopted a stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of Common Stock or a change in control of the Company or any of its Subsidiaries.

 

(uu) Shell Company
Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1) of the 1933 Act.

 

(vv) COVID-19.
Since December 31, 2019, there has not occurred, directly or indirectly as a result of, with respect to or in connection with SARS-CoV-2
or COVID-19, and any evolutions thereof or related or associated epidemics, pandemic or disease outbreaks, any material disruption
in, or material negative impact on, the Company or any of its Subsidiaries’ business or business operations, whether in the
near, medium or long term or of short, medium or long duration, including as a result of, with respect to or in connection with:
(a) any temporary or permanent whole or partial loss of customer(s), supplier(s), service provider(s), systems or technology provider(s),
or infrastructure; (b) any temporary or permanent whole or partial loss of access to, or the services of, facilities (including
offices or co-location facilities), employees, independent contractors or consultants, technology or networks, utilities, services
and repair or other resources; (c) any excessive or unusual costs, expenses, fees, rates, royalties or charges of any nature, including
with respect to compensation of employees, independent contractors or consultants or costs of employee benefits or insurance (including
health insurance and business interruption or similar insurance); (d) any delay in the payment or performance of obligations by
third Persons, regardless of whether caused or allegedly caused by force majeure or a similar concept or otherwise; (e) any cause
similar to any of the forgoing; or (f) any combination of the forgoing.

 

    -24-

     

    

 

(ww) Equity Capitalization.
As of the date hereof, the authorized capital stock of the Company consists of (i) 10,000,000 shares of Common Stock, of which
as of the date hereof, 1,000,000 shares of Common Stock are issued and outstanding, no shares of Common Stock are reserved for
issuance pursuant to the Company’s stock option and purchase plans, of which no shares of Common Stock are subject to outstanding
Company options granted under the Company stock plans and no shares of Common Stock are reserved for issuance pursuant to securities
exercisable or exchangeable for, or convertible into, Common Stock and (ii) no there are no authorized shares of preferred stock.
No Common Stock are held in treasury. All of such outstanding shares are duly authorized and have been, or upon issuance will be,
validly issued and are fully paid and nonassessable. (i) Except as disclosed in Schedule 3(ww)(i) hereto, none of the Company’s
or any Subsidiary’s capital equity is subject to preemptive rights or any other similar rights or any liens or encumbrances
suffered or permitted by the Company or any Subsidiary’s; (ii) except as disclosed in Schedule 3(ww)(ii), there are
no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to,
or securities or rights convertible into, or exercisable or exchangeable for, any capital equity of the Company or any of the Subsidiaries,
or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional capital
stock of the Company or any of the Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any capital equity
of the Company or any of the Subsidiaries; (iii) except as disclosed in Schedule 3(ww)(iii), there are no outstanding debt
securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness of
the Company or any of the Subsidiaries or by which the Company or any of the Subsidiaries is or may become bound; (iv) except as
disclosed in Schedule 3(ww)(iv), there are no financing statements securing obligations in any amounts filed in connection
with the Company or any of the Subsidiaries; (v), except as disclosed in Schedule 3(ww)(v), there are no agreements or arrangements
under which the Company or any of the Subsidiaries is obligated to register the sale of any of their securities under the 1933
Act; (vi) except as disclosed in Schedule 3(ww)(vi), there are no outstanding securities or instruments of the Company or
any of the Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings
or arrangements by which the Company or any of the Subsidiaries is or may become bound to redeem a security of the Company or any
of the Subsidiaries; (vii) except as disclosed in Schedule 3(ww)(vii), there are no securities or instruments containing
anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (viii) except as disclosed in Schedule
3(ww)(viii), neither the Company nor any of its Subsidiaries has any stock appreciation rights or “phantom stock”
plans or agreements or any similar plan or agreement; and (ix) except as disclosed in Schedule 3(ww)(ix), the Company or
any of the Subsidiaries have no liabilities or obligations, other than those incurred in the ordinary course of the Company’s
or any of the Subsidiary’s respective businesses and which, individually or in the aggregate, do not or could not have a
Material Adverse Effect.

 

    -25-

     

    

 

4. COVENANTS.

 

(a) Best
Efforts. Each party shall use its reasonable best efforts timely to satisfy each of the covenants and the conditions to be
satisfied by it as provided in Sections 6 and 7 of this Agreement.

 

(b) Form
D and Blue Sky. The Company agrees to file a Form D with respect to the Notes and Warrants as required under Regulation D and
to provide a copy thereof to each Buyer promptly after such filing. The Company shall, on or before each Closing Date, take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities
for sale to the Buyers at the applicable Closing pursuant to this Agreement under applicable securities or “Blue Sky”
laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any
such action so taken to the Buyers on or prior to the applicable Closing Date. The Company shall make all filings and reports relating
to the offer and sale of the Securities required under applicable securities or “Blue Sky” laws of the states of the
United States following each Closing Date.

 

(c) Use
of Proceeds. The Company will use the proceeds from the sale of the Securities solely as set forth in Schedule 4(c).

 

(d) Fees.
The Company shall pay an expense allowance to the Lead Investor or its designee(s) for all costs and expenses incurred in connection
with the transactions contemplated by the Transaction Documents through each Closing Date (including all legal fees and disbursements
in connection therewith, documentation and implementation of the transactions contemplated by the Transaction Documents and due
diligence in connection therewith) not reimbursed by the Company on or prior to the First Closing, which amount, at the option
of the Lead Investor, may be withheld by such Buyer from its applicable Purchase Price at the applicable Closing; provided,
however, in no event will the amount of costs, fees and expenses of the Lead Investor to be reimbursed by the Company in
connection with this Agreement exceed $100,000 (including any amounts paid to the Lead Investor or its counsel prior to the First
Closing in connection with this Agreement) without the prior approval from the Company. The Company shall be responsible for the
payment of any placement agent’s fees, financial advisory fees, or broker’s commissions (other than for Persons engaged
by any Buyer) relating to or arising out of the transactions contemplated hereby, including, without limitation, any fees or commissions
payable to the Financial Advisor. The Company shall pay, and hold each Buyer harmless against, any liability, loss or expense (including,
without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any claim relating to any such
payment. Except as otherwise set forth in the Transaction Documents, each party to this Agreement shall bear its own expenses in
connection with the sale of the Securities to the Buyers.

 

(e) Pledge
of Securities. The Company acknowledges and agrees that the Securities may be pledged by a Buyer in connection with a bona
fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities shall
not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Buyer effecting a pledge of Securities shall
be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement
or any other Transaction Document, including, without limitation, Section 2(f) hereof; provided that a Buyer and its pledgee
shall be required to comply with the provisions of Section 2(f) hereof in order to effect a sale, transfer or assignment of Securities
to such pledgee. The Company hereby agrees to execute and deliver such documentation as a pledgee of the Securities may reasonably
request in connection with a pledge of the Securities to such pledgee by a Buyer.

 

    -26-

     

    

 

(f) Additional
Notes or Warrants. So long as any Buyer beneficially owns any Notes or Warrants, the Company will not issue any Notes or Warrants
other than to the Buyers as contemplated hereby and the Company shall not issue any other securities that would cause a breach
or default under the Notes of Warrants.

 

(g) Corporate
Existence. Except as contemplated under the Merger Agreement, so long as any Buyer beneficially owns any Securities, the Company
shall (i) maintain its corporate existence and (ii) not be party to any Fundamental Transaction (as defined in the Notes and Warrants)
while any Notes are outstanding and thereafter only if the Company is in compliance with the applicable provisions governing Fundamental
Transactions set forth in the Warrants.

 

(h) Reservation
of Shares. While any Warrants remain outstanding, the Company shall take all action necessary to have authorized, and reserved
for the purpose of issuance, no less than the number of shares of Common Stock equal to the Required Reserve Amount. If at any
time the number of shares of Common Stock authorized and reserved for issuance is not sufficient to meet the requirements set forth
in this Section 4(h), the Company will promptly take all corporate action necessary to authorize and reserve a sufficient number
of shares, including, without limitation, calling a special meeting of stockholders to authorize additional shares to meet the
Company’s obligations under this Section 4(h), in the case of an insufficient number of authorized shares, obtain stockholder
approval of an increase in such authorized number of shares, and voting the management shares of the Company in favor of an increase
in the authorized shares of Common Stock to ensure that the number of authorized shares is sufficient to meet the requirements
set forth in this Section 4(h).

 

(i) Conduct
of Business. The business of the Company and its Subsidiaries shall not be conducted in violation of any law, ordinance or
regulation of any governmental entity, including, without limitation, FCPA and other applicable Anti-Bribery Laws, OFAC regulations
and other applicable Sanctions Laws, and Anti-Money Laundering Laws.

 

(i) None
of the Company nor any of its Subsidiaries or affiliates, directors, officers, employees, representatives or agents shall:

 

(a) conduct
any business or engage in any transaction or dealing with or for the benefit of any Blocked Person, including the making or receiving
of any contribution of funds, goods or services to, from or for the benefit of any Blocked Person;

 

(b) deal
in, or otherwise engage in any transaction relating to, any property or interests in property blocked or subject to blocking pursuant
to the applicable Sanctions Laws;

 

(c) use
any of the proceeds of the transactions contemplated by this Agreement to finance, promote or otherwise support in any manner any
illegal activity, including, without limitation, any Anti-Money Laundering Laws, Sanctions Laws, or Anti-Bribery Laws; or

 

    -27-

     

    

 

(d) violate,
attempt to violate, or engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading
or avoiding, any of the Anti-Money Laundering Laws, Sanctions Laws, or Anti-Bribery Laws, or that would cause Buyers to be in
violation of the Anti-Bribery Laws, Anti-Money Laundering Laws or Sanctions Laws.

 

(ii) The
Company shall maintain in effect and enforce policies and procedures designed to ensure compliance by it and its Subsidiaries and
their directors, officers, employees, agents representatives and affiliates with the Sanctions Laws and Anti-Bribery Laws.

 

(iii) The
Company will promptly notify the Buyers in writing if any of it, or any of its Subsidiaries or affiliates, directors, officers,
employees, representatives or agents, shall become a Blocked Person, or become directly or
indirectly owned or controlled by a Blocked Person.

 

(iv) The
Company shall provide such information and documentation as the Buyers or any of their affiliates may require to satisfy
compliance with the Anti-Money Laundering Laws, Sanctions Laws, or Anti-Bribery Laws.

 

(v) The
Company shall promptly notify the Buyers in writing should it become aware (a) of any changes to these covenants, or (b) if it
cannot comply with the covenants set forth herein. The Company shall also promptly
notify the Buyers in writing should they become aware of an investigation, litigation or regulatory action relating to an alleged
or potential violation of the Anti-Money Laundering Laws, Sanctions Laws, and Anti-Bribery Laws.

 

(vi) The
Company shall not transfer to any Subsidiary of the Company any assets, rights, liabilities, obligations or commitments of any
type whatsoever, nor shall the Company permit any Subsidiary of the Company to acquire any assets or rights, or to incur any liabilities,
obligations or commitments, of any kind.

 

(j) Collateral
Agent.

 

(i) Each
Buyer hereby (a) appoints the Lead Investor as the collateral agent hereunder and under the Security Documents (in such capacity,
the “Collateral Agent”), and (b) authorizes the Collateral Agent (and its officers, directors, employees and
agents) to take such action on such Buyer’s behalf in accordance with the terms hereof and thereof. The Collateral Agent
shall not have, by reason hereof or pursuant to any Security Documents, a fiduciary relationship in respect of any Buyer. Neither
the Collateral Agent nor any of its officers, directors, employees and agents shall have any liability to any Buyer for any action
taken or omitted to be taken in connection hereof or the Security Documents except to the extent caused by its own gross negligence
or willful misconduct, and each Buyer agrees to defend, protect, indemnify and hold harmless the Collateral Agent and all of its
officers, directors, employees and agents (collectively, the “Collateral Agent Indemnitees”) from and against
any losses, damages, liabilities, obligations, penalties, actions, judgments, suits, fees, costs and expenses (including, without
limitation, reasonable attorneys’ fees, costs and expenses) incurred by such Collateral Agent Indemnitee, whether direct,
indirect or consequential, arising from or in connection with the performance by such Collateral Agent Indemnitee of the duties
and obligations of Collateral Agent pursuant hereto or any of the Security Documents.

 

    -28-

     

    

 

(ii) The
Collateral Agent shall be entitled to rely upon any written notices, statements, certificates, orders or other documents or any
telephone message believed by it in good faith to be genuine and correct and to have been signed, sent or made by the proper Person,
and with respect to all matters pertaining to this Agreement or any of the other Transaction Documents and its duties hereunder
or thereunder, upon advice of counsel selected by it.

 

(iii) The
Collateral Agent may resign from the performance of all its functions and duties hereunder and under the Notes and the Security
Documents at any time by giving at least ten (10) Business Days prior written notice to the Company and each holder of the Notes.
Such resignation shall take effect upon the acceptance by a successor Collateral Agent of appointment as provided below. Upon any
such notice of resignation, the holders of a majority of the outstanding principal amount of Notes shall appoint a successor Collateral
Agent. Upon the acceptance of the appointment as Collateral Agent, such successor Collateral Agent shall succeed to and become
vested with all the rights, powers, privileges and duties of the retiring Collateral Agent, and the retiring Collateral Agent shall
be discharged from its duties and obligations under this Agreement, the Notes and the Security Agreement. After any Collateral
Agent’s resignation hereunder, the provisions of this Section 4(i) shall inure to its benefit. If a successor Collateral
Agent shall not have been so appointed within said ten (10) Business Day period, the retiring Collateral Agent shall then appoint
a successor Collateral Agent who shall serve until such time, if any, as the holders of a majority of the outstanding principal
amount of Notes appoints a successor Collateral Agent as provided above. As used herein, “Business Day” means
any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee”
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental
authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New
York, New York generally are open for use by customers on such day.

 

(iv) The
Company hereby covenants and agrees to take all actions as promptly as practicable reasonably requested by either the holders of
a majority of the outstanding principal amount of Notes or the Collateral Agent (or its successor), from time to time pursuant
to the terms of this Section 4(i), to secure a successor Collateral Agent satisfactory to such requesting part(y)(ies), in their
sole discretion, including, without limitation, by paying all fees of such successor Collateral Agent, by having the Company agree
to indemnify any successor Collateral Agent and by each of the Company executing a collateral agency agreement or similar agreement
and/or any amendment to the Security Documents reasonably requested or required by the successor Collateral Agent.

 

    -29-

     

    

 

(k) Additional
Issuances of Securities.

 

(i) For
purposes of this Section 4(j), the following definitions shall apply.

 

(1) “Convertible
Securities” means any stock or securities (other than Options (as defined below)) convertible into or exercisable or
exchangeable for Common Stock.

 

(2) “Options”
means any rights, warrants or options to subscribe for or purchase Common Stock or Convertible Securities.

 

(3) “Common
Stock Equivalents” means, collectively, Options and Convertible Securities.

 

(4) “Subsequent
Placement” means any direct or indirect, offer, sale, grant any option to purchase, or other disposition of any of the
Company’s or its Subsidiaries’ equity or equity equivalent securities, including without limitation any debt, preferred
stock or other instrument or security whether or not such security is, at any time during its life and under any circumstances,
convertible into or exchangeable or exercisable for Common Stock or Common Stock Equivalents.

 

(ii) The
Company shall not enter into any Subsequent Placement other than as contemplated by the Primary Financing SPA, unless the Company
has prepaid the Notes in full pursuant to Section 2(a) or Section 2(b) of the Notes or it has complied with this Section 4(j)(ii).

 

(1) At
least five (3) Business Days prior to any proposed or intended Subsequent Placement (other than as contemplated under the Primary
Financing SPA), the Company shall deliver to each Buyer a written notice (each such notice, a “Pre-Notice”),
which Pre-Notice shall not contain any information (including, without limitation, material, non-public information) other than:
(A) if the proposed Offer Notice (as defined below) constitutes or contains material, non-public information, a statement asking
whether the Buyer is willing to accept material non-public information or (B) if the proposed Offer Notice does not constitute
or contain material, non-public information, (x) a statement that the Company proposes or intends to effect a Subsequent Placement,
(y) a statement that the statement in clause (x) above does not constitute material, non-public information and (z) a statement
informing such Buyer that it is entitled to receive an Offer Notice (as defined below) with respect to such Subsequent Placement
upon its written request. Upon the written request of a Buyer within three (3) Business Days after the Company’s delivery
to such Buyer of such Pre-Notice, and only upon a written request by such Buyer, the Company shall promptly, but no later than
one (1) Business Day after such request, deliver to such Buyer an irrevocable written notice (the “Offer Notice”)
of any proposed or intended issuance or sale or exchange (the “Offer”) of the securities being offered (the
“Offered Securities”) in a Subsequent Placement, which Offer Notice shall (w) identify and describe the Offered
Securities, (x) describe the price and other terms upon which they are to be issued, sold or exchanged, and the number or
amount of the Offered Securities to be issued, sold or exchanged, (y) identify the Persons (if known) to which or with which
the Offered Securities are to be offered, issued, sold or exchanged and (z) offer to issue and sell to or exchange with such Buyers
an amount of the Offered Securities for a purchase price equal to all Outstanding Amounts of the Notes assuming all Notes were
issued pursuant to Section 1(a) including all accrued Interest thereon, allocated among such Buyers (a) based on such Buyer’s
pro rata portion of the aggregate principal amount of Notes purchased hereunder (the “Basic Amount”), and (b)
with respect to each Buyer that elects to purchase its Basic Amount, any additional portion of the Offered Securities attributable
to the Basic Amounts of other Buyers as such Buyer shall indicate it will purchase or acquire should the other Buyers subscribe
for less than their Basic Amounts (the “Undersubscription Amount”), which process shall be repeated until the
Buyers shall have an opportunity to subscribe for any remaining Undersubscription Amount.

 

    -30-

     

    

 

(2) To
accept an Offer, in whole or in part, such Buyer must deliver a written notice to the Company prior to the end of the fifth (5th)
Business Day after such Buyer’s receipt of the Offer Notice (the “Offer Period”), setting forth the portion
of such Buyer’s Basic Amount that such Buyer elects to purchase and, if such Buyer shall elect to purchase all of its Basic
Amount, the Undersubscription Amount, if any, that such Buyer elects to purchase (in either case, the “Notice of Acceptance”).
If the Basic Amounts subscribed for by all Buyers are less than the total of all of the Basic Amounts, then each Buyer who has
set forth an Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to the Basic Amounts
subscribed for, the Undersubscription Amount it has subscribed for; provided, however, that if the Undersubscription
Amounts subscribed for exceed the difference between the total of all the Basic Amounts and the Basic Amounts subscribed for (the
“Available Undersubscription Amount”), each Buyer who has subscribed for any Undersubscription Amount shall
be entitled to purchase only that portion of the Available Undersubscription Amount as the Basic Amount of such Buyer bears to
the total Basic Amounts of all Buyers that have subscribed for Undersubscription Amounts, subject to rounding by the Company to
the extent its deems reasonably necessary. Notwithstanding anything to the contrary contained herein, if the Company desires to
modify or amend the terms and conditions of the Offer prior to the expiration of the Offer Period, the Company may deliver to the
Buyers a new Offer Notice and the Offer Period shall expire on the fifth (5th) Business Day after such Buyer’s
receipt of such new Offer Notice.

 

(3) The
Company shall have five (5) Business Days from the expiration of the Offer Period above to offer, issue, sell or exchange all or
any part of such Offered Securities as to which a Notice of Acceptance has not been given by the Buyers (the “Refused
Securities”) pursuant to a definitive agreement (the “Subsequent Placement Agreement”) but only to
the offerees described in the Offer Notice (if so described therein) and only upon terms and conditions (including, without limitation,
unit prices and interest rates) that are not more favorable to the acquiring Person or Persons or less favorable to the Company
than those set forth in the Offer Notice.

 

(4) In
the event the Company shall propose to sell less than all the Refused Securities (any such sale to be in the manner and on the
terms specified in Section 4(j)(ii)(3) above), then each Buyer may, at its sole option and in its sole discretion, reduce the number
or amount of the Offered Securities specified in its Notice of Acceptance to an amount that shall be not less than the number or
amount of the Offered Securities that such Buyer elected to purchase pursuant to Section 4(j)(ii)(2) above multiplied by a fraction,
(i) the numerator of which shall be the number or amount of Offered Securities the Company actually proposes to issue, sell
or exchange (including Offered Securities to be issued or sold to Buyers pursuant to Section 4(j)(ii)(3) above prior to such reduction)
and (ii) the denominator of which shall be the original amount of the Offered Securities. In the event that any Buyer so elects
to reduce the number or amount of Offered Securities specified in its Notice of Acceptance, the Company may not issue, sell or
exchange more than the reduced number or amount of the Offered Securities unless and until such securities have again been offered
to the Buyers in accordance with Section 4(j)(ii)(1) above.

 

    -31-

     

    

 

(5) Upon
the closing of the issuance, sale or exchange of all or less than all of the Refused Securities, the Buyers shall acquire from
the Company, and the Company shall issue to the Buyers, the number or amount of Offered Securities specified in the Notices of
Acceptance, as may be reduced pursuant to Section 4(j)(ii)(3) above if the Buyers have so elected, upon the terms and conditions
specified in the Offer. The purchase by the Buyers of any Offered Securities is subject in all cases to the preparation, execution
and delivery by the Company and the Buyers of a purchase agreement relating to such Offered Securities reasonably satisfactory
in form and substance to the Buyers and their respective counsel.

 

(6) Any
Offered Securities not acquired by the Buyers or other Persons in accordance with
Section 4(j)(ii)(3) above may not be issued, sold or exchanged until they are again offered to the Buyers under the procedures
specified in this Agreement.

 

(7) The
Company and the Buyers agree that if any Buyer elects to participate in the Offer, neither the Subsequent Placement Agreement with
respect to such Offer nor any other transaction documents related thereto shall include any term or provisions whereby any Buyer
shall be required to agree to any restrictions in trading as to any securities of the Company owned by such Buyer prior to such
Subsequent Placement.

 

(8) Notwithstanding
anything to the contrary in this Section 4(j) and unless otherwise agreed to by the Buyers, the Company shall either confirm in
writing to the Buyers that the transaction with respect to the Subsequent Placement has been abandoned or shall publicly disclose
its intention to issue the Offered Securities, in either case in such a manner such that the Buyers will not be in possession of
material non-public information, by the fifteenth (15th) Business Day following delivery of the Offer Notice. If by
the fifteenth (15th) Business Day following delivery of the Offer Notice no public disclosure regarding a transaction
with respect to the Offered Securities has been made, and no notice regarding the abandonment of such transaction has been received
by the Buyers, such transaction shall be deemed to have been abandoned and the Buyers shall not be deemed to be in possession of
any material, non-public information with respect to the Company. Should the Company decide to pursue such transaction with respect
to the Offered Securities, the Company shall provide each Buyer with another Offer Notice and each Buyer will again have the right
of participation set forth in this Section 4(j)(ii). The Company shall not be permitted to deliver more than one such Offer Notice
to the Buyers in any 60 day period.

 

    -32-

     

    

 

(l) Variable
Securities. While any Warrants remain outstanding, the Company and its Subsidiaries shall be prohibited from effecting or entering
into an agreement to effect any Subsequent Placement involving a Variable Rate Transaction except as contemplated by the Primary
Financing Term Sheet. “Variable Rate Transaction” means a transaction in which the Company or any of its Subsidiaries
(i) issues or sells any Convertible Securities either (A) at a conversion, exercise or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance
of such Convertible Securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future
date after the initial issuance of such Convertible Securities or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock, other than pursuant to a customary “weighted
average” anti-dilution provision or (ii) enters into any agreement (including, without limitation, an equity line of credit
or an “at-the-market” offering) whereby the Company or any of its Subsidiaries may sell securities at a future determined
price (other than standard and customary “preemptive” or “participation” rights). Each Buyer shall be entitled
to obtain injunctive relief against the Company and its Subsidiaries to preclude any such issuance, which remedy shall be in addition
to any right to collect damages for an actual breach of this Section 4(l).

 

(m) Closing
Documents. On or prior to fourteen (14) calendar days after the applicable Closing Date, the Company agrees to deliver, or
cause to be delivered, to each Buyer and Schulte Roth & Zabel LLP a complete closing set of the executed Transaction Documents,
Notes and any other documents required to be delivered to any party pursuant to Section 7 hereof or otherwise.

 

(n) Within
fifteen (15) calendar days after the Closing Date (or such later date as determined by the Collateral Agent in its reasonable discretion),
(i) the Collateral Agent shall have received an account control agreement with respect to each account referred to in Schedule
IV of the Security Agreement as in effect on the date hereof, in form and substance satisfactory to the Collateral Agent, duly
executed by the Company and such bank or financial institution, or (ii) the Company shall enter into such other arrangements as
are satisfactory to the Collateral Agent, as required under Section 5(i) of the Security Agreement and subject to the terms thereof.

 

5. REGISTER;
TRANSFER AGENT INSTRUCTIONS.

 

(a) Register.
The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate
by notice to each holder of Securities), a register for the Notes and Warrants in which the Company shall record the name and address
of the Person in whose name the Notes and Warrants have been issued (including the name and address of each transferee), the principal
amount of Notes held by such Person and the number of Warrant Shares issuable upon exercise of the Warrants held by such Person.
The Company shall keep the register open and available at all times during business hours for inspection of any Buyer or its legal
representatives.

 

    -33-

     

    

 

(b) Transfer
Agent Instructions. If and when the Common Stock is registered under the 1934 Act, the Company shall issue irrevocable instructions
to its transfer agent, and any subsequent transfer agent, in the form attached to the Primary Financing SPA, to issue certificates
or credit shares to the applicable balance accounts at DTC, registered in the name of each Buyer or its respective nominee(s),
upon exercise of the Warrant in such amounts as specified from time to time by each Buyer to the Company upon exercise of the Warrants.
The Company warrants that no instruction other than the Irrevocable Transfer Agent Instructions (as defined in the Primary Financing
SPA) referred to therein, and stop transfer instructions to give effect to Section 2(f) hereof, will be given by the Company to
its Transfer Agent, and that the Securities shall otherwise be freely transferable on the books and records of the Company as and
to the extent provided in this Agreement and the other Transaction Documents. If a Buyer effects a sale, assignment or transfer
of the Securities in accordance with Section 2(f), the Company shall permit the transfer and shall promptly instruct its transfer
agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations
as specified by such Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves
the Warrant Shares sold, assigned or transferred pursuant to an effective registration statement or pursuant to Rule 144, the transfer
agent shall issue such Securities to the Buyer, assignee or transferee, as the case may be, without any restrictive legend. The
Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to a Buyer. Accordingly, the
Company acknowledges that the remedy at law for a breach of its obligations under this Section 5(b) will be inadequate and agrees,
in the event of a breach or threatened breach by the Company of the provisions of this Section 5(b), that a Buyer shall be entitled,
in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance
and transfer, without the necessity of showing economic loss and without any bond or other security being required.

 

6. CONDITIONS
TO THE COMPANY’S OBLIGATION TO SELL.

 

The obligation of the
Company hereunder to issue and sell the applicable Notes and the related Warrants to each Buyer at the applicable Closing is subject
to the satisfaction, at or before the applicable Closing Date, of each of the following conditions, provided that these conditions
are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion by providing each
Buyer with prior written notice thereof:

 

(i) Such
Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Company.

 

(ii) Such
Buyer shall have delivered the applicable Purchase Price (less, in the case of the Lead Investor, the amounts withheld pursuant
to Section 4(d)) for the Notes and related Warrants being purchased by such Buyer at the applicable Closing pursuant to Section
1(d) hereof by wire transfer of immediately available funds pursuant to the wire instructions provided by the Company.

 

(iii) The
representations and warranties of such Buyer shall be true and correct as of the date when made and as of the applicable Closing
Date as though made at that time (except for representations and warranties that speak as of a specific date which shall be true
and correct as of such specified date), and such Buyer shall have performed, satisfied and complied in all respects with the covenants,
agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Buyer at or prior to the
applicable Closing Date.

 

    -34-

     

    

 

(iv)
The Merger Agreement shall not have been terminated as of the applicable Closing Date.

 

7. CONDITIONS
TO EACH BUYER’S OBLIGATION TO PURCHASE.

 

The obligation of each
Buyer hereunder to purchase the applicable Notes and the related Warrants at the applicable Closing is subject to the satisfaction,
at or before the applicable Closing Date, of each of the following conditions, provided that these conditions are for each Buyer’s
sole benefit and may be waived by such Buyer at any time in its sole discretion by providing the Company with prior written notice
thereof:

 

(i) The
Company and each of its Subsidiaries shall have duly executed and delivered to such Buyer each of the Transaction Documents to
which it is a party (with the Notes and Warrants allocated in such principal amounts as such Buyer shall request), being purchased
by such Buyer at the applicable Closing pursuant to this Agreement.

 

(ii) Such
Buyer shall have received the opinion of Dentons US LLP, the Company’s outside counsel, dated as of the applicable Closing
Date, in the form of Exhibit F attached hereto.

 

(iii) The
Company shall have delivered to such Buyer a certificate evidencing the formation and good standing of the Company and each of
its Subsidiaries in each such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office)
of such jurisdiction, as of a date within ten (10) days prior to the applicable Closing Date.

 

(iv) The
Company shall have delivered to such Buyer a certificate evidencing the Company’s and each of its Subsidiaries’ qualification
as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which
the Company and its Subsidiaries conduct business, as of a date within ten (10) days prior to the applicable Closing Date.

 

(v) The
Company shall have delivered to such Buyer a certified copy of the Certificate of Incorporation and the organizational documents
of each of its Subsidiaries as certified by the Secretary of State (or comparable office) of the jurisdiction of formation of the
Company and each of its Subsidiaries within ten (10) days prior to the applicable Closing Date.

 

(vi) The
Company shall have delivered to such Buyer a certificate, executed by the Secretary of the Company and dated as of the applicable
Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the Company’s Board of Directors
and each of its Subsidiaries’ applicable governing body in a form reasonably acceptable to such Buyer and (ii) the Certificate
of Incorporation and Bylaws and the organizational documents of each of its Subsidiaries, each as in effect at the applicable Closing,
in the form attached hereto as Exhibit G.

 

(vii) The
representations and warranties of the Company set forth in (i) Section 3 shall be true and correct as of the date when made and
as of the applicable Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date which shall be true and correct as of such specified date) and (ii) the Merger Agreement are true and correct as of the applicable
Closing Date (except for representations and warranties that speak as of a specific date which shall be true and correct as of
such specified date), and the Company shall have no reason to believe that the Closing (as defined in the Merger Agreement) will
not occur, and the Company shall have performed, satisfied and complied in all respects with the covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the applicable
Closing Date. Such Buyer shall have received a certificate, executed by the Chief Executive Officer of the Company, dated as of
the applicable Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by such Buyer
in the form attached hereto as Exhibit H.

 

    -35-

     

    

 

(viii) The
Company shall have delivered to such Buyer a duly executed Merger Agreement by all parties thereto, which shall not have been terminated
as of the applicable Closing Date, and of which no provision shall have been amended or waived as of the applicable Closing Date
without the prior written consent of the Required Holders (as defined in Section 9(e)).

 

(ix) The
Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale
of the Securities.

 

(x) If
the applicable Closing Date is (i) the Second Closing Date, the First Closing Date shall have been completed and (ii) the Third
Closing, the First Closing Date and the Second Closing Date shall have been completed.

 

(xi) Such
Buyer shall have received the Company’s wire instructions on Company letterhead duly executed by an authorized executive
officer of the Company.

 

(xii) Each
of the Company’s Subsidiaries shall have executed and delivered to such Buyer the Guarantee Agreement.

 

(xiii) The
Collateral Agent shall have received all documents, instruments, filings and recordations and searches reasonably necessary in
connection with the perfection of a valid security interest in the Collateral of the Company and each of its Subsidiaries, and,
in the case of UCC filings, such filings shall be in proper form for filing.

 

(xiv) The
Collateral Agent shall have received the results of searches (including comparable searches in any jurisdiction outside the United
States) for any effective UCC financing statements, tax liens or judgment liens filed against the Company or any of its Subsidiaries
or any property of any of the foregoing, which results shall not show any such liens (other than Permitted Liens acceptable to
the Collateral Agent).

 

(xv) The
Collateral Agent shall have received the Security Agreement, duly executed by the Company and each of its Subsidiaries, together
with the original stock certificates representing all of the equity interests and all promissory notes required to be pledged thereunder,
accompanied by undated stock powers and allonges executed in blank and other proper instruments of transfer.

 

(xvi) The
Company shall have delivered to such Buyer such other documents relating to the transactions contemplated by this Agreement as
such Buyer or its counsel may reasonably request.

 

    -36-

     

    

 

8. TERMINATION.
In the event that the First Closing shall not have occurred with respect to a Buyer on or before five (5) Business Days from the
date hereof due to the Company’s or such Buyer’s failure to satisfy the conditions set forth in Sections 6 and 7 above
(and the nonbreaching party’s failure to waive such unsatisfied condition(s)), the nonbreaching party shall have the option
to terminate this Agreement with respect to such breaching party at the close of business on such date by delivering a written
notice to that effect to each other party to this Agreement and without liability of any party to any other party; provided,
however, that if this Agreement is terminated pursuant to this Section 8, the Company shall remain obligated to reimburse
the Lead Investor or its designee(s), as applicable, for the expenses described in Section 4(d) above.

 

9. MISCELLANEOUS.

 

(a) Governing
Law; Jurisdiction; Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict
of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is
improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY
RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH
OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. In addition to, but not in limitation of, any other
rights of a Buyer hereunder, if (a) this Agreement is placed in the hands of an attorney for collection of any indemnification
or other obligation hereunder then outstanding or enforcement or any such obligation is collected or enforced through any legal
proceeding or a Buyer otherwise takes action to collect amounts due under this Agreement or to enforce the provisions of this Agreement
or (b) there occurs any bankruptcy, reorganization, receivership of the Company or other proceedings affecting Company creditors’
rights and involving a claim under this Agreement, then the Company shall pay the costs incurred by such Buyer for such collection,
enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without
limitation, attorneys’ fees and disbursements.  The Company expressly acknowledges and agrees that no amounts due under
this Agreement shall be affected, or limited, by the fact that the Purchase Price paid for the Notes was less than the original
principal amount thereof.

 

    -37-

     

    

 

(b) Counterparts.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile
or .pdf signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect
as if the signature were an original, not a facsimile or .pdf signature.

 

(c) Headings.
The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this
Agreement.

 

(d) Severability.
If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or
unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(e) Entire
Agreement; Amendments. This Agreement and the other Transaction Documents supersede all other prior oral or written agreements
between the Buyers, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein,
and this Agreement, the other Transaction Documents and the instruments referenced herein and therein contain the entire understanding
of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein,
neither the Company nor any Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. Provisions
of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either
retroactively or prospectively), only with the written consent of the Company and the holders of at least a majority of the applicable
Securities and shall include the Required Holders; provided, however, that the provisions of Section 4(j) cannot
be amended without the additional prior written approval of the Collateral Agent or its successor. Any amendment or waiver effected
in accordance with this Section 9(e) shall be binding upon each Buyer and holders of the applicable Securities and the Company.
No such amendment shall be effective to the extent that it applies to less than all of the Buyers or holders of the applicable
Securities then outstanding. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification
of any provision of any of the Transaction Documents unless the same consideration (other than the reimbursement of legal fees)
also is offered to all of the parties to the Transaction Documents, holders of Notes or holders of the Warrants, as the case may
be. The Company has not, directly or indirectly, made any agreements with any Buyers relating to the terms or conditions of the
transactions contemplated by the Transaction Documents except as set forth in the Transaction Documents. Without limiting the foregoing,
the Company confirms that, except as set forth in this Agreement, no Buyer has made any commitment or promise or has any other
obligation to provide any financing to the Company or otherwise. As used herein, “Required Holders” means the
Lead Investor; provided, however, that, at any time after the First Closing when neither the Lead Investor nor any
of its affiliates holds any Securities, Required Holders shall mean holders of at least a majority of the principal amount of Notes
then outstanding.

 

    -38-

     

    

 

(f) Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement or any
of the other Transaction Documents must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered
personally; (ii) upon delivery, when sent by facsimile (provided confirmation of transmission is mechanically or electronically
generated and kept on file by the sending party) or by electronic mail; (iii) upon delivery, when sent by electronic mail (provided
that the sending party does not receive an automated rejection notice); or (iv) one (1) Business Day after deposit with an overnight
courier service, in each case properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail
addresses for such communications shall be:

 

If to the Company:

 

Quoin Pharmaceuticals, Inc.

42127 Pleasant Forest Ct

Ashburn, VA 20148

Telephone:  +972-9-9741444

Facsimile: +972-9-97678750

Attention: CEO

E-mail:  shai@cellect.co

 

With a copy to:

 

Dentons US LLP

1221 Avenue of the Americas

New York, NY 10020

Telephone:  (212) 768-6700

Attention: Jeffrey A. Baumel,
Esq.

E-mail:  Jeffrey.baumel@dentons.com

 

If to a Buyer, to its address, facsimile
number and e-mail address set forth on the Schedule of Buyers, with copies to such Buyer’s representatives as set forth on
the Schedule of Buyers,

 

With a copy (for informational purposes only) to:

 

Schulte Roth & Zabel LLP

919 Third Avenue

New York, New York 10022

Telephone: (212) 756-2000

Facsimile: (212) 593-5955

Attention: Eleazer N. Klein, Esq.

E-mail: eleazer.klein@srz.com

 

    -39-

     

    

 

or to such other address, facsimile number
and/or e-mail address and/or to the attention of such other Person as the recipient party has specified by written notice given
to each other party five (5) calendar days prior to the effectiveness of such change. Written confirmation of receipt (A) given
by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s
facsimile machine or e-mail containing the time, date, recipient facsimile number and an image of the first page of such transmission
or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt
from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(g) Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
assigns, including any purchasers of the Notes or the Warrants. The Company shall not assign this Agreement or any rights or obligations
hereunder without the prior written consent of the Required Holders, including by way of a Fundamental Transaction (unless the
Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Notes and Warrants).
A Buyer may assign some or all of its rights hereunder without the consent of the Company, in which event such assignee shall be
deemed to be a Buyer hereunder with respect to such assigned rights. For the avoidance of doubt, each Buyer may, without the consent
of the Company, assign some or all of its right of participation set forth in Section 4(k)(ii) to any other Person approved by
the Required Holders, in which event such assignee shall be deemed to be a Buyer hereunder with respect to such assigned rights,
and which assignment may occur (x) prior to receiving an Offer Notice or (y) after receiving an Offer Notice up to the date of
execution and delivery by the Company and the Buyers of a purchase agreement relating to the Offered Securities.

 

(h) No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except that
each Indemnitee (as defined below) shall have the right to enforce the obligations of the Company with respect to Section 9(k).

 

(i) Survival.
Unless this Agreement is terminated under Section 8, the representations and warranties of the Buyers and the Company contained
in Sections 2 and 3, and the agreements and covenants set forth in Sections 4, 5 and 9 shall survive the Closing. Each Buyer shall
be responsible only for its own representations, warranties, agreements and covenants hereunder.

 

(j) Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

    -40-

     

    

 

(k) Indemnification.

 

(i) In
consideration of each Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder
and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend, protect,
indemnify and hold harmless each Buyer and each other holder of the Securities and all of their stockholders, partners, members,
officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives
(including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively,
the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties,
fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to
the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the
“Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a)
any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or any other
certificate, instrument or document contemplated hereby or thereby (provided that for purposes of establishing a misrepresentation
or breach of a representation or warranty, such representation or warranty shall be read without giving effect to any materiality
or Material Adverse Effect qualifiers set forth therein), (b) any breach of any covenant, agreement or obligation of the Company
contained in the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby or (c) any
cause of action, suit or claim brought or made against such Indemnitee by a third party (including for these purposes a derivative
action brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance or enforcement
of the Transaction Documents or any other certificate, instrument or document contemplated hereby or thereby, (ii) any transaction
financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, or
(iii) the status of such Buyer or holder of the Securities as an investor in the Company pursuant to the transactions contemplated
by the Transaction Documents. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason,
the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is
permissible under applicable law.

 

(ii) Promptly
after receipt by an Indemnitee under this Section 9(k) of notice of the commencement of any action or proceeding (including any
governmental action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim for indemnification in
respect thereof is to be made against any indemnifying party under this Section 9(k), deliver to the indemnifying party a written
notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying
party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel
mutually satisfactory to the indemnifying party and the Indemnitee; provided, however, that an Indemnitee shall have
the right to retain its own counsel with the fees and expenses of not more than one counsel for such Indemnitee to be paid by the
indemnifying party, if, in the reasonable opinion of the Indemnitee, the representation by such counsel of the Indemnitee and the
indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnitee and any other
party represented by such counsel in such proceeding. Legal counsel referred to in the immediately preceding sentence shall be
selected by the Buyers holding at least a majority of the Securities issued and issuable hereunder. The Indemnitee shall cooperate
fully with the indemnifying party in connection with any negotiation or defense of any such action or Indemnified Liabilities by
the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnitee that
relates to such action or Indemnified Liabilities. The indemnifying party shall keep the Indemnitee fully apprised at all times
as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for
any settlement of any action, claim or proceeding effected without its prior written consent, provided, however,
that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without
the prior written consent of the Indemnitee, which consent shall not be unreasonably withheld conditioned or delayed, consent to
entry of any judgment or enter into any settlement or other compromise which (i) does not include as an unconditional term thereof
the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liabilities
or litigation, (ii) requires any admission of wrongdoing by such Indemnitee, or (iii) obligates or requires an Indemnitee
to take, or refrain from taking, any action. Following indemnification as provided for hereunder, the indemnifying party shall
be subrogated to all rights of the Indemnitee with respect to all third parties, firms or corporations relating to the matter for
which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of
the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnitee under this Section
9(k), except to the extent that the indemnifying party is prejudiced in its ability to defend such action.

 

    -41-

     

    

 

(iii) The
indemnification required by this Section 9(k) shall be made by periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills are received or Indemnified Liabilities are incurred.

 

(iv) The
indemnity agreements contained herein shall be in addition to (x) any cause of action or similar right of the Indemnitee against
the indemnifying party or others, and (y) any liabilities the indemnifying party may be subject to pursuant to the law.

 

(l) No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(m) Remedies.
Each Buyer and each holder of the Securities shall have all rights and remedies set forth in the Transaction Documents and all
rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights
which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to
enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any
provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Company recognizes that in the event
that it fails to perform, observe, or discharge any or all of its obligations under the Transaction Documents, any remedy at law
may prove to be inadequate relief to the Buyers. The Company therefore agrees that the Buyers shall be entitled to seek temporary
and permanent injunctive relief in any such case without the necessity of proving actual damages and without posting a bond or
other security.

 

(n) Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
the Transaction Documents, whenever any Buyer exercises a right, election, demand or option under a Transaction Document and the
Company does not timely perform its related obligations within the periods therein provided, then such Buyer may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or
in part without prejudice to its future actions and rights.

 

(o) Payment
Set Aside. To the extent that the Company makes a payment or payments to the Buyers hereunder or pursuant to any of the other
Transaction Documents or the Buyers enforce or exercise their rights hereunder or thereunder, and such payment or payments or the
proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential,
set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal law, common
law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended
to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement
or setoff had not occurred.

 

(p) Independent
Nature of Buyers’ Obligations and Rights. The obligations of each Buyer under any Transaction Document are several and
not joint with the obligations of any other Buyer, and no Buyer shall be responsible in any way for the performance of the obligations
of any other Buyer under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action
taken by any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and the Company acknowledges that the
Buyers do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Buyers are in any way acting in concert or as a group, and the Company shall not assert any such claim with respect to
such obligations or the transactions contemplated by the Transaction Documents and the Company acknowledges that the Buyers are
not acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.
The Company acknowledges and each Buyer confirms that it has independently participated in the negotiation of the transaction contemplated
hereby with the advice of its own counsel and advisors. Each Buyer shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this Agreement or out of any other Transaction Documents, and it shall
not be necessary for any other Buyer to be joined as an additional party in any proceeding for such purpose.

 

[Signature Pages Follow]

 

    -42-

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement to be duly executed
as of the date first written above.

 

	   	COMPANY: 
	 	 
	 	QUOIN PHARMACEUTICALS, INC.
	 	 	 
	 	By:	              
	 	 	Name:
	 	 	Title:

 

[Signature Page to Securities Purchase
Agreement]

 

     

     

    

 

IN WITNESS WHEREOF,
each Buyer and the Company have caused their respective signature page to this Securities Purchase Agreement to be duly executed
as of the date first written above.

 

	 	BUYERS:
	 	 
	 	ALTIUM GROWTH FUND, LP
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

	 	Maximum
    Percentage to be included in the Warrants:
	 	☒
    4.99%
	 	☐
    9.99%

 

[Signature Page to Securities Purchase
Agreement]

 

     

     

    

 

SCHEDULE OF BUYERS

 

	(1)	 	(2)	 	 	(3)		 	 	(4)		 	 	(5)		 	 	(6)		 	 	(7)		 	 	(8)		 	 	(9)		 	 	(10)		 	 	(11)		 	(9)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Buyer	 	Address and
 Facsimile Number	 	 	Aggregate
 Principal
 Amount of Notes at First Closing	 	 	 	Number
of Warrant Shares at First Closing	 	 	 	Aggregate

Principal
 Amount of Notes at Second Closing	 	 	 	Number of

 Warrant Shares at Second Closing	 	 	 	
Aggregate
 Principal
 Amount of Notes at Third Closing	 	 	 	 Number of Warrant Shares at Third Closing	 	 	 	First Purchase Price	 	 	 	Second Purchase Price	 	 	 	Third Purchase Price	 	 	Legal Representative’s Address and Facsimile Number
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Altium Growth Fund, LP	 	 c/o Altium Capital Management, LP 152 West 57th Street, 20th Floor New York, NY 10019 Attention: Joshua Thomas Telephone: 212-259-8404 E-mail: jthomas@altiumcap.com	 	$	2,000,000.00	 	 	 	41,230	 	 	$	1,666,666.67	 	 	 	34,359	 	 	$	1,333,333.34	 	 	 	27,487	 	 	$	1,500,000	 	 	$	1,250,000	 	 	$	1,000,000	 	 	Schulte Roth & Zabel LLP

    919 Third Avenue
 New York, New York 10022
 Attention: Eleazer Klein, Esq.
 Facsimile: (212) 593-5955
 Telephone:
    (212) 756-2376
 E-mail: eleazer.klein@srz.com
	TOTAL	 	 	 	$	2,000,000.00	 	 	 	41,230	 	 	$	1,666,666.67	 	 	 	34,359	 	 	$	1,333,333.34	 	 	 	27,487	 	 	$	1,500,000	 	 	$	1,250,000	 	 	$	1,000,000	 	 	 

 

     

     

    

 

EXHIBITS

 

Exhibit A Form of Notes

Exhibit B Form of Warrants

Exhibit C Form of Guarantee Agreement

Exhibit D Form of Security Agreement

Exhibit E Private Placement Memorandum

Exhibit F Form of Opinion of Company Outside Counsel

Exhibit G Form of Secretary’s Certificate

Exhibit H Form of Officer’s Certificate

 

SCHEDULES

 

Schedule 3(a) Subsidiaries

Schedule 3(b) Authorization; Enforcement; Validity

Schedule 3(d) No Conflicts

Schedule 3(e) Consents

Schedule 3(i) Private Placement Memorandum; Financial Statements

Schedule 3(j) Absence of Certain Changes

Schedule 3(m) Transactions with Affiliates

Schedule 3(n) Indebtedness and Other Contracts

Schedule 3(o) Absence of Litigation

Schedule 3(q) Employee Benefits

Schedule 3(s) Real Property

Schedule 3(t) Intellectual Property Rights

Schedule 3(y) Internal Accounting

Schedule 3(dd) FDA

Schedule 3(ww) Equity Capitalization

Schedule 4(c) Use of Proceeds

 

     

     

    

 

EXHIBIT A

 

Form of Notes

 

THE ISSUANCE AND SALE OF THE SECURITY
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER,
IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE
TO BE SOLD (X) PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT OR (Y) TO AN ACCREDITED INVESTOR IN A PRIVATE TRANSACTION. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE, INCLUDING SECTION 14(a)
HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION
4.

 

THIS NOTE HAS BEEN ISSUED WITH ORIGINAL
ISSUE DISCOUNT (“OID”). PURSUANT TO TREASURY REGULATION §1.1275-3(b)(1), THE CHIEF OPERATING OFFICER, A REPRESENTATIVE
OF THE COMPANY HEREOF WILL, BEGINNING TEN DAYS AFTER THE ISSUANCE DATE OF THIS NOTE, PROMPTLY MAKE AVAILABLE TO THE HOLDER UPON
REQUEST THE INFORMATION DESCRIBED IN TREASURY REGULATION §1.1275-3(b)(1)(i). THE CHIEF OPERATING OFFICER MAY BE REACHED AT
TELEPHONE NUMBER 610-662-4025.

 

Quoin
Pharmaceuticals, Inc.

 

SENIOR
SECURED NOTE

 

	
        Issuance Date: [•]1
	Original Principal Amount: U.S. $[•]

 

FOR VALUE RECEIVED,
Quoin Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby promises to pay to [BUYER] or registered
assigns (the “Holder”) in cash the amount set out above as the Original Principal Amount (as reduced pursuant
to the terms hereof pursuant to redemption or otherwise, the “Principal”) when due, whether upon the Maturity
Date (as defined below), prepayment, acceleration, redemption or otherwise (in each case in accordance with the terms hereof) and
to pay interest (“Interest”) on any outstanding Principal at the applicable Interest Rate (as defined below)
when the same becomes due and payable, whether upon the Maturity Date, prepayment, acceleration, redemption or otherwise (in each
case in accordance with the terms hereof). This Senior Secured Note (including all Senior Secured Notes issued in exchange, transfer
or replacement hereof, this “Note”) is one of an issue of Senior Secured Notes issued pursuant to the Bridge
Securities Purchase Agreement on one or more Closing Date(s) (collectively, the “Notes” and such other Senior
Secured Notes issued on a Closing Date (which, for the avoidance of doubt, may be a different Closing Date than the Closing Date
that occurred on the Issuance Date), the “Other Notes”). Certain capitalized terms used herein are defined in
Section 27.

 

 

1 Insert
date of applicable Closing Date.

 

    -2-

     

    

 

(1) ORIGINAL
ISSUE DISCOUNT; PAYMENTS OF PRINCIPAL. The Company acknowledges and agrees that this Note was issued at an original issue discount.
On the Maturity Date, the Company shall pay to the Holder an amount in cash representing 100% of the Outstanding Amount. The Holder
and the Company acknowledge and agree that if the Holder shall enter into the Primary Financing
SPA, the Holder may, at its election, offset the purchase price otherwise payable by the Holder to the Company pursuant to the
Primary Financing SPA, by an amount equal to the Outstanding Amount under this Note, and, upon such set-off, the portion of this
Note equal to the Outstanding Amount shall be deemed to have been paid in its entirety and all obligations hereunder shall be deemed
to be fully satisfied without any further obligations on, or liability to, the Company. If the Holder elects to offset the purchase
price under the Primary Financing SPA as contemplated in this Section 1, the purchase price payable by the Holder to the Company
pursuant to the Primary Financing SPA shall be reduced by the Outstanding Amount so deemed satisfied pursuant to this Section 1.

 

(2) PREPAYMENTS.

 

(a) Optional
Prepayment. The Company may prepay (each, an “Optional Prepayment”) the Note in whole or in part at any
time or from time to time without penalty or premium by paying the Outstanding Amount being prepaid at a price equal to 150% of
the Outstanding Amount being prepaid (the “Optional Prepayment Price”); provided, however, that
the aggregate Outstanding Amount under this Note and the Other Notes being prepaid in any Optional Prepayment pursuant to this
Section 2(a) (and analogous provisions under the Other Notes) shall be at least $250,000, or such lesser amount that then remains
outstanding under this Note and the Other Notes. The Company may exercise its right to prepay the Note under this Section 2(a)
by delivering a written notice thereof by electronic mail and overnight courier to the Holder and all, but not less than all, of
the holders of the Other Notes (an “Optional Prepayment Notice” and the date all of the holders of the Notes
received such notice is referred to as the “Optional Prepayment Notice Date”). Each Optional Prepayment Notice
shall be irrevocable. Each Optional Prepayment Notice shall (i) state the date on which the Optional Prepayment shall occur (the
“Optional Prepayment Date”), which date shall not be less than two (2) Business Days nor more than fifteen (15)
Business Days following such Optional Prepayment Notice Date and (ii) state the aggregate Outstanding Amount of the Notes which
the Company has elected to be subject to Optional Prepayment from the Holder and all of the other holders of the Other Notes pursuant
to this Section 2(a) (and analogous provisions under the Other Notes) on the Optional Prepayment Date.

 

    -3-

     

    

 

(b) Mandatory
Prepayments. At any time and from time to time after the Issuance Date, to the extent the Company or any of its Subsidiaries
consummates an Alternative Transaction (the date of the consummation of such Alternative Transaction, the “Mandatory Prepayment
Event Date”), the Company shall be required to redeem all, but not less than all, the Outstanding Amount then outstanding
under this Note and the Other Notes on the Mandatory Prepayment Date (as defined below) (the “Mandatory Prepayment”
and together with an “Optional Prepayment”, a “Prepayment”). The portion of this Note subject
to prepayment pursuant to this Section 2(b) shall be prepaid by the Company in cash at a price equal to 150% of the Outstanding
Amount being prepaid (the “Mandatory Prepayment Price” and together with an Optional Prepayment Price, a “Prepayment
Price”). The Company shall effect the Mandatory Prepayment under this Section 2(b) by delivering a written notice thereof
within no later than one (1) Business Day prior to the Mandatory Prepayment Event Date by electronic mail and overnight courier
to the Holder and all, but not less than all, of the holders of the Other Notes (the “Mandatory Prepayment Notice”).
The Mandatory Prepayment Notice shall be irrevocable. The Mandatory Prepayment Notice shall (x) state the date on which the Mandatory
Prepayment shall occur (the “Mandatory Prepayment Date” and together with an Optional Prepayment Date, a “Prepayment
Date”) which date shall not be more than two (2) Business Days following the Mandatory Prepayment Event Date and (y)
state the aggregate Outstanding Amount of the Notes which is being prepaid in such Mandatory Prepayment from the Holder pursuant
to this Section 2(b) and all of the holders of the Other Notes pursuant to analogous provisions under the Other Notes on the Mandatory
Prepayment Date.

 

(c) Pro
Rata Prepayment Requirement. If the Company elects to cause an Optional Prepayment of this Note pursuant to Section 2(a) or
is required to cause the Mandatory Prepayment pursuant to Section 2(b), then it must simultaneously take the same action with respect
to all of the Other Notes, and if any Optional Prepayment of this Note pursuant to this Section 2 is for a portion of this Note,
then, it must simultaneously take the same action in the same proportion with respect to all of the Other Notes on a pro rata basis
based on the principal amount of Notes then outstanding. Prepayments made pursuant to this Section 2 shall be made in accordance
with Section 7.

 

(d) Conflict.
In the event any transaction triggers a redemption pursuant to Section 2(b) and Section 2(c) as well as pursuant to Section 5,
unless the Holder otherwise elects by written notice to the Company, the provisions of this Section 2 shall govern such transaction.

 

(3) INTEREST.
Interest on this Note shall commence accruing on the Issuance Date at the Interest Rate and shall be computed on the basis of a
360-day year and twelve 30-day months and shall be payable in arrears on the Maturity Date. Interest shall be payable on the Maturity
Date or, if such date falls on a day that is not a Business day, the next day that is a Business Day, to the record holder of this
Note on the Maturity Date in cash by wire transfer of immediately available funds pursuant to wire instructions provided by the
Holder in writing to the Company. Prior to the payment of Interest on the Maturity Date, Interest on this Note shall accrue at
the Interest Rate and be payable by way of inclusion of the Interest in the Outstanding Amount on each Redemption Date. From and
after the occurrence and during the continuance of an Event of Default, the Interest Rate shall be increased to twenty five percent
(25.0%) per annum. In the event that such Event of Default is subsequently cured, the adjustment referred to in the preceding sentence
shall cease to be effective as of the date of such cure; provided, that the Interest as calculated and unpaid at such increased
rate during the continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence
of such Event of Default through and including the date of cure of such Event of Default; provided, further, that
for the purpose of this Section 3, such Event of Default shall not be deemed cured unless and until any accrued and unpaid Interest
shall be paid to the Holder, including, without limitation, Interest accrued at the increased rate of twenty five percent (25.0%)
per annum.

 

    -4-

     

    

 

(4) REGISTRATION;
BOOK-ENTRY. The Company shall maintain a register (the “Register”) for the recordation of the names and
addresses of the holders of each Note and the Principal amount of the Notes (and stated interest thereon) held by such holders
(the “Registered Notes”). The entries in the Register shall be conclusive and binding for all purposes absent
manifest error. The Company and the holders of the Notes shall treat each Person whose name is recorded in the Register as the
owner of a Note for all purposes, including, without limitation, the right to receive payments of Principal and Interest, if any,
hereunder, notwithstanding notice to the contrary. A Registered Note may be assigned or sold in whole or in part only by registration
of such assignment or sale on the Register. Upon its receipt of a request to assign or sell all or part of any Registered Note
by the Holder, the Company shall record the information contained therein in the Register and issue one or more new Registered
Notes in the same aggregate Principal amount as the Principal amount of the surrendered Registered Note to the designated assignee
or transferee pursuant to Section 13. Notwithstanding anything to the contrary in this Section 4, the Holder may assign any Note
or any portion thereof to an Affiliate of the Holder or a Related Fund of the Holder without delivering a request to assign or
sell the Note to the Company and the recordation of such assignment or sale in the Register (a “Related Party Assignment”);
provided, that (x) the Company may continue to deal solely with such assigning or selling Holder unless and until the Holder
has delivered a request to assign or sell the Note or portion thereof to the Company for recordation in the Register; (y) the failure
of such assigning or selling Holder to deliver a request to assign or sell the Note or portion thereof to the Company shall not
affect the legality, validity, or binding effect of such assignment or sale and (z) such assigning or selling Holder shall, acting
solely for this purpose as a non-fiduciary agent of the Company, maintain a register (the “Related Party Register”)
comparable to the Register on behalf of the Company, and any such assignment or sale shall be effective upon recordation of such
assignment or sale in the Related Party Register.

 

(5) RIGHTS
UPON EVENT OF DEFAULT.

 

(a) Event
of Default. Each of the following events shall constitute an “Event of Default” and each of the events described
in clauses (ii) and (iii) shall also constitute a “Bankruptcy Event of Default”:

 

(i) the
Company’s failure to pay to the Holder any amount of Principal, Interest, Late Charges (as defined in Section 20(b)) or other
amounts when and as due under this Note (including, without limitation, the Company’s failure to pay any redemption amounts
hereunder) or any other Transaction Document;

 

    -5-

     

    

 

(ii) the
Company or any of its Subsidiaries, pursuant to or within the meaning of Title 11, U.S. Code, or any similar Federal, foreign or
state law for the relief of debtors (collectively, “Bankruptcy Law”), (A) commences a voluntary bankruptcy case,
(B) consents to the entry of an order for relief against it in an involuntary bankruptcy case, (C) consents to the appointment
of a receiver, trustee, assignee, liquidator or similar official (a “Custodian”), (D) makes a general assignment
for the benefit of its creditors or (E) admits in writing that it is generally unable to pay its debts as they become due;

 

(iii) a
court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (A) is for relief against the Company or
any of its Subsidiaries in an involuntary case, (B) appoints a Custodian of the Company or any of its Subsidiaries or (C) orders
the liquidation of the Company or any of its Subsidiaries;

 

(iv) a
final judgment or judgments for the payment of money aggregating in excess of $100,000 are rendered against the Company or any
of its Subsidiaries and which judgments are not, within sixty (60) days after the entry thereof, bonded, discharged or stayed pending
appeal, or are not discharged within sixty (60) days after the expiration of such stay; provided, however, that any
judgment which is covered by insurance or an indemnity from a credit worthy party shall not be included in calculating the $100,000
amount set forth above so long as the Company provides the Holder a written statement from such insurer or indemnity provider (which
written statement shall be reasonably satisfactory to the Holder) to the effect that such judgment is covered by insurance or an
indemnity and the Company will receive the proceeds of such insurance or indemnity within thirty (30) days of the issuance of such
judgment;

 

(v) other
than as specifically set forth in another clause of this Section 5(a), the Company or any of its Subsidiaries breaches any representation,
warranty, covenant or other term or condition of any Transaction Document, except, in the case of a breach of a covenant or other
term or condition of any Transaction Document which is curable, only if such breach continues for a period of an aggregate of ten
(10) Business Days;

 

(vi) any
breach or failure in any respect to comply with (A) Section 11 of this Note and, if such breach or failure is capable of remedy,
it is not remedied within ten (10) Business days of such breach or failure or (B) Section 10 of this Note;

 

(vii) the
Company or any Subsidiary shall fail to perform or comply with any covenant or agreement contained in any Security Document to
which it is a party;

 

(viii) any
material provision of any Security Document (as determined in good faith by the Collateral Agent in its sole discretion) shall
at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against
the Company or any Subsidiary intended to be a party thereto, or the validity or enforceability thereof shall be contested by any
party thereto, or a proceeding shall be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction
over any of them, seeking to establish the invalidity or unenforceability thereof, or the Company or any Subsidiary shall deny
in writing that it has any liability or obligation purported to be created under any Security Document;

 

    -6-

     

    

 

(ix) any
Security Document, after delivery thereof pursuant hereto, shall for any reason fail or cease to create a valid and perfected and,
except to the extent permitted by the terms hereof or thereof, first priority Lien (as defined in Section 10(b)) in favor of the
Collateral Agent for the benefit of the holders of the Notes on any Collateral purported to be covered thereby, except to the extent
the Collateral Agent determines not to pursue perfection of any applicable Lien;

 

(x) any
bank at which any deposit account, blocked account, or lockbox account of the Company or any Subsidiary is maintained shall fail
to comply with any material term of any deposit account, blocked account, lockbox account or similar agreement to which such bank
is a party or any securities intermediary, commodity intermediary or other financial institution at any time in custody, control
or possession of any investment property of the Company or any Subsidiary shall fail to comply with any of the terms of any investment
property control agreement to which such Person is a party (it being understood that only accounts pursuant to which the Collateral
Agent has requested account control agreements should be subject to this clause (x));

 

(xi) any
material damage to, or loss, theft or destruction of the Collateral or a material amount of property of the Company, whether or
not insured, or any strike, lockout, labor dispute, embargo, condemnation, act of God or public enemy, or other casualty which
causes, for more than thirty (30) consecutive days, the cessation or substantial curtailment of revenue producing activities at
any facility of the Company or any Subsidiary, if, in each case, any such event or circumstance could reasonably be expected to
have a Material Adverse Effect;

 

(xii) any
default under, redemption of or acceleration prior to maturity of any Indebtedness of the Company or any of its Subsidiaries other
than with respect to this Note or any Other Notes;

 

(xiii) a
false or inaccurate certification by the Company as to whether any Event of Default has occurred;

 

(xiv) any
Material Adverse Effect occurs;

 

(xv) any
default by the Company of the Primary Financing SPA; or

 

(xvi) any
Event of Default (as defined in the Other Notes) occurs with respect to any Other Notes.

 

    -7-

     

    

 

(b) Redemption
Right. Upon the occurrence of an Event of Default with respect to this Note or any Other Note, the Company shall within one
(1) Business Day deliver written notice thereof via electronic mail and overnight courier (an “Event of Default Notice”)
to the Holder. At any time after the earlier of the Holder’s receipt of an Event of Default Notice and the Holder becoming
aware of an Event of Default, the Holder may until the termination of the applicable Event of Default Redemption Right Period require
the Company to redeem (an “Event of Default Redemption”) all or any portion of this Note by delivering written
notice thereof (the “Event of Default Redemption Notice”) to the Company, which Event of Default Redemption
Notice shall indicate the portion of this Note the Holder is electing to require the Company to redeem. Each portion of this Note
subject to redemption by the Company pursuant to this Section 5(b) shall be redeemed by the Company in cash by wire transfer of
immediately available funds at a price equal to 125% of the Outstanding Amount being redeemed (the “Event of Default Redemption
Price”). Redemptions required by this Section 5(b) shall be made in accordance with the provisions of Section 7. To the
extent redemptions required by this Section 5(b) are deemed or determined by a court of competent jurisdiction to be prepayments
of the Note by the Company, such redemptions shall be deemed to be voluntary prepayments. The parties hereto agree that in the
event of the Company’s redemption of any portion of the Note under this Section 5(b), the Holder’s damages would be
uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty
of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any Event of Default redemption
premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s
actual loss of its investment opportunity and not as a penalty.

 

(c) Mandatory
Redemption upon Bankruptcy Event of Default. Notwithstanding anything to the contrary herein, upon any Bankruptcy Event of
Default, whether occurring prior to or following the Maturity Date, the Company shall immediately pay to the Holder an amount in
cash equal to the Event of Default Redemption Price, in addition to any and all other amounts due hereunder, without the requirement
for any notice or demand or other action by the Holder or any other Person, provided that the Holder may, in its sole discretion,
waive such right to receive payment upon a Bankruptcy Event of Default, in whole or in part, and any such waiver shall not affect
any other rights of the Holder hereunder, including any other rights in respect of such Bankruptcy Event of Default, and any right
to payment of the Event of Default Redemption Price or any other Redemption Price, as applicable.

 

(6) NONCIRCUMVENTION.
The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation or Bylaws or
through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Note, and will
at all times in good faith carry out all of the provisions of this Note and take all action as may be required to protect the rights
of the Holder of this Note.

 

(7) REDEMPTIONS.

 

(a) The
Company shall deliver the applicable Event of Default Redemption Price to the Holder within three (3) Business Days after the Company’s
receipt of the Holder’s Event of Default Redemption Notice (the “Event of Default Redemption Date”). The
Company shall deliver or shall cause to be delivered to the Holder the applicable Prepayment Price on the applicable Prepayment
Date. The Company shall pay the applicable Redemption Price to the Holder in cash by wire transfer of immediately available funds
pursuant to wire instructions provided by the Holder in writing to the Company on the applicable due date. In the event of a redemption
of less than all of the Outstanding Amount of this Note, the Company shall promptly cause to be issued and delivered to the Holder
a new Note (in accordance with Section 14(d)) representing the outstanding Principal which has not been redeemed and
any accrued Interest on such Principal which shall be calculated as if no Redemption Notice has been delivered. In the event
that the Company does not pay the applicable Redemption Price to the Holder within the time period required, at any time thereafter
and until the Company pays such unpaid Redemption Price in full, the Holder shall have the option, in lieu of redemption, to require
the Company to promptly return to the Holder all or any portion of this Note representing the Outstanding Amount that was submitted
for redemption and for which the applicable Redemption Price (together with any Late Charges thereon) has not been paid. Upon the
Company’s receipt of such notice, (x) the applicable Redemption Notice shall be null and void with respect to such Outstanding
Amount and (y) the Company shall immediately return this Note, or issue a new Note (in accordance with Section 14(d)) to the Holder
representing such Outstanding Amount to be redeemed. The Holder’s delivery of a notice voiding a Redemption Notice and exercise
of its rights following such notice shall not affect the Company’s obligations to make any payments of Late Charges which
have accrued prior to the date of such notice with respect to the Outstanding Amount subject to such notice.

 

    -8-

     

    

 

(b) Redemption
by Other Holders. Upon the Company’s receipt of notice from any of the holders of the Other Notes for redemption or repayment
as a result of an event or occurrence substantially similar to the events or occurrences described in Section 5(b) or pursuant
to equivalent provisions set forth in the Other Notes (each, an “Other Redemption Notice”), the Company shall
immediately, but no later than one (1) Business Day of its receipt thereof, forward to the Holder by electronic mail a copy of
such notice. If the Company receives a Redemption Notice and one or more Other Redemption Notices, during the five (5) Business
Day period beginning on and including the date which is two (2) Business Days prior to the Company’s receipt of the Holder’s
Redemption Notice and ending on and including the date which is two (2) Business Days after the Company’s receipt of the
Holder’s Redemption Notice and the Company is unable to redeem all Principal, Interest and other amounts designated in such
Redemption Notice and such Other Redemption Notices received during such five (5) Business Day period, then the Company shall redeem
a pro rata amount from the Holder and each holder of the Other Notes (including the Holder) based on the Principal amount of the
Notes submitted for redemption pursuant to such Redemption Notice and such Other Redemption Notices received by the Company during
such five (5) Business Day period.

 

(c) Insufficient
Assets. If upon a Redemption Date, the assets of the Company are insufficient to pay the applicable Redemption Price, the Company
shall (i) take all appropriate action reasonably within its means to maximize the assets available for paying the applicable Redemption
Price, (ii) redeem out of all such assets available therefor on the applicable Redemption Date the maximum possible Outstanding
Amount that it can redeem on such date, pro rata among the Holder and the holders of the Other Notes to be redeemed in proportion
to the aggregate Principal amount of this Note and the Other Notes outstanding on the applicable Redemption Date and (iii) following
the applicable Redemption Date, at any time and from time to time when additional assets of the Company become available to redeem
the remaining Outstanding Amounts of this Note and the Other Notes, the Company shall use such assets, at the end of the then current
calendar month, to redeem the balance of such Outstanding Amount of this Note and the Other Notes, or such portion thereof for
which assets are then available, on the basis set forth above at the applicable Redemption Price, and such assets will not be used
prior to the end of such calendar month for any other purpose. Interest on the Principal
amount of this Note and the Other Notes that have not been redeemed shall continue to accrue until such time as the Company redeems
this Note and the Other Notes. The Company shall pay to the Holder the applicable Redemption Price without regard to the
legal availability of funds unless expressly prohibited by applicable law or unless the payment of the applicable Redemption Price
could reasonably be expected to result in personal liability to the directors of the Company.

 

(8) SECURITY.
This Note and the Other Notes are secured to the extent and in the manner set forth in the Security Documents.

 

    -9-

     

    

 

(9) RANK.
All payments due under this Note shall rank pari passu with all Other Notes and all other Indebtedness of the Company and
its Subsidiaries.

 

(10) NEGATIVE
COVENANTS. Until all of the Notes have been redeemed or otherwise satisfied in accordance with their terms, the Company shall
not, and the Company shall not permit any of its Subsidiaries without the prior written consent of the Required Holders to, directly
or indirectly:

 

(a) incur
or guarantee, assume or suffer to exist any Indebtedness, other than Permitted Indebtedness;

 

(b) allow
or suffer to exist any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets
(including accounts and contract rights) owned by the Company or any of its Subsidiaries (collectively, “Liens”)
other than Permitted Liens;

 

(c) redeem,
defease, repurchase, repay or make any payments in respect of, by the payment of cash or Cash Equivalents (in whole or in part,
whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any Indebtedness
(other than this Note and the Other Notes) of the Company or any other Person, whether by way of payment in respect of Principal
of (or premium, if any) or interest on, such Indebtedness if at the time such payment is due or is otherwise made or, after giving
effect to such payment, an event constituting, or an event or condition that upon notice, lapse of time or both would constitute
an Event of Default, has occurred and is continuing;

 

(d) redeem,
defease, repurchase, repay or make any payments in respect of, by the payment of cash or Cash Equivalents (in whole or in part,
whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any Indebtedness
(including, without limitation Permitted Indebtedness other than this Note and the Other Notes), by way of payment in respect of
principal of (or premium, if any) such Indebtedness. For clarity, such restriction shall not preclude the payment of regularly
scheduled interest payments which may accrue under such Permitted Indebtedness;

 

(e) redeem
or repurchase its Equity Interests;

 

    -10-

     

    

 

(f) declare
or pay any cash dividend or distribution on any Equity Interest of the Company or of its Subsidiaries;

 

(g) make,
or permit any of its Subsidiaries to make, any change in the nature of its business as conducted on the Subscription Date or modify
its corporate structure or purpose in a manner or to an extent that could reasonably be expected to cause a Material Adverse Effect;

 

(h) encumber
or allow any Liens on, any of its own or its licensed Intellectual Property Rights, and any claims for damage by way of any past,
present, or future infringement of the foregoing, other than Permitted Liens;

 

(i) enter
into, renew, extend or be a party to, any transaction or series of related transactions (including, without limitation, the purchase,
sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate,
except in the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable
for the prudent operation of its business, for fair consideration and on terms no less favorable to it or its Subsidiaries than
would be obtainable in a comparable arm’s length transaction with a Person that is not an Affiliate thereof;

 

(j) amend,
repeal, restate, supplement or otherwise modify its or any Subsidiary’s Organizational Documents in
a manner or to an extent that could reasonably be expected to adversely affect the Holder’s interest under the Transaction
Documents or that could reasonably be expected to cause a Material Adverse Effect;

 

(k) make
or commit any Investment in any other Person, except for Permitted Investments; provided, however, that in no event
shall the Company be permitted to make or commit any Investment in any Subsidiary;

 

(l) effect
any Asset Sale other than: (i) sales of inventory to customers in the ordinary course of business, (ii) dispositions of obsolete
or worn-out equipment no longer used in the business or (iii) the use or transfer of cash in the ordinary course of business;

 

(m) issue
any Notes (other than as contemplated by the Bridge Securities Purchase Agreement) or (ii) issue any other securities that would
cause a breach or default under the Notes;

 

(n) form
any Subsidiary;

 

(o) authorize
or effect any (i) Fundamental Transaction, or (ii) Liquidation Event; or

 

(p) other
than as contemplated by the Merger Agreement or the Primary Financing SPA, enter into any agreement to do any of the foregoing.

 

    -11-

     

    

 

(11) AFFIRMATIVE
COVENANTS. Until all of the Notes have been redeemed or otherwise satisfied in accordance with
their terms, the Company shall, and the Company shall cause each Subsidiary to, directly or indirectly:

 

(a) maintain
and preserve, and cause each of its Subsidiaries to maintain and preserve, its existence, rights and privileges, and become or
remain, and cause each of its Subsidiaries to become or remain, duly qualified and
in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction
of its business makes such qualification necessary, except, in each case, where a failure to do so could not reasonably be expected
to have a Material Adverse Effect;

 

(b) maintain
and preserve, and cause each of its Subsidiaries to maintain and preserve, all of
its properties which are necessary or useful in the proper conduct of its business in good working order and condition, ordinary
wear and tear excepted, and comply, and cause each of its Subsidiaries to comply, at all times with the provisions of all leases
to which it is a party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder,
except, in each case, where a failure to do so could not reasonably be expected to have a Material Adverse Effect;

 

(c) maintain
all of the Intellectual Property Rights of the Company and/or any of its Subsidiaries that are necessary or material to the conduct
of its business in full force and effect; and

 

(d) maintain,
and cause each of its Subsidiaries to maintain, insurance with responsible and reputable insurance companies or associations (including,
without limitation, comprehensive general liability, hazard, rent and business interruption insurance) with respect to its properties
(including all real properties leased or owned by it) and business, in such amounts and covering such risks as is required by any
governmental authority having jurisdiction with respect thereto or as is carried generally in accordance with sound business practice
by companies in similar businesses similarly situated.

 

(12) CHANGING
THE TERMS OF THIS NOTE. The affirmative vote at a meeting duly called for such purpose or the written consent without a meeting
of the Required Holders shall be required for any change or amendment or waiver of any provision to this Note or any of the Other
Notes. Any change, amendment or waiver by the Company and the Required Holders shall be binding on the Holder of this Note and
all holders of the Other Notes.

 

(13) TRANSFER.
This Note may be offered, sold, assigned or transferred by the Holder without the consent of the Company, subject only to the provisions
of Section 2(f) of the Bridge Securities Purchase Agreement.

 

(14) REISSUANCE
OF THIS NOTE.

 

(a) Transfer.
If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company will forthwith issue
and deliver upon the order of the Holder a new Note (in accordance with Section 14(d) and subject to Section 4), registered as
the Holder may request, representing the outstanding Principal being transferred by the Holder and, if less than the entire outstanding
Principal is being transferred, a new Note (in accordance with Section 14(d)) to the Holder representing the outstanding Principal
not being transferred. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provision
of Section 4, following redemption of any portion of this Note, the outstanding Principal represented by this Note may be less
than the Principal stated on the face of this Note.

 

    -12-

     

    

 

(b) Lost,
Stolen or Mutilated Note. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Note, and, in the case of loss, theft or destruction, of any indemnification undertaking by the
Holder to the Company in customary form (but without any obligation to post a surety or other bond) and, in the case of mutilation,
upon surrender and cancellation of this Note, the Company shall execute and deliver to the Holder a new Note (in accordance with
Section 14(d)) representing the outstanding Principal.

 

(c) Note
Exchangeable for Different Denominations. This Note is exchangeable, upon the surrender hereof by the Holder at the principal
office of the Company, for a new Note or Notes (in accordance with Section 14(d)) representing in the aggregate the outstanding
Principal of this Note, and each such new Note will represent such portion of such outstanding Principal as is designated by the
Holder at the time of such surrender.

 

(d) Issuance
of New Notes. Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such new Note (i) shall
be of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Principal remaining outstanding
(or in the case of a new Note being issued pursuant to Section 14(a) or Section 14(c), the Principal designated by the Holder which,
when added to the Principal represented by the other new Notes issued in connection with such issuance, does not exceed the Principal
remaining outstanding under this Note immediately prior to such issuance of new Notes), (iii) shall have an issuance date, as indicated
on the face of such new Note, which is the same as the Issuance Date of this Note, (iv) shall have the same rights and conditions
as this Note and (v) shall represent accrued and unpaid Interest and Late Charges, if any,
on the Principal and Interest of this Note from the Issuance Date.

 

(15) REMEDIES,
CHARACTERIZATIONS, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Note shall be cumulative
and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity
(including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder’s
right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company
covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein.
Amounts set forth or provided for herein with respect to payments, redemption and the like (and the computation thereof) shall
be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation
of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause
irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that,
in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies,
to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security
being required.

 

    -13-

     

    

 

(16) PAYMENT
OF COLLECTION, ENFORCEMENT AND OTHER COSTS. If (a) this Note is placed in the hands of an attorney for collection or enforcement
or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under this
Note or to enforce the provisions of this Note or (b) there occurs any bankruptcy, reorganization, receivership of the Company
or other proceedings affecting Company creditors’ rights and involving a claim under this Note, then the Company shall pay
the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization,
receivership or other proceeding, including, but not limited to, attorneys’ fees and disbursements. The Company expressly
acknowledges and agrees that no amounts due under this Note shall be affected, or limited, by the fact that the purchase price
paid for this Note was less than the original Principal amount hereof.

 

(17) CONSTRUCTION;
HEADINGS. This Note shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be construed against
any person as the drafter hereof. The headings of this Note are for convenience of reference and shall not form part of, or affect
the interpretation of, this Note.

 

(18) FAILURE
OR INDULGENCE NOT WAIVER. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other
or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and
signed by an authorized representative of the waiving party.

 

(19) DISPUTE
RESOLUTION. In the case of a dispute as to the determination of any Redemption Price, the Company shall submit the disputed
determinations or arithmetic calculations via electronic mail within one (1) Business Day of receipt, or deemed receipt, of the
Redemption Notice or other event giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company
are unable to agree upon such determination or calculation within two (2) Business Days of such disputed determination or arithmetic
calculation being submitted to the Holder, then the Company shall, within one (1) Business Day submit via electronic mail the disputed
arithmetic calculation of the Redemption Price to an independent, outside accountant, selected by the Holder and approved by the
Company, such approval not to be unreasonably withheld, delayed or conditioned. The Company, at the Company’s expense, shall
cause the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company
and the Holder of the results no later than five (5) Business Days from the time it receives the disputed determinations or calculations.
Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all
parties absent demonstrable error.

 

(20) NOTICES;
PAYMENTS.

 

(a) Notices.
Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance
with Section 9(f) of the Bridge Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice
of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason therefore.
Without limiting the generality of the foregoing, the Company will give written notice to the Holder at least twenty (20) days
prior to the date on which the Company closes its books or takes a record for determining rights to vote with respect to any Fundamental
Transaction or Liquidation Event, provided in each case that such information shall be made known to the public prior to or in
conjunction with such notice being provided to the Holder.

 

    -14-

     

    

 

(b) Payments.
Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, such payment shall be made via wire
transfer of immediately available funds by providing the Company with prior written notice setting out the Holder’s wire
transfer instructions; provided that the Holder may with prior written notice setting out such request elect to receive a payment
of cash in lawful money of the United States of America by a check drawn on the account of the Company and sent via overnight courier
service to such Person at such address as previously provided to the Company in writing (which address, in the case of each Buyer,
shall initially be as set forth on the Schedule of Buyers attached to the Bridge Securities Purchase Agreement). Whenever any amount
expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the
next succeeding day which is a Business Day. Any amount of Principal or other amounts due hereunder or pursuant to any other Transaction
Document which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal
to additional interest on such amount at the rate of eighteen percent (18.0%) per annum from the calendar day immediately following
the date such amount was due until the same is paid in full (collectively, the “Late Charges”).

 

(21) CANCELLATION.
After all Principal, accrued Interest and other amounts at any time owed on this Note have been paid in full, this Note shall automatically
be deemed canceled, shall be surrendered to the Company for cancellation and shall not be reissued.

 

(22) WAIVER
OF NOTICE. To the extent permitted by law, the Company hereby waives demand, notice, protest and all other demands and notices
in connection with the delivery, acceptance, performance, default or enforcement of this Note and the Bridge Securities Purchase
Agreement.

 

(23) GOVERNING
LAW; JURISDICTION; JURY TRIAL. This Note shall be construed and enforced in accordance with, and all questions concerning the
construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New
York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any
other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough
of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient
forum or that the venue of such suit, action or proceeding is improper. The Company hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party
at the address set forth in Section 9(f) of the Bridge Securities Purchase Agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from
bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations
to the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court
ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A
JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED
HEREBY.

 

    -15-

     

    

 

(24) Severability.
If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material
change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability
of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties
or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good
faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which
comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(25) DISCLOSURE.
From and after the Public Company Date, upon receipt or delivery by the Company of any notice in accordance with the terms of this
Note, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, nonpublic
information relating to the Company or its Subsidiaries, the Company shall contemporaneously with any such receipt or delivery
publicly disclose such material, nonpublic information on a Current Report on Form 8-K, press release or otherwise. In the event
that the Company believes that a notice contains material, nonpublic information relating to the Company or its Subsidiaries, the
Company so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication,
the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, nonpublic information
relating to the Company or its Subsidiaries.

 

(26) USURY.
This Note is subject to the express condition that at no time shall the Company be obligated or required to pay interest hereunder
at a rate or in an amount which could subject the Holder to either civil or criminal liability as a result of being in excess of
the maximum interest rate or amount which the Company is permitted by applicable law to contract or agree to pay. If by the terms
of this Note, the Company is at any time required or obligated to pay interest hereunder, including by way of an original issue
discount, at a rate or in an amount in excess of such maximum rate or amount, the rate or amount of interest under this Note shall
be deemed to be immediately reduced to such maximum rate or amount and the interest payable shall be computed at such maximum rate
or be in such maximum amount and all prior interest payments in excess of such maximum rate or amount shall be applied and shall
be deemed to have been payments in reduction of the principal balance of this Note.

 

    -16-

     

    

 

(27) CERTAIN
DEFINITIONS. For purposes of this Note, the following terms shall have the following meanings:

 

(a) “1934
Act” means the Securities Exchange Act of 1934, as amended.

 

(b) “Affiliate”
has the meaning ascribed to such term in Rule 405 promulgated under the Securities Act of 1933, as amended.

 

(c) “Alternative
Transaction” means any capital raising transaction other than the transactions contemplated by the Primary Financing
SPA.

 

(d) “APOP”
means Cellect Biotechnology Ltd., an Israeli company limited by shares.

 

(e) “APOP
Ordinary Shares” means (i) APOP’s ordinary shares, no par value, and (ii) any share capital into which such
ordinary shares shall have been changed or any share capital resulting from a reorganization, recapitalization or reclassification
of such ordinary shares, including, without limitation, as a result of the transactions contemplated by the Merger Agreement.

 

(f) “Asset
Sale” means any Disposition of any business, property, Intellectual Property Rights or other assets of the Company or
any of its Subsidiaries, whether now owned or hereafter acquired (or entering into an agreement to do any of the foregoing).

 

(g) “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to
be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential
employee” or any other similar orders or restrictions or the closure of any physical branch locations at the direction of
any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks
in The City of New York, New York generally are open for use by customers on such day.

 

(h) “Buyer”
means each of the initial holders of Notes party to the Bridge Securities Purchase Agreement.

 

(i) “Cash
Equivalents” means (a) marketable direct obligations issued or unconditionally guaranteed by the United States Government
or issued by any agency thereof and backed by the full faith and credit of the United States, in each case, maturing within six
months from the date of acquisition thereof, (b) commercial paper, maturing not more than 270 days after the date of issue rated
P-1 by Moody’s or A-1 by Standard & Poor’s, (c) certificates of deposit maturing not more than 270 days after the
date of issue, issued by commercial banking institutions and money market or demand deposit accounts maintained at commercial banking
institutions, each of which is a member of the Federal Reserve System and has a combined capital and surplus and undivided profits
of not less than $500,000,000 and a Thomson Bank Watch Rating of “BBB” or better, (d) money market accounts maintained
with mutual funds having assets in excess of $2,500,000,000, and (e) marketable tax exempt securities rated A or higher by Moody’s
or A+ or higher by Standard & Poor’s, in each case, maturing within six months from the date of acquisition thereof.

 

    -17-

     

    

 

(j) “Closing
Date” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(k) “Collateral”
shall have the meaning ascribed to such term in the Security Documents.

 

(l) “Collateral
Agent” shall have the meaning ascribed to such term in the Security Documents.

 

(m) “Company
Common Stock” means the Company’s common stock, par value $0.01 per share.

 

(n) “Contingent
Obligation” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect
to any Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring
such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will
be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will
be protected (in whole or in part) against loss with respect thereto.

 

(o) “Disposition”
means any transaction, or series of related transactions, pursuant to which any Person or any of its Subsidiaries sells, assigns,
transfers, leases, exclusively and non-exclusively licenses (as licensor) or otherwise disposes of any property, Intellectual Property
Rights or other assets (whether now owned or hereafter acquired) to any other Person, in each case, whether or not the consideration
therefor consists of cash, Cash Equivalents, securities or other assets owned by the acquiring Person.

 

(p) “Equity
Interests” means (i) all shares of capital stock (whether denominated as common capital stock or preferred capital stock),
equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or
profit interests in or equivalents (regardless of how designated) of or in a Person (other than an individual), whether voting
or non-voting and (ii) all securities convertible into or exchangeable for any of the foregoing and all warrants, options or other
rights to purchase, subscribe for or otherwise acquire any of the foregoing, whether or not presently convertible, exchangeable
or exercisable.

 

(q) “Event
of Default Redemption Right Period” means, with respect to any Event of Default, the period starting upon the occurrence
of such Event of Default and ending on the twentieth (20th) Trading Day, inclusive, following any cure of such Event
of Default. For the avoidance of doubt, the Event of Default Redemption Right Period with respect to an Event of Default shall
continue indefinitely if such Event of Default is not curable or is not cured.

 

    -18-

     

    

 

(r) “Fundamental
Transaction” means (i) that the Company shall, directly or indirectly, including through Subsidiaries, Affiliates or
otherwise, in one or more related transactions, (a) consolidate or merge with or into (whether or not the Company is the surviving
corporation) another Subject Entity, or (b) sell, assign, transfer, convey or otherwise dispose of all or substantially all of
the properties or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation
S-X) to one or more Subject Entities, or (c) make, or allow one or more Subject Entities to make, or allow the Company to be subject
to or have its Company Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange
offer that is accepted by the holders of at least either (1) 50% of the outstanding shares of Company Common Stock, (2) 50% of
the outstanding shares of Company Common Stock calculated as if any shares of Company Common Stock held by all Subject Entities
making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not
outstanding; or (3) such number of shares of Company Common Stock such that all Subject Entities making or party to, or Affiliated
with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners
(as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Company Common Stock, or (d) consummate
a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with one or more Subject Entities whereby such Subject Entities, individually or in the aggregate, acquire,
either (1) at least 50% of the outstanding shares of Company Common Stock, (2) at least 50% of the outstanding shares of Company
Common Stock calculated as if any shares of Company Common Stock held by all the Subject Entities making or party to, or Affiliated
with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or
(3) such number of shares of Company Common Stock such that the Subject Entities become collectively the beneficial owners (as
defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding shares of Company Common Stock, or (e) reorganize,
recapitalize or reclassify its shares of Company Common Stock, (ii) that the Company shall, directly or indirectly, including through
Subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject
Entities in the aggregate to be or become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act),
directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction
in outstanding shares of Company Common Stock, merger, consolidation, business combination, reorganization, recapitalization, spin-off,
scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (a)
at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Company Common Stock, (b) at
least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Company Common Stock not held
by all such Subject Entities as of the Subscription Date calculated as if any shares of Company Common Stock held by all such Subject
Entities were not outstanding, or (c) a percentage of the aggregate ordinary voting power represented by issued and outstanding
shares of Company Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a
statutory short form merger or other transaction requiring other stockholders of the Company to surrender their shares of Company
Common Stock without approval of the stockholders of the Company or (iii) directly or indirectly, including through Subsidiaries,
Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction
structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary
to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment
of such instrument or transaction. For the avoidance of doubt, the transactions contemplated by the Primary Financing SPA shall
constitute a Fundamental Transaction.

 

    -19-

     

    

 

(s) “GAAP”
means United States generally accepted accounting principles, consistently applied for the periods covered thereby.

 

(t) “Group”
means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.

 

(u) “Indebtedness”
of any Person means, without duplication (i) all indebtedness for borrowed money, (ii) all obligations issued, undertaken or assumed
as the deferred purchase price of property or services, including (without limitation) “finance leases” in accordance
with GAAP (other than trade payables entered into in the ordinary course of business consistent with past practice), (iii) all
reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (iv) all obligations
evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the
acquisition of property, assets or businesses, (v) all indebtedness created or arising under any conditional sale or other title
retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds
of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are
limited to repossession or sale of such property), (vi) all monetary obligations under any leasing or similar arrangement which,
in connection with GAAP is classified as a finance lease, (vii) all indebtedness referred to in clauses (i) through (vi) above
secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any
mortgage, deed of trust, lien, pledge, charge, security interest or other encumbrance of any nature whatsoever upon or in any property
or assets (including accounts and contract rights) with respect to any asset or property owned by any Person, even though the Person
which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (viii) all Contingent
Obligations in respect of indebtedness or obligations of others of the kinds referred to in clauses (i) through (vii) above.

 

(v) “Intellectual
Property Rights” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(w) “Interest
Rate” means 15.0% per annum, subject to adjustment as set forth in Section 3.

 

(x) “Investment”
means, with respect to any Person, (a) any investment by such Person in any other Person (including Affiliates) in the form of
loans, guarantees, advances or other extensions of credit (excluding accounts receivable arising in the ordinary course of business),
capital contributions or acquisitions of Indebtedness (including, any bonds, notes, debentures or other debt securities), Equity
Interests, or all or substantially all of the assets of such other Person (or of any division or business line of such other Person),
(b) the purchase or ownership of any futures contract or liability for the purchase or sale of currency or other commodities at
a future date in the nature of a futures contract, or (c) any investment in any other items that are or would be classified as
investments on a balance sheet of such Person prepared in accordance with GAAP.

 

    -20-

     

    

 

(y) “Lead
Investor” means Altium Growth Fund, LP.

 

(z) “Liquidation
Event” means the voluntary or involuntary liquidation, dissolution or winding up of the Company or such Subsidiaries
the assets of which constitute all or substantially all of the assets of the business of the Company and its Subsidiaries taken
as a whole, in a single transaction or series of transactions, or adoption of any plan for the same.

 

(aa) “Material
Adverse Effect” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(bb) “Maturity
Date” means the earliest to occur of: (i) [•]2,
(ii) the Public Company Date and (iii) the time immediately prior to the consummation of the transactions contemplated by the Primary
Financing SPA.

 

(cc) “Merger
Agreement” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(dd) “Organization
Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws (or
equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction); (b) with respect to any limited liability
company, the certificate or articles of formation or organization and operating agreement; (c) with respect to any partnership,
joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation
or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or
organization with the applicable governmental authority in the jurisdiction of its formation or organization and, if applicable,
any certificate or articles of formation or organization of such entity, and (d) in each case, all shareholder or other equity
holder agreements, voting trusts and similar arrangements to which such Person is a party or which is applicable to its Equity
Interests and all other arrangements relating to the control or management of such Person.

 

(ee) “Outstanding
Amount” means (i) the portion of the Principal to be prepaid or redeemed or otherwise with respect to which this determination
is being made, (ii) all accrued and unpaid Interest with respect to such portion of the Principal and (iii) accrued and unpaid
Late Charges with respect to such portion of such Principal and such Interest, if any.

 

 

2 Insert date that is nine (9) months
immediately following the first Closing Date occurring under the Bridge Securities Purchase Agreement.

 

    -21-

     

    

 

(ff) “Permitted
Indebtedness” means (i) Indebtedness evidenced by this Note and the Other Notes, (ii) trade payables incurred in the
ordinary course of business consistent with past practice in an amount not to exceed $250,000 in the aggregate, (iii) existing
Indebtedness, as set forth on Schedule 3(n) of the Bridge Securities Purchase Agreement, provided, that such Indebtedness
is not increased, refinanced, amended, changed or modified on or after the Subscription Date and (iv) Indebtedness not to exceed
$1,000,000 in the aggregate pursuant to that certain Exclusive License Agreement, dated as of October 17, 2019, by and between
the Company and Skinvisible Inc. (“Skinvisible”), pursuant to which Skinvisible granted to the Company a license
to use certain patented technology for (x) the development of products for commercial sale in the orphan rare skin disease field
and (y) the use of a proprietary polymer deliver system technology.

 

(gg) “Permitted
Investments” means (i) Investments in cash and Cash Equivalents, (ii) advances made in connection with purchases of goods
or services in the ordinary course of business consistent with past practice, (iii) Investments existing on the Closing Date and
disclosed in writing to the Holder, provided, that such Investments are not increased, refinanced, amended, changed or modified
on or after the Subscription Date and (iv) Investments consisting of accounts receivable of, or prepaid royalties and other credit
extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business

 

(hh) “Permitted
Liens” means (i) any Lien for taxes not yet due or delinquent or being contested in good faith by appropriate proceedings
for which adequate reserves have been established in accordance with GAAP, (ii) any statutory Lien arising in the ordinary course
of business by operation of law with respect to a liability that is not yet due or delinquent, (iii) any Lien created by operation
of law, such as materialmen’s liens, mechanics’ liens and other similar liens, arising in the ordinary course of business
with respect to a liability that is not yet due or delinquent or that are being contested in good faith by appropriate proceedings,
(iv) Liens (A) upon or in any equipment acquired or held by the Company or any of its Subsidiaries to secure the purchase price
of such equipment or Indebtedness incurred solely for the purpose of financing the acquisition or lease of such equipment, or (B)
existing on such equipment at the time of its acquisition, provided that the Lien is confined solely to the equipment so acquired
and improvements thereon, and the proceeds of such equipment, (v) Liens incurred in connection with the extension, renewal or refinancing
of the Indebtedness secured by Liens of the type described in clause (iv) above, provided that any extension, renewal or replacement
Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended,
renewed or refinanced does not increase, (vi) leases or subleases and licenses and sublicenses granted to others in the ordinary
course of the Company’s business, not interfering in any material respect with the business of the Company and its Subsidiaries
taken as a whole, (vii) Liens in favor of customs and revenue authorities arising as a matter of law to secure payments of
custom duties in connection with the importation of goods, (viii) Liens arising from judgments, decrees or attachments in circumstances
not constituting an Event of Default under Section 5(a)(iv) and (ix) Liens on the Collateral in favor of the Collateral Agent.

 

(ii) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.

 

    -22-

     

    

 

(jj) “Primary
Financing SPA” means that certain Securities Purchase Agreement dated as of the Subscription Date by and among the Company,
APOP, the Holder (or an Affiliate of the Holder) and certain other investors pursuant to which, among other transactions, the Company
is expected to issue shares of Company Common Stock and APOP is expected to issue certain warrants to purchase shares of APOP Ordinary
Shares, all in accordance with the terms thereof.

 

(kk) “Public
Company Date” means the date on which the shares of Company Common Stock of the Company (or its successor or parent company
by merger, recapitalization, reorganization or otherwise) are registered under the 1934 Act, or are exchanged for equity capital
of the Company’s successor or parent company by merger, recapitalization, reorganization or otherwise which are registered
under the 1934 Act.

 

(ll) “Redemption
Dates” means, collectively, the Optional Prepayment Dates, the Mandatory Prepayment Date and the Event of Default Redemption
Dates, each of the foregoing, individually, a Redemption Date.

 

(mm) “Redemption
Notices” means, collectively, the Optional Prepayment Notices, the Mandatory Prepayment Notice and the Event of Default
Redemption Notices, each of the foregoing, individually, a Redemption Notice.

 

(nn) “Redemption
Prices” means, collectively, the Optional Prepayment Prices, the Mandatory Prepayment Price and the Event of Default
Redemption Prices, each of the foregoing, individually, a Redemption Price.

 

(oo) “Related
Fund” means, with respect to any Person, a fund or account managed by such Person or an Affiliate of such Person.

 

(pp) “Required
Holders” means the holders of Notes representing at least a majority of the aggregate Principal amount of the Notes then
outstanding and shall include the Lead Investor so long as the Lead Investor or any of its Affiliates holds any Notes.

 

(qq) “Securities
Purchase Agreement” means that certain securities purchase agreement dated as of the Subscription Date by and among the
Company and the Buyers pursuant to which the Company issued the Notes to the Buyers.

 

(rr) “Security
Documents” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(ss) “Subject
Entity” means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.

 

(tt) “Subscription
Date” means March 24, 2021.

 

(uu) “Subsidiaries”
means all joint ventures or entities in which the Company, directly or indirectly, owns capital stock or an equity or similar interest,
including any Subsidiaries formed or acquired after the Subscription Date.

 

(vv) “Transaction
Documents” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

[Signature Page Follows]

 

    -23-

     

    

 

IN WITNESS WHEREOF, the
Company has caused this Note to be duly executed as of the Issuance Date set out above.

 

	 	Quoin Pharmaceuticals, Inc.
	 	 
	 	By:	
	 	 	Name:
	 	 	Title:

 

    -24-

     

    

 

EXHIBIT B

 

Form of Warrants

 

NEITHER THE ISSUANCE AND SALE OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL SELECTED BY THE HOLDER, IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD (X) PURSUANT TO RULE 144 OR RULE 144A UNDER
SAID ACT OR (Y) TO AN ACCREDITED INVESTOR IN A PRIVATE TRANSACTION. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

QUOIN PHARMACEUTICALS, INC.

 

Warrant
To Purchase Common Stock

 

Warrant No.: ____________  

Date of Issuance: [●]3
(“Issuance Date”)

 

Quoin Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, [HOLDER],
the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set
forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, at any time or times on or
after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ___________________
(__________)4 fully paid nonassessable
shares of Common Stock, subject to adjustment as provided herein (the “Warrant Shares” and such initial number
of Warrant Shares, as adjusted pursuant to Section 2 (other than Section 2(d)) the “Initial Maximum Eligibility Number”).
Except as otherwise defined herein, capitalized terms in this Warrant to Purchase Common Stock (including any Warrants to Purchase
Common Stock issued in exchange, transfer or replacement hereof, this “Warrant”), shall have the meanings set
forth in Section 18. This Warrant is one of the Warrants to purchase Common Stock (which, for the avoidance of doubt, may be issued
on a different Closing Date than the Closing Date that occurred on the Issuance Date, the “Bridge SPA Warrants”)
issued pursuant to Section 1 of that certain Securities Purchase Agreement, dated as of March 24, 2021 (the “Subscription
Date”), by and among the Company and the investors (the “Buyers”) referred to therein (as may be amended,
amended and restated, supplemented or otherwise modified from time to time in accordance with its terms, the “Bridge Securities
Purchase Agreement”). Capitalized terms used herein and not otherwise defined shall have the definitions ascribed to
such terms in the Bridge Securities Purchase Agreement.

 

 

3 Insert the applicable Closing
Date (as defined in the Bridge Securities Purchase Agreement).

4 Insert a number of shares of Common Stock
that equals 100% of the quotient determined by dividing (i) the Principal amount of the Note being issued to the Holder at
the applicable Closing Date, by (ii) a price reflecting fully-diluted pre-Merger valuation of $56,250,000.

 

    -25-

     

    

 

1. EXERCISE
OF WARRANT.

 

(i) Mechanics
of Exercise. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in
Section 1(f)), this Warrant may be exercised by the Holder at any time or times on or after the Issuance Date, in whole or in
part, by (i) delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise
Notice”), of the Holder’s election to exercise this Warrant and (ii) (A) payment to the Company of an
amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being
exercised (the “Aggregate Exercise Price”) in cash by wire transfer of immediately available funds or (B)
if the provisions of Section 1(d) are applicable, by notifying the Company that this Warrant is being exercised pursuant to a
Cashless Exercise (as defined in Section 1(d)). The Holder shall not be required to deliver the original Warrant in order to
effect an exercise hereunder, nor shall any ink-original signature or medallion guarantee (or other type of guarantee or
notarization) with respect to any Exercise Notice be required. Execution and delivery of the Exercise Notice with respect to
less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new
Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or before the first (1st)
Trading Day following the date on which the Holder has delivered the applicable Exercise Notice to the Company, the Company
shall transmit by electronic mail an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and the
Company’s transfer agent, if any (the “Transfer Agent”). On or before the applicable Share Delivery
Date, the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company
(“DTC”) Fast Automated Securities Transfer Program, credit such aggregate number of Warrant Shares to
which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with DTC
through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast
Automated Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Exercise
Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall be responsible for all
fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC, if
any, including, without limitation, for same day processing. Upon delivery of the Exercise Notice, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has
been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of
delivery of the certificates evidencing such Warrant Shares, as the case may be. If this Warrant is submitted in connection
with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for
exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as
practicable and in no event later than five (5) Trading Days after any exercise and at its own expense, issue a new Warrant
(in accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares issuable immediately prior
to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No
fractional Warrant Shares are to be issued upon the exercise of this Warrant, but rather the number of Warrant Shares to be
issued shall be rounded up to the nearest whole number. The Company shall pay any and all taxes which may be payable with
respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant (other than the Holder’s income
taxes). The Company’s obligations to issue and deliver Warrant Shares in accordance with the terms and subject to the
conditions hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same,
any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to
enforce the same, or any setoff, counterclaim, recoupment, limitation or termination. From and after the Public Company Date
and while any Bridge SPA Warrants remain outstanding, the Company shall use a transfer
agent that participates in the DTC Fast Automated Securities Transfer Program. Notwithstanding
any provision of this Warrant to the contrary, no more than the Maximum Eligibility Number of Warrant Shares shall be
exercisable IN the AGGREGATE hereunder.

 

(ii) Exercise
Price. For purposes of this Warrant, “Exercise Price” means $48.51 per share (the “Initial
Exercise Price”), subject to adjustment as provided herein.

 

    -26-

     

    

 

(iii) Company’s
Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason to issue to the Holder on
or prior to the applicable Share Delivery Date either (I) if the Transfer Agent is not participating in the DTC Fast
Automated Securities Transfer Program, a certificate for the number of shares of Common Stock to which the Holder is entitled
and register such shares of Common Stock on the Company’s share register or if the Transfer Agent is participating in
the DTC Fast Automated Securities Transfer Program, to credit the Holder’s balance account with DTC, for such number of
shares of Common Stock to which the Holder is entitled upon the Holder’s exercise of this Warrant or (II) if after the
Public Company Date, the Warrant Shares that are the subject of the Exercise Notice (the “Unavailable Warrant
Shares”) are not eligible for resale without restriction or limitation (including, for the avoidance of doubt, if
the Holder exercises this Warrant by paying the applicable Exercise Price in cash) and the Company fails to promptly (x) so
notify the Holder in writing and (y) deliver the Warrant Shares electronically without any restrictive legend by crediting
such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder’s or
its designee’s balance account with DTC through its Deposit / Withdrawal At Custodian system (the event described in
the immediately foregoing clause (II) is hereinafter referred as a “Notice Failure” and together with the
event described in clause (I) above, an “Exercise Failure”), then, in addition to all other remedies
available to the Holder, (X) from and after the Public Company Date, the Company shall pay in cash to the Holder on each day
after the applicable Share Delivery Date and during such Exercise Failure an amount equal to 1.5% of the product of (A) the
number of shares of Common Stock not issued to the Holder on or prior to the applicable Share Delivery Date and to which the
Holder is entitled, and (B) any trading price of the Common Stock selected by the Holder in writing as in effect at any time
during the period beginning on the applicable date of delivery of the applicable Exercise Notice and ending on the applicable
Share Delivery Date, and (Y) the Holder, upon written notice to the Company, may void its Exercise Notice with respect to,
and retain or have returned, as the case may be, any portion of this Warrant that has not been exercised pursuant to such
Exercise Notice; provided that the voiding of an Exercise Notice shall not affect the Company’s obligations to make any
payments which have accrued prior to the date of such notice pursuant to this Section 1(c) or otherwise. In addition to the
foregoing, if on or prior to the applicable Share Delivery Date occurring from and after the Public Company Date either (I)
if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, the Company shall fail to
issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company’s share register
or, if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit the Holder’s
balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s
exercise hereunder or pursuant to the Company’s obligation pursuant to clause (ii) below or (II) a Notice Failure
occurs, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of
Common Stock relating to the applicable Exercise Failure (a “Buy-In”), then the Company shall, within five
(5) Trading Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in
an amount equal to the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses,
if any) for the shares of Common Stock so purchased (the “Buy-In Price”), at which point the
Company’s obligation to deliver such certificate (and to issue such shares of Common Stock) or credit the
Holder’s balance account with DTC for such shares of Common Stock shall terminate, or (ii) promptly honor its
obligation to deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the
Holder’s balance account with DTC, as applicable, and pay cash to the Holder in an amount equal to the excess (if any)
of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) any trading price of the Common
Stock selected by the Holder in writing as in effect at any time during the period beginning on the date of delivery of the
applicable Exercise Notice and ending on the applicable Share Delivery Date. Nothing herein shall limit the Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of
specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates
representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the exercise of this
Warrant as required pursuant to the terms hereof. Notwithstanding the forgoing, any payments made by the Company to the
Holder pursuant to this Section ‎1(c) shall be made without withholding or deduction for any taxes (as defined in the
Securities Purchase Agreement), unless required by law, in which case the Company will pay such additional amounts as will
result, after such withholding or deduction, in the receipt by the Holder of the amounts that would otherwise have been
receivable in respect thereof.

 

    -27-

     

    

 

(iv) Cashless
Exercise. Notwithstanding anything contained herein to the contrary, if from and after the Public Company Date, the
Unavailable Warrant Shares are not eligible for resale without restriction or limitation (including, for the avoidance of
doubt, if the Holder exercises this Warrant by paying the applicable Exercise Price in cash), the Holder may, in its sole
discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be
made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such
exercise the “Net Number” of shares of Common Stock determined according to the following formula (a
“Cashless Exercise”):

 

Net Number = (A x B) - (A
x C)

B

 

For purposes of the foregoing
formula:

 

		A=	the total number of shares with respect to which this
Warrant is then being exercised.

 

		B=	as applicable: (i) the Weighted Average Price of the Common
Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice if such Exercise Notice is (1) both
executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 1(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(68)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(x) the Weighted Average Price of the Common Stock on the Trading Day immediately preceding the date of the applicable Exercise
Notice or (y) the Bid Price of the Common Stock on the principal trading market for the Common Stock as reported by Bloomberg
as of the time of the Holder’s execution of the applicable Exercise Notice if such Exercise Notice is executed during “regular
trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the
close of “regular trading hours” on a Trading Day) pursuant to Section 1(a) hereof or (iii) the Weighted Average Price
of the Common Stock on the date of the applicable Exercise Notice if the date of such Exercise Notice is a Trading Day and such
Exercise Notice is both executed and delivered pursuant to Section 1(a) hereof after the close of “regular trading hours”
on such Trading Day.

 

		C=	the Exercise Price then in effect for the applicable Warrant
Shares at the time of such exercise.

 

For purposes of Rule 144(d), the Company
hereby acknowledges and agrees that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the
Holder, and the holding period for the Warrant Shares for purposes of Rule 144(d), shall be deemed to have commenced, on the date
this Warrant was originally issued pursuant to the Bridge Securities Purchase Agreement. The Company agrees not to take any position
contrary to this Section 1(d) as long as the rules and interpretations of the SEC in effect as of the Subscription Date remain
unchanged in this respect.

 

(v) Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares,
the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in
accordance with Section 12.

 

    -28-

     

    

 

(vi) Beneficial
Ownership Limitation on Exercises. Notwithstanding anything to the contrary contained herein, from and after the Public
Company Date, the Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the
right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise
shall be null and void and treated as if never made, to the extent that after giving effect to such exercise, the Holder
together with the other Attribution Parties collectively would beneficially own in excess of [4.99] [9.99]%5 (the
“Maximum Percentage”) of the number of shares of Common Stock outstanding immediately after giving effect
to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned
by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all
other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to
which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of
the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other
securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants)
beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous
to the limitation contained in this Section 1(f). For purposes of this Section 1(f), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “1934 Act”). For
purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the
exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of
Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q,
Current Report on Form 8-K or other public filing with the Securities and Exchange Commission (the “SEC”),
as the case may be, (y) a more recent public announcement by the Company or (z) any other written notice by the Company or
the Transfer Agent setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share
Number”). If the Company receives an Exercise Notice from the Holder at a time when the actual number of
outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) promptly notify
the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice
would otherwise cause the Holder’s beneficial ownership, as determined pursuant to this Section 1(f), to exceed the
Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such
Exercise Notice (the number of shares by which such purchase is reduced, the “Reduction Shares”) and (ii)
as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the
Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Company shall within two
(2) Trading Days confirm in writing by electronic mail to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or
exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date
as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to
the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially
own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined
under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution
Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall
be deemed null and void and shall be cancelled ab initio and any portion of this Warrant so exercised shall be reinstated,
and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the
issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid
by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time
increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice;
provided that (i) any such increase in the Maximum Percentage will not be effective until the sixty-first (61st)
day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and
the other Attribution Parties and not to any other holder of Bridge SPA Warrants that is not an Attribution Party of the
Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the
Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of
Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to
exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this
paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f) to the extent necessary
to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section 1(f) or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a
successor holder of this Warrant.

 

 

5 Insert Maximum Percentage as indicated on the
Buyer's signature page attached to the Bridge Securities Purchase Agreement.

 

    -29-

     

    

 

(vii)
Insufficient Authorized Shares. If at any time while this Warrant remains outstanding the Company does not have a
sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon
exercise of this Warrant at least a number of shares of Common Stock equal to: (i) until the Primary Financing Closing Date,
the quotient obtained by dividing (x) the Principal amount of the Note issued to the initial Holder of this Warrant, by (y)
the Initial Exercise Price (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations,
reclassification, combinations, reverse stock splits or other similar events occurring after the Subscription Date), (ii)
from and after the Primary Financing Closing Date until the Final Reset Date, the quotient obtained by dividing (x) the
Principal amount of the Note issued to the initial Holder of this Warrant, by (y) the lower of (1) the Initial Exercise Price
(as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse
stock splits or other similar events occurring after the Subscription Date) and (2) 25% of the Closing Per Share Price and
(iii) from and after the Final Reset Date, the maximum number of shares of Common Stock as shall from time to time be
necessary to effect the exercise in full of all of this Warrant then outstanding without regard to any limitation on exercise
set forth herein (the foregoing clauses (i), (ii) and (iii), as applicable, the “Required Reserve Amount”
and the failure to have such sufficient number of authorized and unreserved shares of Common Stock, an “Authorized
Share Failure”), then the Company shall immediately take all action necessary to increase the Company’s
authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for
this Warrant then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the
date of the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the occurrence of
such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the
number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each stockholder with
a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized
shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal.
Notwithstanding the foregoing, if any such time of an Authorized Share Failure, the Company is able to obtain the written
consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve the increase in the
number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent and, from and
after the Public Company Date, submitting for filing with the SEC an Information Statement on Schedule 14C. In the event that
upon any exercise of this Warrant, the Company does not have sufficient authorized shares to deliver in satisfaction of such
exercise, then unless the Holder elects to void such attempted exercise, the Holder may require the Company to pay to the
Holder within five (5) Trading Days of the applicable exercise, cash in an amount equal to the product of (i) the number of
Warrant Shares that the Company is unable to deliver pursuant to this Section 1(g) and (ii) the highest Weighted Average
Price of the Common Stock during the period beginning on the date of such attempted exercise and the date that the Company
makes the applicable cash payment.

 

2. ADJUSTMENT
OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant Shares shall be adjusted from
time to time as follows:

 

(a) Adjustment
Upon Issuance of Shares of Common Stock. If and whenever on or after the Subscription Date until the date that is the second
(2nd) anniversary of the Registration Date, inclusive, except for the issuance or deemed issuance of Excluded Securities,
the Company publicly announces, issues or sells, enters into a definitive, binding agreement pursuant to which the Company is required
to issue or sell or, in accordance with this Section 2(a), is deemed to have issued or sold, any shares of Common Stock (including
the issuance or sale of shares of Common Stock owned or held by or for the account of the Company, but excluding, for the avoidance
of doubt, shares of Common Stock deemed to have been issued or sold by the Company in connection with any Excluded Securities)
for a consideration per share (the “New Issuance Price”) less than a price (the “Applicable Price”)
equal to the Exercise Price in effect immediately prior to such public announcement, issue or sale or deemed issuance or sale or
entry into such a definitive, binding agreement (the foregoing a “Dilutive Issuance”), then immediately after
such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal to the New Issuance Price. For purposes
of determining the adjusted Exercise Price under this Section 2(a), the following shall be applicable:

 

    -30-

     

    

 

(i) Issuance
of Options. If the Company in any manner grants or sells or enters into a definitive, binding agreement pursuant to which the
Company is required to grant or sell, or the Company publicly announces the issuance or sale of, any Options and the lowest price
per share for which one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or
exchange of any Convertible Securities issuable upon exercise of any such Option is less than the Applicable Price, then such share
of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or
sale of such Option for such price per share. For purposes of this Section 2(a)(i), the “lowest price per share for which
one share of Common Stock is issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible
Securities issuable upon exercise of any such Option” shall be equal to the sum of the lowest amounts of consideration (if
any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale of the Option,
upon exercise of the Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such
Option less any consideration paid or payable by the Company with respect to such one share of Common Stock upon the granting or
sale of such Option, upon exercise of such Option and upon conversion exercise or exchange of any Convertible Security issuable
upon exercise of such Option. No further adjustment of the Exercise Price shall be made upon the actual issuance of such shares
of Common Stock or of such Convertible Securities upon the exercise of such Options or upon the actual issuance of such shares
of Common Stock upon conversion, exercise or exchange of such Convertible Securities.

 

(ii) Issuance
of Convertible Securities. If the Company in any manner issues or sells, or enters into a definitive, binding agreement pursuant
to which the Company is required to grant or sell or the Company publicly announces the issuance or sale of, any Convertible Securities
and the lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof
is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and
sold by the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes
of this Section 2(a)(ii), the “lowest price per share for which one share of Common Stock is issuable upon the conversion,
exercise or exchange thereof” shall be equal to the sum of the lowest amounts of consideration (if any) received or receivable
by the Company with respect to any one share of Common Stock upon the issuance or sale of the Convertible Security and upon conversion,
exercise or exchange of such Convertible Security less any consideration paid or payable by the Company with respect to such one
share of Common Stock upon the issuance or sale of such Convertible Security and upon conversion, exercise or exchange of such
Convertible Security. No further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common
Stock upon conversion, exercise or exchange of such Convertible Securities, and if any such issue or sale of such Convertible Securities
is made upon exercise of any Options for which adjustment of this Warrant has been or is to be made pursuant to other provisions
of this Section 2(a), no further adjustment of the Exercise Price shall be made by reason of such issue or sale.

 

(1)(iii) Change
in Option Price or Rate of Conversion. If the purchase price provided for in any Options, the additional consideration, if
any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible
Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time, the
Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price, which would have been
in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional
consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold. For
purposes of this Section 2(a)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Subscription
Date are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible
Security and the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been
issued as of the date of such increase or decrease. No adjustment pursuant to this Section 2(a) shall be made if such adjustment
would result in an increase of the Exercise Price then in effect.

 

    -31-

     

    

 

(iv) Calculation
of Consideration Received. If any Option and/or Convertible Security and/or Adjustment Right is issued in connection with the
issuance or sale or deemed issuance or sale of any other securities of the Company (as reasonably determined by the Holder, the
“Primary Security”, and such Option and/or Convertible Security and/or Adjustment Right, the “Secondary
Securities”), together comprising one integrated transaction, (or one or more transactions if such issuances or sales
or deemed issuances or sales of securities of the Company either (A) have at least one investor or purchaser in common, (B) are
consummated in reasonable proximity to each other and/or (C) are consummated under the same plan of financing) the aggregate consideration
per share of Common Stock with respect to such Primary Security shall be deemed to be equal to the difference of (x) the lowest
price per share for which one share of Common Stock was issued (or was deemed to be issued pursuant to Section 2(a)(i) or Section
2(a)(ii), as applicable) in such integrated transaction solely with respect to such Primary Security, minus (y) with respect to
such Secondary Securities, the sum of (I) the Black Scholes Consideration Value of each such Option, if any, (II) the fair market
value (as determined by the Holder in good faith) or the Black Scholes Consideration Value, as applicable, of such Adjustment Right,
if any, and (III) the fair market value (as determined by the Holder) of such Convertible Security, if any, in each case, as determined
on a per share basis in accordance with this Section 2(a)(iv). If any shares of Common Stock, Options or Convertible Securities
are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor (for the purpose of determining
the consideration paid for such Common Stock, Option or Convertible Security, but not for the purpose of the calculation of the
Black Scholes Consideration Value) will be deemed to be the net amount of consideration received by the Company therefor. If any
shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of
such consideration received by the Company (for the purpose of determining the consideration paid for such Common Stock, Option
or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will be the fair
value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of
consideration received by the Company for such securities will be the arithmetic average of the Weighted Average Prices of such
security for each of the five (5) Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options
or Convertible Securities are issued to the owners of the non-surviving entity in connection with any merger in which the Company
is the surviving entity, the amount of consideration therefor (for the purpose of determining the consideration paid for such Common
Stock, Option or Convertible Security, but not for the purpose of the calculation of the Black Scholes Consideration Value) will
be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to
such shares of Common Stock, Options or Convertible Securities (as the case may be). The fair value of any consideration other
than cash or publicly traded securities will be determined jointly by the Company and the Holder. If such parties are unable to
reach agreement within ten (10) days after the occurrence of an event requiring valuation (the “Valuation Event”),
the fair value of such consideration will be determined within five (5) Trading Days after the tenth (10th) day following
such Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder. The determination of
such appraiser shall be final and binding upon all parties absent manifest error and the fees and expenses of such appraiser shall
be borne by the Company. Notwithstanding anything to the contrary contained herein, if a calculation pursuant to this Section 2(a)(iv)
would result in an Exercise Price that is lower than the par value of the Common Stock, then the Exercise Price shall be deemed
to equal the par value of the Common Stock.

 

(v) Record
Date. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to
receive a dividend or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to
subscribe for or purchase shares of Common Stock, Options or Convertible Securities, then such record date will be deemed to be
the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend
or the making of such other distribution or the date of the granting of such right of subscription or purchase, as the case may
be.

 

(vi) No
Readjustments. For the avoidance of doubt, in the event the Exercise Price has been adjusted pursuant to this Section 2(a)
and the Dilutive Issuance that triggered such adjustment does not occur, is not consummated, is unwound or is cancelled after the
facts for any reason whatsoever, in no event shall the Exercise Price be readjusted to the Exercise Price that would have been
in effect if such Dilutive Issuance had not occurred or been consummated.

 

    -32-

     

    

 

(b) Voluntary
Adjustment By Company. The Company may at any time during the term of this Warrant, with the prior written consent of the Holder,
(i) reduce the then current Exercise Price and/or (ii) increase the then current number of Warrant Shares, in each case, to any
amount or number and for any period of time deemed appropriate by the Board of Directors of the Company.

 

(c) Adjustment
Upon Subdivision or Combination of Common Stock. If the Company at any time on or after the Subscription Date subdivides (by
any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into
a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced
and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date
combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into
a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased
and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(c) shall become effective
at the close of business on the date the subdivision or combination becomes effective.

 

(d) Resets.
On each Reset Date (i) the Exercise Price shall be adjusted (downward only) to equal the
Reset Price related to such Reset Date and (ii) the Maximum Eligibility Number shall be increased (but not decreased) by
the applicable Reset Share Amount.

 

(e) Other
Events. If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided for by
such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights
with equity features), then the Company’s Board of Directors will make an appropriate adjustment in the Exercise Price and
the number of Warrant Shares, as mutually determined by the Company’s Board of Directors and the Required Holders, so as
to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(e) will increase the Exercise
Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.

 

3. RIGHTS
UPON DISTRIBUTION OF ASSETS. If the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to any or all holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property, Options, evidence of indebtedness or any other assets
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a “Distribution”), at any time after the Subscription Date, then, in each such case, the Holder shall be entitled
to participate in such Distribution to the same extent that the Holder would have participated therein as if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions
on exercise of this Warrant, including without limitation, the Maximum Percentage if applicable) immediately before the date of
which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (provided, however, that to the extent
that the Holder’s right to participate in any such Distribution would result in the Holder and the other Attribution Parties
exceeding the Maximum Percentage if applicable, then the Holder shall not be entitled to participate in such Distribution to such
extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and
beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder
until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage if applicable, at which time or times the Holder shall be granted such Distribution (and any Distributions declared
or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there
had been no such limitation).

 

    -33-

     

    

 

4. PURCHASE
RIGHTS; FUNDAMENTAL TRANSACTIONS; CHANGE OF CONTROL.

 

(a) Purchase
Rights. In addition to any adjustments pursuant to Section 2 above, if at any time following the Subscription Date the Company
grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of Common Stock (the “Purchase Rights”), then the Holder will be
entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage if
applicable) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or,
if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to participate
in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage if applicable,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial
ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such
Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto
would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage if applicable, at which time
or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right
or on any subsequent Purchase Right held similarly in abeyance) to the same extent as if there had been no such limitation).

 

(b) Fundamental
Transactions. The Company shall not enter into, allow or be a party to a Fundamental Transaction (other than the
Merger) until the Final Reset Date. If, at any time after the Final Reset Date
until this Warrant ceases to be outstanding, a Fundamental Transaction occurs or is consummated, then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 1(f) on the exercise of this Warrant), the number of shares of capital stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 1(f) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The
Company shall cause any Successor Entity to assume in writing all of the obligations of the Company under this Warrant in
accordance with the provisions of this Section 4(b) pursuant to written agreements in form and substance reasonably
satisfactory to the Required Holders and approved by the Required Holders (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its Parent Entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of
Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of
capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
Required Holders. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be
substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to
the “Company” shall be added to the term “Company” under this Warrant (so
that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant referring
to the “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities,
jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the
obligations of the Company prior thereto under this Warrant with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company in
this Warrant.

 

    -34-

     

    

 

(c)
Notwithstanding the foregoing and subject to the last sentence of this Section 4(c), in the event of a Change of Control, at the
request of the Holder delivered before the ninetieth (90th) day after the occurrence or consummation of such Change
of Control, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five
(5) Business Days after such request (or, if later, on the effective date of the Change of Control), cash in an amount equal to
the Black Scholes Value of the remaining unexercised portion of this Warrant on the effective date of such Change of Control; provided,
however, that, if such Change of Control is not within the Company’s control, including not approved by the Company’s
Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity, the same type or form
of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being
offered and paid to the holders of Common Stock of the Company in connection with such Change of Control, whether that consideration
be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive
from among alternative forms of consideration in connection with such Change of Control; provided, further, that
if holders of Common Stock of the Company are not offered or paid any consideration in such Change of Control, such holders of
Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following
such Change of Control) in such Change of Control. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds (or such other consideration) within the later of (i) five (5) Business Days of the Holder’s election and
(ii) the date of consummation of the applicable Change of Control. Notwithstanding
anything herein to the contrary, in no event shall the Merger be deemed to be a “Change of Control” solely for purposes
of this Section 4(c).

 

5. NONCIRCUMVENTION.
The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation or Bylaws,
or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of
securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
and will at all times in good faith carry out all of the provisions of this Warrant and take all action as may be required to protect
the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value
of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall
take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the Bridge SPA Warrants
are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock,
solely for the purpose of effecting the exercise of the Bridge SPA Warrants, the Required Reserve Amount of shares of Common Stock.

 

6. WARRANT
HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in such Person’s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock
of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in
such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote,
give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to
the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.
In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company
or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices
and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.

 

    -35-

     

    

 

7. REISSUANCE
OF WARRANTS.

 

(a) Transfer
of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company
will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the
Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less
than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section
7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

 

(b) Lost,
Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by
the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the
Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase
the Warrant Shares then underlying this Warrant.

 

(c) Exchangeable
for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the
Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the
number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion
of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Bridge
SPA Warrants for fractional Warrant Shares shall be given.

 

(d) Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to
purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a)
or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying
the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this
Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date,
and (iv) shall have the same rights and conditions as this Warrant.

 

8. NOTICES.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
with Section 9(f) of the Bridge Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice
of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor.
Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment
of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least
fifteen (15) Business Days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend
or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible
Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for
determining rights to vote with respect to any Fundamental Transaction, Change of Control, dissolution or liquidation; provided
in each case that from and after the Public Company Date, such information shall be made known to the public prior to or in conjunction
with such notice being provided to the Holder. It is expressly understood and agreed that the time of exercise specified by the
Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company.

 

    -36-

     

    

 

9. AMENDMENT
AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended or waived and the Company may
take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained
the written consent of the Required Holders. Any change, amendment or waiver pursuant to the immediately preceding sentence shall
be binding on the Holder of this Warrant and all holders of the Bridge SPA Warrants. Notwithstanding the foregoing, after the Final
Reset Date, the provisions of this Warrant may be amended or waived and the Company may take any action herein prohibited, or omit
to perform any act herein required to be performed by it, if the Company has obtained the written consent of the Holder.

 

10. GOVERNING
LAW; JURISDICTION; JURY TRIAL. This Warrant shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of
the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of
New York. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City
of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought
in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The Company hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
to the Company at the address set forth in Section 9(f) of the Bridge Securities Purchase Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude
the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s
obligations to the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or
other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO
REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY
TRANSACTION CONTEMPLATED HEREBY.

 

    -37-

     

    

 

11. CONSTRUCTION;
HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and all of the Buyers and shall not be construed
against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part
of, or affect the interpretation of, this Warrant.

 

2. DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall cause the Transfer Agent to issue to the Holder the number of Warrant Shares that is not disputed and
the Company shall submit the disputed determinations or arithmetic calculations via electronic mail within two (2) Business Days
of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company
are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within one (1) Business
Day of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within one
(1) Business Day submit via electronic mail (a) the disputed determination of the Exercise Price to an independent, reputable investment
bank selected by the Holder and approved by the Company, such approval not to be unreasonably withheld, conditioned or delayed
or (b) the disputed arithmetic calculation of the Warrant Shares to an independent, outside accountant, selected by the Holder
and approved by the Company, such approval not to be unreasonably withheld, conditioned or delayed. The Company shall cause at
its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify
the Company and the Holder of the results no later than five (5) Business Days from the time it receives the disputed determinations
or calculations. Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be
binding upon all parties absent demonstrable error.

 

12. REMEDIES,
OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition
to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree
of specific performance and/or other injunctive relief). No remedy contained herein shall
be deemed a waiver of compliance with the provisions giving rise to such remedy. Nothing herein shall limit the right of
the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such
breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of
this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the
necessity of showing economic loss and without any bond or other security being required.

 

13. TRANSFER. This
Warrant and the Warrant Shares may be offered for sale, sold, transferred, pledged or assigned without the consent of the Company,
except as may otherwise be required by Section 2(f) of the Bridge Securities Purchase Agreement.

 

    -38-

     

    

  

14. SEVERABILITY. If
any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material
change, the original intentions of the Company and the Holder as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the Company or the Holder or the practical realization of the benefits that would otherwise be conferred upon the Company and
the Holder. The Company and the Holder will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable
provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable
provision(s).

 

15. DISCLOSURE.
Upon receipt or delivery by the Company of any notice in accordance with the terms of this Warrant, from and after the Public Company
Date, unless the Company has in good faith determined that the matters relating to such notice do not constitute material, nonpublic
information relating to the Company or its Subsidiaries, the Company shall contemporaneously with any such receipt or delivery
publicly disclose such material, nonpublic information on a Current Report on Form 8-K or otherwise. In the event that the Company
believes that a notice contains material, nonpublic information relating to the Company or its Subsidiaries, the Company so shall
indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall
be allowed to presume that all matters relating to such notice do not constitute material, nonpublic information relating to the
Company or its Subsidiaries.

 

16. PAYMENT
OF COLLECTION, ENFORCEMENT AND OTHER COSTS. If (a) this Warrant is placed in the hands of an attorney for collection or enforcement
or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under this
Warrant or to enforce the provisions of this Warrant or (b) there occurs any bankruptcy, reorganization, receivership of the company
or other proceedings affecting company creditors’ rights and involving a claim under this Warrant, then the Company shall
pay the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization,
receivership or other proceeding, including, without limitation, attorneys’ fees and disbursements.

 

17. CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a) “1933
Act” means the Securities Act of 1933, as amended.

 

(b) “Adjustment
Right” means any right granted with respect to any securities issued in connection with, or with respect to, any issuance
or sale (or deemed issuance or sale in accordance with Section 2(a)(i) or Section 2(a)(ii)) of shares of Common Stock (other than
rights of the type described in Section 3 and 4 hereof) that could result in a decrease in the net consideration received by the
Company in connection with, or with respect to, such securities (including, without limitation, any cash settlement rights, cash
adjustment or other similar rights).

 

    -39-

     

    

 

(c) “ADS”
shall have the meaning ascribed to such term in the Primary Financing SPA.

 

(d) “Affiliate”
shall have the meaning ascribed to such term in Rule 405 promulgated under the 1933 Act or any successor rule.

 

(e) “APOP”
means Cellect Biotechnology Ltd., an Israeli company.

 

(f) “Approved
Stock Plan” means any employee benefit or incentive plan which has been approved by the Board of Directors of the Company
prior to or subsequent to the Issuance Date, pursuant to which the Company’s securities may be issued to any employee, officer,
consultant or director for services provided to the Company.

 

(g) “Attribution
Parties” means, collectively, the following Persons: (i) any investment vehicle, including, any funds, feeder funds or
managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder’s
investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing,
(iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv)
any other Person whose beneficial ownership of the Common Stock would or could be aggregated with the Holder’s and the other
Attribution Parties for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively
the Holder and all other Attribution Parties to the Maximum Percentage.

 

(h) “Bid
Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on an Eligible Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Eligible Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a
Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (f/k/a OTC
Pink) published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (c) in all other cases (including, without limitation,
prior to the Public Company Date), the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the Required Holders and reasonably acceptable to the Company, the fees and expenses of which shall be paid by
the Company.

 

    -40-

     

    

 

(i) “Black
Scholes Consideration Value” means (a) prior to the Public Company Date, the fair
market value of the applicable Option or Adjustment Right, as the case may be, as determined by an independent appraiser selected
in good faith by the Required Holders and reasonably acceptable to the Company, the fees and expenses of which shall be paid by
the Company and (b) from and after the Public Company Date, the value of the applicable Option or Adjustment Right (as the
case may be) calculated using the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined
as of the date of issuance and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the remaining term of such Option or Adjustment Right (as the case may be) as of the date of issuance of such Option or Adjustment
Right (as the case may be), (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the
HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the issuance of such Option or
Adjustment Right (as the case may be), or, if the issuance of such Option or Adjustment Right (as the case may be) is not publicly
announced, the date of issuance of such Option or Adjustment Right (as the case may be), (iii) the underlying price per share used
in such calculation shall be the highest Weighted Average Price of the Common Stock during the period beginning on the Trading
Day prior to the execution of definitive documentation relating to the issuance of such Option or Adjustment Right (as the case
may be) and ending on (A) the Trading Day immediately following the public announcement of the execution of definitive documents
with respect to the issuance of such Option or Adjustment Right (as the case may be), or, (B) if the execution of definitive documents
with respect to the issuance of such Option or Adjustment Right (as the case may be) is not publicly announced, the date of such
issuance, (iv) a remaining option time equal to the time between the date of the public announcement of the execution of definitive
documents with respect to the issuance of such Option or Adjustment Right (as the case may be) or, if the execution of definitive
documents with respect to the issuance of such Option or Adjustment Right (as the case may be) is not publicly announced, the date
of such issuance, (v) a zero cost of borrow and (vi) a 365 day annualization factor.

 

(j) “Black
Scholes Value” means (a) prior to the Public Company Date, the fair market value
of this Warrant, as determined by an independent appraiser selected in good faith by the Required Holders and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company and (b) from and after the Public Company Date,
the value of this Warrant calculated using the Black-Scholes Option Pricing Model obtained from the “OV” function on
Bloomberg determined as of the day immediately following the public announcement of the applicable contemplated Change of Control,
or, if such contemplated Change of Control is not publicly announced, the date such Change of Control has occurred or is consummated,
for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to
the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the
100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement
of the applicable contemplated Change of Control, or, if such contemplated Change of Control is not publicly announced, the date
such Change of Control has occurred or is consummated, (iii) the underlying price per share used in such calculation shall be the
greater of (x) the highest Weighted Average Price of the Common Stock during the period beginning on the Trading Day prior to the
execution of definitive documentation relating to the applicable Change of Control and ending on (A) the Trading Day immediately
following the public announcement of such contemplated Change of Control, if the applicable contemplated Change of Control is publicly
announced or (B) the Trading Day immediately following the consummation of the applicable Change of Control if the applicable contemplated
Change of Control is not publicly announced and (y) the sum of the price per share being offered in cash, if any, plus the value
of any non-cash consideration, if any, being offered in such Change of Control, (iv) a remaining option time equal to the time
between the date of the public announcement of the applicable contemplated Change of Control or, if such applicable contemplated
Change of Control is not publicly announced, the date such Change of Control has occurred or is consummated, (v) a zero cost of
borrow and (vi) a 365 day annualization factor.

 

    -41-

     

    

 

(k) “Bloomberg”
means Bloomberg Financial Markets.

 

(l) “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York, New York
are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall
not be deemed to be authorized or required by law to remain closed due to “stay at home”, “shelter-in-place”,
“non-essential employee”  or any other similar orders or restrictions or the closure of any physical branch
locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers)
of commercial banks in The City of New York, New York generally are open for use by customers on such day.

 

(m) “Change
of Control” means any Fundamental Transaction other than (i) any reorganization, recapitalization or reclassification
of the Ordinary Shares in which holders of the Company’s voting power immediately prior to such reorganization, recapitalization
or reclassification continue after such reorganization, recapitalization or reclassification to hold publicly traded securities
and, directly or indirectly, are, in all material respect, the holders of the voting power of the surviving entity (or entities
with the authority or voting power to elect the members of the board of directors (or their equivalent if other than a corporation)
of such entity or entities) after such reorganization, recapitalization or reclassification or (ii) pursuant to a migratory merger
effected solely for the purpose of changing the jurisdiction of incorporation of the Company. Notwithstanding anything herein to
the contrary, any transaction or series of transaction that, directly or indirectly, results in the Company or the Successor Entity
not having Ordinary Shares or common stock, as applicable, registered under the 1934 Act and listed on an Eligible Market shall
be deemed a Change of Control.

 

(n) “Closing
Date” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(o) “Closing
Per Share Price” shall have the meaning ascribed to such term in the Primary Financing SPA.

 

(p) “Common
Stock” means (i) the Company’s shares of common stock, par value $0.01 per share, and (ii) any capital
stock into which such Common Stock shall be changed or any capital stock resulting from a reclassification, reorganization or recapitalization
of such Common Stock, including, without limitation, as a result from the transactions contemplated by the Merger Agreement.

 

(q) “Convertible
Securities” means any stock or securities (other than Options) directly or indirectly convertible into or exercisable
or exchangeable for shares of Common Stock.

 

    -42-

     

    

 

(r) “Eligible
Market” means the Principal Market, the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Select Market, The
Nasdaq Global Market or The New York Stock Exchange.

 

(s) “Excluded
Securities” means any Common Stock issued or issuable or deemed to be issued in accordance with Section 2(a)(i) or Section
2(a)(ii) by the Company: (i) under any Approved Stock Plan; provided, however, that no more than three percent (3.0%)
of the number of Ordinary Shares (as adjusted for any stock dividend, stock split, stock combination, reclassification or similar
transaction occurring relating to the Ordinary Shares after the Warrant Closing Date (as defined in the Securities Purchase Agreement))
issued and outstanding as of the Warrant Closing Date are issued or issuable to consultants pursuant to an Approved Stock Plan
hereunder as Excluded Securities, (ii) upon exercise of any Bridge SPA Warrants and any Primary Financing Warrants; provided,
that the terms of such Bridge SPA Warrants and Primary Financing Warrants are not amended, modified or changed on or after the
Subscription Date, (iii) upon conversion, exercise or exchange of any Options or Convertible Securities which are outstanding on
the day immediately preceding the Subscription Date; provided, that such issuance of Common Stock upon exercise of such
Options or Convertible Securities is made pursuant to the terms of such Options or Convertible Securities in effect on the date
immediately preceding the Subscription Date and such Options or Convertible Securities are not amended, modified or changed on
or after the Subscription Date, (iv) pursuant to the Merger Agreement or the Form F-4 (as defined in the Primary Financing SPA)
or (v) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors
of the Company, provided that any such issuance shall only be to a Person which is, itself or through its Subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and shall be entered into for bona fide
reasons other than capital raising and shall provide to the Company additional benefits in addition to the investment of funds,
but shall not include a transaction in which the Company is issuing securities for the purpose of raising capital or to an entity
whose primary business is investing in securities.

 

(t) “Expiration
Date” means the date sixty (60) months after the Registration Date or, if such date falls on a Holiday, the next day
that is not a Holiday.

 

(u) “Final
Reset Date” means the one hundred thirty-fifth (135th) day following the Primary Financing Closing Date or,
if such date falls on a Holiday, the next day that is not a Holiday.

 

    -43-

     

    

 

(v) “Fundamental
Transaction” means (A) that the Company shall, directly or indirectly, including through Subsidiaries, Affiliates or
otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving
corporation) another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of
the properties or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation
S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be
subject to or have its Common Stock be subject to or party to one or more Subject Entities making, a purchase, tender or exchange
offer that is accepted by the holders of at least either (x) 50% of the outstanding shares of Common Stock, (y) 50% of the outstanding
shares of Common Stock calculated as if any shares of Common Stock held by all Subject Entities making or party to, or Affiliated
with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number
of shares of Common Stock such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party
to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934
Act) of at least 50% of the outstanding shares of Common Stock, or (iv) consummate a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or
more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of
the outstanding shares of Common Stock, (y) at least 50% of the outstanding shares of Common Stock calculated as if any shares
of Common Stock held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to,
such stock purchase agreement or other business combination were not outstanding; or (z) such number of shares of Common Stock
such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least
50% of the outstanding shares of Common Stock, or (v) reorganize, recapitalize or reclassify its Common Stock, (B) that the Company
shall, directly or indirectly, including through Subsidiaries, Affiliates or otherwise, in one or more related transactions, allow
any Subject Entity individually or the Subject Entities in the aggregate to be or become the “beneficial owner” (as
defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance,
tender, tender offer, exchange, reduction in outstanding shares of Common Stock, merger, consolidation, business combination, reorganization,
recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner
whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common
Stock, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock not
held by all such Subject Entities as of the Subscription Date calculated as if any shares of Common Stock held by all such Subject
Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding
shares of Common Stock or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory
short form merger or other transaction requiring other stockholders of the Company to surrender their shares of Common Stock without
approval of the stockholders of the Company or (C) that the Company shall, directly or indirectly, including through Subsidiaries,
Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction
structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary
to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment
of such instrument or transaction. For the avoidance of doubt, the Merger shall be deemed to be a “Fundamental Transaction”.

 

(w) “Group”
means a “group” as that term is used in Section 13(d) of the 1934 Act and as defined in Rule 13d-5 thereunder.

 

(x) “Holiday”
means a day other than a Business Day or a day from and after the Public Company date on which trading does not take place on the
Principal Market.

 

    -44-

     

    

 

(y) “Interim
Reset Date” means each of the tenth (10th) Trading Day, the forty-fifth (45th) day and the ninetieth
(90th) day, in each case, immediately following the Primary Financing Closing Date or, if any such date falls on a Holiday,
the next day that is not a Holiday.

 

(z) “Lead
Investor” means Altium Growth Fund, LP.

 

(aa) “Maximum
Eligibility Number” means, initially, the Initial Maximum Eligibility Number, and such number shall be increased (but
not decreased) on each Reset Date by the applicable Reset Share Amount.

 

(bb) “Merger”
shall have the meaning ascribed to such term in the Merger Agreement.

 

(cc) “Merger
Agreement” shall have the meaning ascribed to such term in the Bridge Securities Purchase Agreement.

 

(dd) “Notes”
means those certain Senior Secured Notes issued by the Company pursuant to the Bridge Securities Purchase Agreement.

 

(ee) “Options”
means any rights, warrants or options to subscribe for or purchase (i) shares of Common Stock or (ii) Convertible Securities.

 

(ff) “Parent
Entity” of a Person means an entity that, directly or indirectly, controls the applicable Person, including such entity
whose common capital or equivalent equity security is quoted or listed on an Eligible Market (or, if so elected by the Holder,
any other market, exchange or quotation system), or, if there is more than one such Person or such entity, the Person or such entity
designated by the Required Holders or in the absence of such designation, such Person or entity with the largest public market
capitalization as of the date of consummation of the Fundamental Transaction or Change of Control, as applicable.

 

(gg) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.

 

(hh) “Primary
Financing Closing Date” means the Closing Date as such term is defined in the Primary Financing SPA.

 

(ii) “Primary
Financing SPA” means that certain Securities Purchase Agreement dated as of the Subscription Date by and among the Company,
APOP, the Holder (or an Affiliate of the Holder) and certain other investors listed on the signature pages attached thereto pursuant
to which, among other transactions, the Company is expected to issue shares of Common Stock and APOP is expected to issue certain
Warrants to purchase ADSs, all in accordance with the terms thereof.

 

(jj) “Primary
Financing Warrants” means the three (3) series of warrants to purchase Common Stock expected to be issued by APOP pursuant
to the Primary Financing SPA.

 

    -45-

     

    

 

(kk) “Principal”
shall have the meaning ascribed to such term in the Notes.

 

“Principal
Market” means the Eligible Market that is the principal securities exchange market for the issuer’s listed common
capital stock from and after the Public Company Date.

 

“Public Company
Date” means the date on which the shares of Common Stock (or its successor or parent company by merger, recapitalization,
reorganization or otherwise) are registered under the 1934 Act, or are exchanged for equity capital of the Company’s successor
or parent company by merger, recapitalization, reorganization or otherwise which are registered under the 1934 Act, including,
without limitation, upon consummation of the transaction contemplated by the Merger Agreement.

 

(ll) “Registration
Date” means the earlier to occur of the first date on which the Bridge SPA Warrants and the Warrant Shares are freely
tradable by the holders thereof without any restriction or limitation (including, for the avoidance of doubt, if the holder thereof
exercises the Bridge Warrants by paying the applicable Exercise Price in cash).

 

(mm) “Required
Holders” means the holders of the Bridge SPA Warrants representing at least a majority of the shares of Common Stock
underlying the Bridge SPA Warrants then outstanding (without regard to any limitation on exercise set forth therein) and shall
include the Lead Investor so long as the Lead Investor or any of its Affiliates holds any Bridge SPA Warrants.

 

(nn) “Reset
Date” means the Primary Financing Closing Date, each Interim Reset Date and the Final Reset Date.

 

(oo) “Reset
Price” means (i) with respect to the Primary Financing Closing Date, the Closing Per Share Price and (ii) with respect
to all other Reset Dates occurring hereunder, 85% of the arithmetic average of the three (3) lowest Weighted Average Prices of
the ADSs during the ten (10) Trading Day period immediately preceding the applicable Reset Date (as adjusted for stock splits,
stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or other similar events
during such period) (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification,
combinations, reverse stock splits or other similar events occurring after the applicable Reset Date).

 

(pp) “Reset
Share Amount” means the difference obtained by subtracting (i) the quotient obtained by dividing (x) the Principal amount
of the Note issued to the initial Holder of this Warrant on the Issuance Date, by (y) (1) with respect to the Primary Financing
Closing Date, the Closing Per Share Price and (2) with respect to all other Reset Dates occurring hereunder, the lowest of (A)
the Closing Per Share Price, (B) the lowest Reset Price related to all the Reset Date(s) preceding the applicable Reset Date, if
any (as adjusted for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse
stock splits or other similar events occurring after the applicable Reset Date) and (C) the Initial Exercise Price (as adjusted
for stock splits, stock dividends, recapitalizations, reorganizations, reclassification, combinations, reverse stock splits or
other similar events occurring after the Subscription Date), from (ii) the quotient obtained by dividing (x) the Principal amount
of the Note issued to the initial Holder of this Warrant on the Issuance Date, by (y) the Reset Price related to the applicable
Reset Date.

 

(qq) “Rule
144” means Rule 144 promulgated under the 1933 Act or any successor rule.

 

    -46-

     

    

 

(rr) “Share
Delivery Date” means (a) prior to the Public Company Date, the second (2nd) Trading Day and (b) from and after
the Public Company Date, the earlier of (i) the second (2nd) Trading Day and (ii) the number of Trading Days comprising
the Standard Settlement Period, in each case, following the date on which the Holder delivers the applicable Exercise Notice to
the Company, so long as the Holder delivers the applicable Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior
to the earlier of (i) the second (2nd) Trading Day following the date on which the Holder has delivered the applicable
Exercise Notice to the Company and (ii) the number of Trading Days comprising the Standard Settlement Period following the date
on which the Holder has delivered the applicable Exercise Notice to the Company (provided that if the applicable Aggregate Exercise
Price (or applicable notice of a Cashless Exercise) has not been delivered to the Company by such date, the applicable Share Delivery
Date shall be one (1) Trading Day after the Holder has delivered the applicable Aggregate Exercise Price (or applicable notice
of a Cashless Exercise) to the Company.

 

(ss) “Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Principal Market
with respect to the Company’s listed common capital stock as in effect on the date of delivery of the applicable Exercise
Notice.

 

(tt) “Subject
Entity” means any Person, Persons or Group or any Affiliate or associate of any such Person, Persons or Group.

 

(uu) “Subsidiary”
means any entity in which the Company, directly or indirectly, owns any of the capital stock or holds an equity or similar interest.

 

(vv) “Successor
Entity” means one or more Person or Persons (or, if so elected by the Holder, the Company or Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or Change of Control, as applicable, or one or more Person or Persons (or,
if so elected by the Holder, the Company or the Parent Entity) with which such Fundamental Transaction or Change of Control, as
applicable, shall have been entered into.

 

(ww) “taxes”
shall have the meaning ascribed to such term in the Securities Purchase Agreement.

 

(xx) “Trading
Day” means (i) prior to the Public Company Date, any Business Day, and (ii) from and after the Public Company Date, any
day on which the Company’s common capital stock is traded on the Principal Market.

 

(yy) “Weighted
Average Price” means, for any security as of any date from and after the Public Company Date, the dollar volume-weighted
average price for such security on the Principal Market during the period beginning at 9:30 a.m., New York time (or such other
time as the Principal Market publicly announces is the official open of trading), and ending at 4:00 p.m., New York time (or such
other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg through its “Volume
at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the
over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30 a.m., New York time
(or such other time as such market publicly announces is the official open of trading), and ending at 4:00 p.m., New York time
(or such other time as such market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar
volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid
price and the lowest closing ask price of any of the market makers for such security as reported
in the OTC Link or Pink Open Market (f/k/a OTC Pink) published by the OTC Markets Group, Inc. (or similar organization or agency
succeeding to its functions of reporting prices). If the Weighted Average Price cannot be calculated for a security on a
particular date on any of the foregoing bases (including, without limitation, prior to the
Public Company Date), the Weighted Average Price of such security on such date shall be the fair market value as mutually
determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved pursuant to Section 12 with the term “Weighted Average Price” being substituted
for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any stock dividend, stock
split, stock combination, reclassification or other similar transaction relating to the Common Stock during the applicable calculation
period.

 

[Signature Page Follows]

 

    -47-

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

 

	 	QUOIN
    PHARMACEUTICALS, INC.
	 	 
	 	By:	                                                 
	 	Name:
	 	Title:

 

    -48-

     

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT
TO PURCHASE COMMON STOCK

 

QUOIN
PHARMACEUTICALS, INC.

 

The
undersigned holder hereby exercises the right to purchase _________________ shares of Common Stock (“Warrant Shares”)
of Quoin Pharmaceuticals, Inc., a Delaware corporation (the “Company”), evidenced by the attached Warrant to
Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the
respective meanings set forth in the Warrant.

 

1.
Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as:

 

____________
a “Cash Exercise” with respect to _________________ Warrant Shares; and/or

 

____________
a “Cashless Exercise” with respect to _______________ Warrant Shares, resulting in a delivery obligation of
the Company to the Holder of __________ shares of Common Stock representing the applicable Net Number.

 

2.
Payment of Exercise Price. In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant
Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the
Company in accordance with the terms of the Warrant.

 

3.
Delivery of Warrant Shares. The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of
the Warrant.

 

4.
Please issue the Common Stock into which the Warrant is being exercised to the Holder, or for its benefit, as follows:

 

☐
  Check here if requesting delivery as a certificate to the following name and to the following address:

 

Issue
to: _____________________________

_______________________________

Address:
_________________________________________

Telephone
Number: ________________________________

Email
Address: _____________________________

 

     

     

    

 

☐
  Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:

 

DTC
Participant: _____________________________

 

DTC
Number: _________________________________________

Account
Number: ________________________________

 

Authorization:

By:
_____________________________

Title:
_____________________________

Dated:

Account
Number (if electronic book entry transfer):

Transaction
Code Number (if electronic book entry transfer):_____

 

Date:
_______________ __, ______

 

_____________________________

Name
of Registered Holder

 

	By:	 	 
	 	Name:	 
	 	Title:	 

 

    -2-

     

    

 

ACKNOWLEDGMENT

 

The
Company hereby acknowledges this Exercise Notice and hereby directs its transfer agent, if any, to issue the above indicated number
of shares of Common Stock.

 

	 	QUOIN
    PHARMACEUTICALS, INC.
	 	 
	 	By	                                    
	 	Name: 	 
	 	Title:	 

 

    -3-

     

    

 

EXHIBIT
C

 

Form
of Guarantee Agreement

 

GUARANTEE
(this “Guarantee”), dated as of March 25, 2021, made by each of the undersigned (together with each other Person
that executes a joinder agreement and becomes a “Guarantor” hereunder, each a “Guarantor”, and
collectively, the “Guarantors”), in favor of the Buyers (as defined below) party to the Securities Purchase
Agreement referenced below.

 

W
I T N E S S E T H :

 

WHEREAS,
Quoin Pharmaceuticals, Inc., a Delaware corporation (the ”Company”), and each party listed as a
“Buyer” on the Schedule of Buyers attached to the Securities Purchase Agreement (each a “Buyer”,
and collectively, the “Buyers”) are parties to that certain Securities Purchase Agreement, dated as of March
25 2021, (the “Securities Purchase Agreement”), pursuant to which, among other things, the Buyers shall purchase
from the Company certain senior secured Notes (collectively, as amended, amended and restated, supplemented or otherwise modified
from time to time, the “Notes”);

 

WHEREAS,
the Buyers have requested, and the Guarantors have agreed, that the Guarantors shall execute and deliver to the Buyers a guarantee
guaranteeing all of the obligations of the Company under the Securities Purchase Agreement, the Notes, the Security Documents,
any Perfection Certificate and any other agreement, instrument, certificate, report and other document executed and delivered
pursuant hereto or thereto or otherwise evidencing or securing any Note or any other obligation (collectively, the “Transaction
Documents”);

 

WHEREAS,
pursuant to a Pledge and Security Agreement, dated as of March 25, 2021, (as amended or otherwise modified from time to time,
the “Security Agreement”), the Company and the Guarantors have granted to Altium Growth Fund, LP, as collateral
agent for the Buyers (in such capacity, the “Collateral Agent”), a security interest in and lien on certain
assets to secure their respective obligations under this Guarantee, the Securities Purchase Agreement, the Notes and the other
Transaction Documents; and

 

WHEREAS,
each Guarantor has determined that the execution, delivery and performance of this Guarantee directly benefits, and is in the
best interest of, such Guarantor.

 

NOW,
THEREFORE, in consideration of the premises and the agreements herein and for other consideration, the sufficiency of which is
hereby acknowledged, each Guarantor hereby agrees with each Buyer as follows:

 

10.
Definitions. Reference is hereby made to the Securities Purchase Agreement and the Notes for a statement of the terms thereof.
All terms used in this Guarantee which are defined in the Securities Purchase Agreement or the Notes and not otherwise defined
herein shall have the same meanings as set forth therein.

 

    -4-

     

    

 

11.
Guarantee. The Guarantors, jointly and severally, hereby unconditionally and irrevocably, guarantee (a) the punctual payment,
as and when due and payable, by stated maturity or otherwise, of all obligations and any other amounts now or hereafter owing
by the Company in respect of the Securities Purchase Agreement, the Notes and the other Transaction Documents, including, without
limitation, all interest that accrues after the commencement of any proceeding commenced by or against the Company or any Guarantor
under any provision of the Bankruptcy Code (Chapter 11 of Title 11 of the United States Code) or under any other bankruptcy
or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, or extensions generally
with creditors, or proceedings seeking reorganization, arrangement, or other similar relief (an “Insolvency Proceeding”),
whether or not the payment of such interest is unenforceable or is not allowable due to the existence of such Insolvency Proceeding,
and all fees, commissions, expense reimbursements, indemnifications and all other amounts due or to become due under any of the
Transaction Documents, and any and all expenses (including reasonable counsel fees and expenses) reasonably incurred by the Buyers
or the Collateral Agent in enforcing any rights under this Guarantee (such obligations, to the extent not paid by the Company,
being the “Guaranteed Obligations”) and (b) the punctual and faithful performance, keeping, observance and
fulfillment by the Company of all of the agreements, conditions, covenants and obligations of the Company contained in the Securities
Purchase Agreement, the Notes and the other Transaction Documents. Without limiting the generality of the foregoing, each Guarantor’s
liability hereunder shall extend to all amounts that constitute part of the Guaranteed Obligations and would be owed by the Company
to the Buyers under the Securities Purchase Agreement and the Notes but for the fact that they are unenforceable or not allowable
due to the existence of an Insolvency Proceeding involving any Guarantor or the Company (each, a “Transaction Party”).

 

12.
Guarantee Absolute; Continuing Guarantee; Assignments.

 

(a)
The Guarantors, jointly and severally, guarantee that the Guaranteed Obligations will be paid strictly in accordance with the
terms of the Transaction Documents, regardless of any law, regulation or order now or hereafter in effect in any jurisdiction
affecting any of such terms or the rights of the Buyers with respect thereto. The obligations of each Guarantor under this Guarantee
are independent of the Guaranteed Obligations, and a separate action or actions may be brought and prosecuted against any Guarantor
to enforce such obligations, irrespective of whether any action is brought against any Transaction Party or whether any Transaction
Party is joined in any such action or actions. The liability of any Guarantor under this Guarantee shall be irrevocable, absolute
and unconditional irrespective of, and each Guarantor hereby irrevocably waives, to the extent permitted by law, any defenses
it may now or hereafter have in any way relating to, any or all of the following:

 

(i)
any lack of validity or enforceability of any Transaction Document or any agreement or instrument relating thereto;

 

(ii)
any change in the time, manner or place of payment of, or in any other term of, all or any of the Guaranteed Obligations, or any
other amendment or waiver of or any consent to departure from any Transaction Document, including, without limitation, any increase
in the Guaranteed Obligations resulting from the extension of additional credit to any Transaction Party or otherwise;

 

    -5-

     

    

 

(iii)
any taking, exchange, release or non-perfection of any collateral with respect to the Guaranteed Obligations, or any taking, release
or amendment or waiver of or consent to departure from any other guarantee, for all or any of the Guaranteed Obligations; or

 

(iv)
any change, restructuring or termination of the corporate, limited liability company or partnership structure or existence of
any Transaction Party.

 

This
Guarantee shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Guaranteed
Obligations is rescinded or must otherwise be returned by any Buyer or any other Person upon the insolvency, bankruptcy or reorganization
of any Transaction Party or otherwise, all as though such payment had not been made.

 

(b)
This Guarantee is a continuing guarantee and shall (i) remain in full force and effect until the indefeasible payment in full
in cash of all obligations under the Notes (together with any matured indemnification obligations as of the date of such payment,
but excluding any inchoate or unmatured contingent indemnification obligations) and payment of all other amounts payable under
this Guarantee (excluding any inchoate or unmatured contingent indemnification obligations) and (ii) be binding upon each Guarantor
and its respective successors and assigns. This Guarantee shall inure to the benefit of and be enforceable by the Buyers and their
respective successors, and permitted pledgees, transferees and assigns. Without limiting the generality of the foregoing sentence,
any Buyer may pledge, assign or otherwise transfer all or any portion of its rights and obligations under and subject to the terms
of any Transaction Document to any other Person, and such other Person shall thereupon become vested with all the benefits in
respect thereof granted to such Buyer herein or otherwise, in each case as provided in the Securities Purchase Agreement or such
Transaction Document. Notwithstanding the foregoing and for the avoidance of doubt, this Guarantee will expire and each Guarantor
will be released from its obligation hereunder upon the indefeasible payment in full in cash of all obligations under the Notes
(together with any matured indemnification obligations as of the date of such payment, but excluding any inchoate or unmatured
contingent indemnification obligations) and payment of all other amounts payable under this Guarantee (excluding any inchoate
or unmatured contingent indemnification obligations).

 

13.
Waivers. To the extent permitted by applicable law, each Guarantor hereby waives promptness, diligence, notice of acceptance
and any other notice with respect to any of the Guaranteed Obligations and this Guarantee and any requirement that the Buyers
or the Collateral Agent exhaust any right or take any action against any Transaction Party or any other Person or any Collateral.
Each Guarantor acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated herein
and that the waiver set forth in this Section 4 is knowingly made in contemplation of such benefits. The Guarantors
hereby waive any right to revoke this Guarantee, and acknowledge that this Guarantee is continuing in nature and applies to all
Guaranteed Obligations, whether existing now or in the future.

 

    -6-

     

    

 

14.
Subrogation. No Guarantor may exercise any rights that it may now or hereafter acquire against any Transaction Party or
any other guarantor that arise from the existence, payment, performance or enforcement of any Guarantor’s obligations under
this Guarantee, including, without limitation, any right of subrogation, reimbursement, exoneration, contribution or indemnification
and any right to participate in any claim or remedy of the Buyers or the Collateral Agent against any Transaction Party or any
other guarantor or any Collateral, whether or not such claim, remedy or right arises in equity or under contract, statute or common
law, including, without limitation, the right to take or receive from any Transaction Party or any other guarantor, directly or
indirectly, in cash or other property or by set-off or in any other manner, payment or security solely on account of such claim,
remedy or right, unless and until the indefeasible payment in full in cash of all obligations under the Notes (together with any
matured indemnification obligations as of the date of such payment, but excluding any inchoate or unmatured contingent indemnification
obligations) and payment of all other amounts payable under this Guarantee (excluding any inchoate or unmatured contingent indemnification
obligations). If any amount shall be paid to a Guarantor in violation of the immediately preceding sentence at any time prior
to the later of the payment in full in cash of the Guaranteed Obligations and all other amounts payable under this Guarantee,
such amount shall be held in trust for the benefit of the Buyers and shall forthwith be paid ratably to the Buyers to be credited
and applied to the Guaranteed Obligations and all other amounts payable under this Guarantee, whether matured or unmatured, in
accordance with the terms of the Transaction Documents, or to be held as collateral for any Guaranteed Obligations or other amounts
payable under this Guarantee thereafter arising. If (a) any Guarantor shall make payment to the Buyers of all or any part
of the Guaranteed Obligations, and (b) the Buyers receive the indefeasible payment in full in cash of all obligations under
the Notes (together with any matured indemnification obligations as of the date of such payment, but excluding any inchoate or
unmatured contingent indemnification obligations) and payment of all other amounts payable under this Guarantee (excluding any
inchoate or unmatured contingent indemnification obligations), the Buyers will, at such Guarantor’s request and expense,
execute and deliver to such Guarantor appropriate documents, without recourse and without representation or warranty, necessary
to evidence the transfer by subrogation to such Guarantor of an interest in the Guaranteed Obligations resulting from such payment
by such Guarantor.

 

15.
Representations, Warranties and Covenants.

 

(a)
Each Guarantor hereby represents and warrants as of the date first written above as follows:

 

(i)
Such Guarantor (A) is a corporation, limited liability company or limited partnership duly organized, validly existing and in
good standing under the laws of the jurisdiction of its organization as set forth on the signature pages hereto, (B) has all requisite
corporate, limited liability company or limited partnership power and authority to conduct its business as now conducted and as
presently contemplated and to execute and deliver this Guarantee and each other Transaction Document to which such Guarantor is
a party, and to consummate the transactions contemplated hereby and thereby and (C) is duly qualified to do business and is in
good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction
of its business makes such qualification necessary except where the failure to be so qualified would not result in a Material
Adverse Effect.

 

    -7-

     

    

 

(ii)
The execution, delivery and performance by such Guarantor of this Guarantee and each other Transaction Document to which such
Guarantor is a party (A) have been duly authorized by all necessary corporate, limited liability company or limited partnership
action, (B) do not and will not contravene its charter or by-laws, its limited liability company or operating agreement or its
certificate of partnership or partnership agreement, as applicable, or any applicable law or any contractual restriction binding
on such Guarantor or its properties do not and will not result in or require the creation of any lien (other than pursuant to
any Transaction Document) upon or with respect to any of its properties, and (C) do not and will not result in any default, noncompliance,
suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable
to it or its operations or any of its properties.

 

(iii)
No authorization or approval or other action by, and no notice to or filing with, any governmental authority is required in connection
with the due execution, delivery and performance by such Guarantor of this Guarantee or any of the other Transaction Documents
to which such Guarantor is a party (other than expressly provided for in any of the Transaction Documents).

 

(iv)
Each of this Guarantee and the other Transaction Documents to which such Guarantor is or will be a party, when delivered, will
be, a legal, valid and binding obligation of such Guarantor, enforceable against such Guarantor in accordance with its terms,
except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, suretyship or
other similar laws and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

(v)
There is no pending or, to the best knowledge of such Guarantor, threatened action, suit or proceeding against such Guarantor
or to which any of the properties of such Guarantor is subject, before any court or other governmental authority or any arbitrator
that (A) if adversely determined, could reasonably be expected to have a Material Adverse Effect or (B) relates to this
Guarantee or any of the other Transaction Documents to which such Guarantor is a party or any transaction contemplated hereby
or thereby.

 

(vi)
Such Guarantor (A) has read and understands the terms and conditions of the Securities Purchase Agreement, the Notes and the other
Transaction Documents, and (B) now has and will continue to have independent means of obtaining information concerning the
affairs, financial condition and business of the Company and the other Transaction Parties, and has no need of, or right to obtain
from the Collateral Agent or any Buyer, any credit or other information concerning the affairs, financial condition or business
of the Company or the other Transaction Parties that may come under the control of the Collateral Agent or any Buyer.

 

(b)
Each Guarantor covenants and agrees that until the indefeasible payment in full in cash of all obligations under the Notes (together
with any matured indemnification obligations as of the date of such payment, but excluding any inchoate or unmatured contingent
indemnification obligations) and payment of all other amounts payable under this Guarantee (excluding any inchoate or unmatured
contingent indemnification obligations), it will comply with each of the covenants (except to the extent applicable only to a
public company) which are set forth in Section 4 of the Securities Purchase Agreement as if such Guarantor were a
party thereto.

 

    -8-

     

    

 

16.
Right of Set-off. Upon the occurrence and during the continuance of any Event of Default, the Collateral Agent and
any Buyer may, and is hereby authorized to, at any time and from time to time, without notice to the Guarantors (any such notice
being expressly waived by each Guarantor) and to the fullest extent permitted by law, set-off and apply any and all deposits (general
or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by any Buyer to or
for the credit or the account of any Guarantor against any and all obligations of the Guarantors now or hereafter existing under
this Guarantee or any other Transaction Document, irrespective of whether or not Collateral Agent or any Buyer shall have made
any demand under this Guarantee or any other Transaction Document and although such obligations may be contingent or unmatured.
Collateral Agent and each Buyer agrees to notify the relevant Guarantor promptly after any such set-off and application made by
such Buyer, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights
of the Collateral Agent or any Buyer under this Section 7 are in addition to other rights and remedies (including,
without limitation, other rights of set-off) which the Collateral Agent or such Buyer may have under this Guarantee or any other
Transaction Document in law or otherwise.

 

17.
Notices, Etc. All notices and other communications provided for hereunder shall be in writing and shall be mailed (by overnight
mail or by certified mail, postage prepaid and return receipt requested), telecopied, sent via electronic mail, sent via overnight
courier or delivered, if to any Guarantor, to the address for such Guarantor set forth on the signature page hereto, or if to
any Buyer, to it at its respective address set forth in the Securities Purchase Agreement; or as to any Person at such other address
as shall be designated by such Person in a written notice to such other Person complying as to delivery with the terms of this
Section 8. All such notices and other communications shall be effective (i) if mailed (by certified mail, postage prepaid
and return receipt requested), when received or three Business Days after deposited in the mails, whichever occurs first; (ii)
if telecopied, when transmitted and confirmation is received, provided it is transmitted during regular business hours on a Business
Day and, if not, on the next Business Day; (iii) if sent via electronic mail, when transmitted (provided that such sent electronic
mail is kept on file (whether electronically or otherwise) by the sending party and the sending party does not immediately receive
an automatically generated message from the recipient’s electronic mail server that such electronic mail could not be delivered
to such recipient), (d) if sent via overnight courier service, one Business Day after deposit with an overnight courier service,
or (iii) if delivered by hand, upon delivery, provided it is delivered during regular business hours on a Business Day and, if
not, on the next Business Day.

 

18.
CONSENT TO JURISDICTION; SERVICE OF PROCESS AND VENUE. ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS GUARANTEE OR
ANY OTHER TRANSACTION DOCUMENT MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK IN THE COUNTY OF NEW YORK OR OF THE UNITED
STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, AND, BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH GUARANTOR
HEREBY IRREVOCABLY ACCEPTS IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE JURISDICTION OF THE AFORESAID COURTS.
NOTHING HEREIN SHALL AFFECT THE RIGHT OF THE BUYERS TO SERVICE OF PROCESS IN ANY OTHER MANNER PERMITTED BY LAW OR TO COMMENCE
LEGAL PROCEEDINGS OR OTHERWISE PROCEED AGAINST EACH GUARANTOR IN ANY OTHER JURISDICTION. ANY GUARANTOR HEREBY EXPRESSLY AND IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE JURISDICTION OR LAYING
OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT
IN AN INCONVENIENT FORUM. TO THE EXTENT THAT ANY GUARANTOR HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY
COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION
OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, EACH GUARANTOR HEREBY IRREVOCABLY WAIVES SUCH IMMUNITY IN RESPECT OF ITS
OBLIGATIONS UNDER THIS GUARANTEE AND THE OTHER TRANSACTION DOCUMENTS.

 

    -9-

     

    

 

19.
WAIVER OF JURY TRIAL, ETC. EACH GUARANTOR HEREBY WAIVES ANY RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM
CONCERNING ANY RIGHTS UNDER THIS GUARANTEE OR THE OTHER TRANSACTION DOCUMENTS, OR UNDER ANY AMENDMENT, WAIVER, CONSENT, INSTRUMENT,
DOCUMENT OR OTHER AGREEMENT DELIVERED OR WHICH IN THE FUTURE MAY BE DELIVERED IN CONNECTION HEREWITH OR THEREWITH, OR ARISING
FROM ANY FINANCING RELATIONSHIP EXISTING IN CONNECTION WITH THIS GUARANTEE OR THE OTHER TRANSACTION DOCUMENTS, AND AGREES THAT
ANY SUCH ACTION, PROCEEDING OR COUNTERCLAIM SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. EACH GUARANTOR CERTIFIES THAT
NO OFFICER, REPRESENTATIVE, AGENT OR ATTORNEY OF ANY BUYER HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT ANY BUYER WOULD NOT,
IN THE EVENT OF ANY ACTION, PROCEEDING OR COUNTERCLAIM, SEEK TO ENFORCE THE FOREGOING WAIVERS. EACH GUARANTOR HEREBY ACKNOWLEDGES
THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE BUYERS ENTERING INTO THE OTHER TRANSACTION DOCUMENTS.

 

20.
Taxes.

 

(a)
All payments made by any Guarantor hereunder or under any other Transaction Document shall be made in accordance with the terms
of the respective Transaction Document and shall be made without set-off, counterclaim, deduction or other defense. All such payments
shall be made free and clear of and without deduction for any present or future taxes, levies, imposts, deductions, charges or
withholdings, and all liabilities with respect thereto, excluding taxes imposed on the net income of any Buyer by the jurisdiction
in which such Buyer is organized or where it has its principal lending office (all such nonexcluded taxes, levies, imposts, deductions,
charges, withholdings and liabilities, collectively or individually, “Taxes”). If any Guarantor shall be required
to deduct or to withhold any Taxes from or in respect of any amount payable hereunder or under any other Transaction Document:

 

(i)
the amount so payable shall be increased to the extent necessary so that after making all required deductions and withholdings
(including Taxes on amounts payable to any Buyer pursuant to this sentence) each Buyer receives an amount equal to the sum it
would have received had no such deduction or withholding been made,

 

(ii)
such Guarantor shall make such deduction or withholding,

 

    -10-

     

    

 

(iii)
such Guarantor shall pay the full amount deducted or withheld to the relevant taxation authority in accordance with applicable
law, and

 

(iv)
as promptly as possible thereafter, such Guarantor shall send the Buyers an official receipt (or, if an official receipt is not
available, such other documentation as shall be satisfactory to the Buyers, as the case may be) showing payment.  In addition,
each Guarantor agrees to pay any present or future stamp or documentary taxes or any other excise or property taxes, charges or
similar levies that arise from any payment made hereunder or from the execution, delivery, registration or enforcement of, or
otherwise with respect to, this Agreement or any other Transaction Document (collectively, “Other Taxes”).

 

(b)
Each Guarantor hereby indemnifies and agrees to hold the Collateral Agent and each Buyer (each an “Indemnified Party”)
harmless from and against Taxes or Other Taxes (including, without limitation, any Taxes or Other Taxes imposed by any jurisdiction
on amounts payable under this Section 11) paid by any Indemnified Party  as a result of any payment made hereunder
or from the execution, delivery, registration or enforcement of, or otherwise with respect to, this Agreement or any other Transaction
Document, and any liability (including penalties, interest and expenses for nonpayment, late payment or otherwise) arising therefrom
or with respect thereto, whether or not such Taxes or Other Taxes were correctly or legally asserted.  This indemnification
shall be paid within 30 days from the date on which such Buyer makes written demand therefor, which demand shall identify the
nature and amount of such Taxes or Other Taxes.

 

(c)
If any Guarantor fails to perform any of its obligations under this Section 11, such Guarantor shall indemnify the
Collateral Agent and each Buyer for any taxes, interest or penalties that may become payable as a result of any such failure.
The obligations of the Guarantors under this Section 11 shall survive the termination of this Guarantee and the payment
of the Obligations and all other amounts payable hereunder.

 

21.
Miscellaneous.

 

(a)
Each Guarantor will make each payment hereunder in lawful money of the United States of America and in immediately available funds
to each Buyer, at such address specified by such Buyer from time to time by notice to the Guarantors.

 

(b)
Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance
and either retroactively or prospectively), only with the written consent of the Company and the Required Holders. Any amendment
or waiver effected in accordance with this Section 12 shall be binding upon each Buyer and holder of Securities and the Company.

 

(c)
No failure on the part of the Collateral Agent or any Buyer to exercise, and no delay in exercising, any right hereunder or under
any other Transaction Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder
or under any Transaction Document preclude any other or further exercise thereof or the exercise of any other right. The rights
and remedies of the Collateral Agent and the Buyers provided herein and in the other Transaction Documents are cumulative and
are in addition to, and not exclusive of, any rights or remedies provided by law. The rights of the Collateral Agent and the Buyers
under any Transaction Document against any party thereto are not conditional or contingent on any attempt by the Collateral Agent
or any Buyer to exercise any of their respective rights under any other Transaction Document against such party or against any
other Person.

 

    -11-

     

    

 

(d)
Any provision of this Guarantee that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining portions hereof or affecting the validity
or enforceability of such provision in any other jurisdiction.

 

(e)
This Guarantee shall (i) be binding on each Guarantor and its respective successors and assigns, and (ii) inure, together with
all rights and remedies of the Collateral Agent and the Buyers hereunder, to the benefit of the Collateral Agent and the Buyers
and their respective successors, transferees and assigns. Without limiting the generality of clause (ii) of the immediately preceding
sentence, the Collateral Agent and any Buyer may assign or otherwise transfer its rights and obligations under the Securities
Purchase Agreement or any other Transaction Document to any other Person in accordance with the terms thereof, and such other
Person shall thereupon become vested with all of the benefits in respect thereof granted to the Collateral Agent or such Buyer,
as the case may be, herein or otherwise. None of the rights or obligations of any Guarantor hereunder may be assigned or otherwise
transferred without the prior written consent of each Buyer.

 

(f)
This Guarantee reflects the entire understanding of the transaction contemplated hereby and shall not be contradicted or qualified
by any other agreement, oral or written, entered into before the date hereof.

 

(g)
Section headings herein are included for convenience of reference only and shall not constitute a part of this Agreement for any
other purpose.

 

(h)
This Guarantee may be executed by each party hereto on a separate counterpart, each of which when so executed and delivered shall
be an original, but all of which together shall constitute one agreement. Delivery of an executed counterpart by facsimile or
other method of electronic transmission shall be equally effective as delivery of an original executed counterpart.

 

(i) This
GuarantEE shall be governed by and construed in accordance with the law of the State of New York applicable to contracts made
and to be performed therein without regard to conflict of law principles.

 

[REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

    -12-

     

    

 

IN
WITNESS WHEREOF, each Guarantor has caused this Guarantee to be executed by its respective duly authorized officer, as of the
date first above written.

 

	 	[GUARANTOR]
	 	 	 
	 	By:	                     
	 	Name:
	 	Title:

 

	 	Address for Notices:
	 	 	 
	 	Attention:	[        ]
	 	Facsimile:	[        ]
	 	Email:	[        ]

 

     

     

    

 

EXHIBIT
D

 

Form
of Security Agreement

 

PLEDGE
AND SECURITY AGREEMENT, dated as of March 25, 2021 (this “Agreement”), made by Quoin Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), and each Subsidiary of the Company that is a signatory hereto
(together with the Company and each other Person that executes a joinder and becomes a “Grantor” hereunder, each a
“Grantor” and, collectively, the “Grantors”), in favor of Altium Growth Fund, LP, in its
capacity as collateral agent (in such capacity, the “Collateral Agent”) for the Buyers (as defined below) party
to the Securities Purchase Agreement, dated as of March 25, 2021 (as amended, restated or otherwise modified from time to time,
the “Securities Purchase Agreement”).

 

W I T N E S S E T H:

 

WHEREAS,
the Company and each party listed as a “Buyer” on the Schedule of Buyers (as such schedule may be amended, restated
or otherwise modified from time to time) attached thereto, each a “Buyer”, and collectively, the “Buyers”)
are parties to the Securities Purchase Agreement, pursuant to which the Company shall be required to sell, and the Buyers shall
purchase or have the right to purchase, certain senior secured notes;

 

WHEREAS,
it is a condition precedent to the Buyers consummating the transactions contemplated by the Securities Purchase Agreement that
the Grantors execute and deliver to the Collateral Agent this Agreement providing for the grant to the Collateral Agent for the
benefit of the Buyers of a security interest in all personal property of the Grantors to secure all of the Company’s obligations
under the Securities Purchase Agreement and the “Notes” (as defined therein) issued pursuant thereto (as such Notes
may be amended, restated, replaced or otherwise modified from time to time in accordance with the terms thereof, collectively,
the “Notes”) and the other Transaction Documents (as defined in the Securities Purchase Agreement);

 

WHEREAS,
the Grantors (i) are mutually dependent on each other in the conduct of their respective businesses as an integrated operation,
with the credit needed from time to time by one often being provided through financing obtained by the other Grantors and the
ability to obtain such financing being dependent on the successful operations of the Grantors and (ii) will receive a mutual benefit
from the proceeds received by the Company in respect of the issuance of the Notes; and

 

WHEREAS,
each Grantor has determined that the execution, delivery and performance of this Agreement directly benefits, and are in the best
interest of the Company and such Grantor.

 

    -14-

     

    

 

NOW,
THEREFORE, in consideration of the premises and the agreements herein and in order to induce the Buyers to perform under the Securities
Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Buyers, as follows:

 

●
Definitions.

 

		●	Reference
                                         is hereby made to the Securities Purchase Agreement and the Notes for a statement of
                                         the terms thereof. All terms used in this Agreement and the recitals hereto which are
                                         defined in the Securities Purchase Agreement, the Notes or in Articles 8 or 9 of the
                                         Uniform Commercial Code (the “Code”) as in effect from time to time
                                         in the State of New York, and which are not otherwise defined herein shall have the same
                                         meanings herein as set forth therein; provided that terms used herein which are
                                         defined in the Code as in effect in the State of New York on the date hereof shall continue
                                         to have the same meaning notwithstanding any replacement or amendment of such statute
                                         except as the Collateral Agent may otherwise determine.

 

		●	The
                                         following terms shall have the respective meanings provided for in the Code: “Accounts”,
                                         “Account Debtor”, “Cash Proceeds”, “Chattel Paper”,
                                         “Commercial Tort Claim”, “Commodity Account”, “Commodity
                                         Contracts”, “Deposit Account”, “Documents”, “Electronic
                                         Chattel Paper”, “Equipment”, “Fixtures”, “General
                                         Intangibles”, “Goods”, “Instruments”, “Inventory”,
                                         “Investment Property”, “Letter-of-Credit Rights”, “Noncash
                                         Proceeds”, “Payment Intangibles”, “Proceeds”, “Promissory
                                         Notes”, “Security”, “Record”, “Security Account”,
                                         “Software”, and “Supporting Obligations”.

 

		●	As
                                         used in this Agreement, the following terms shall have the respective meanings indicated
                                         below, such meanings to be applicable equally to both the singular and plural forms of
                                         such terms:

 

“Cash
Management Accounts” means the deposit accounts, securities accounts, commodity accounts and other accounts of each
Grantor (other than Excluded Accounts) maintained at one or more cash management banks listed on Schedule IV hereto.

 

“Collateral”
shall have the meaning set forth in Section 2 hereof.

 

“Copyright
Licenses” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee
or licensor and providing for the grant of any rights with respect to any copyright.

 

“Copyrights”
means all domestic and foreign copyrights, whether registered or not, including, without limitation, all copyright rights throughout
the universe (whether now or hereafter arising) in any and all media (whether now or hereafter developed), in and to all original
works of authorship fixed in any tangible medium of expression (including computer software and internet website content), and
all other general intangibles of like nature, now or hereafter owned, acquired, licensed, used or held for use by any Grantor,
all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings
in the United States Copyright Office or in any similar office or agency of the United States or any other country or any political
subdivision thereof), and all renewals thereof.

 

“Domestic
Subsidiary” means any Subsidiary that is organized and existing under the laws of the United States or any state or
commonwealth thereof or under the laws of the District of Columbia.

 

    -15-

     

    

 

“Event
of Default” means (i) any defined event of default under any one or more of the Transaction Documents, in each instance,
after giving effect to any notice, grace, or cure periods provided for in the applicable Transaction Document, (ii) the failure
by the Company to pay any amounts when due under the Notes or any other Transaction Document, or (iii) the breach of any representation,
warranty or covenant by any Grantor under this Agreement.

 

“Excluded
Accounts” shall have the meaning set forth in Section 5(i) hereof.

 

“Excluded
Assets” means, collectively, (i) any right, title or interest in any personal property and fixtures, the pledge or grant
of a security interest in which would violate any requirement of law, (ii) any lease, license or agreement to which a Grantor
is a party or any of its right, title or interest thereunder, to the extent, but only to the extent, that such a grant (A) would,
under the express terms of such lease, license or agreement, violate or invalidate such lease, license or agreement, create a
right of termination in favor of any party thereto (other than a Grantor) or (B) is prohibited by, or would result in a breach
of, the terms of, or constitute a default under, such lease, license or agreement, (iii) in the case of an Excluded Foreign
Subsidiary of any Grantor, more than 65% (or such greater percentage that, due to a change in applicable law after the date hereof,
(A) would not reasonably be expected to cause the undistributed earnings of such Excluded Foreign Subsidiary as determined
for United States federal income tax purposes to be treated as a deemed dividend to such Excluded Foreign Subsidiary’s United
States parent and (B) would not reasonably be expected to cause any material adverse tax consequences) of the issued and
outstanding shares of equity interests entitled to vote (within the meaning of Treas. Reg. Section 1.956 2(c)(2)) (it being understood
and agreed that the Collateral shall include 100% of the issued and outstanding shares of equity interests not entitled to vote
(within the meaning of Treas. Reg. Section 1.956 2(c)(2))), and (iv) Excluded Accounts.

 

“Excluded
Foreign Subsidiary” means (a) any direct or indirect Subsidiary of the Company that is a “controlled foreign corporation”
as defined in the Code or (b) any Subsidiary of the Company all or substantially all of the assets of which consist of equity
interests of one or more Subsidiaries described in clause (a) above, so long as in each case of clauses (a) and (b) above
and this clause (b), (i) such Subsidiary has not guaranteed any indebtedness or pledged any of its assets or suffered a pledge
of more than sixty-five percent (65%) of its voting equity interests to secure, directly or indirectly, any indebtedness of the
Grantors and (ii) the guaranty of the Obligations by any such Subsidiary would cause a material adverse tax consequence to the
Grantors or the direct, or immediately taxable indirect, equityholders of the equity interests of such Subsidiary, taken as a
whole.

 

“Existing
Issuer” has the meaning specified therefor in the definition of the term “Pledged Shares”.

 

“Foreign
Subsidiary” means any Subsidiary of the Company that is not a Domestic Subsidiary.

 

“Insolvency
Proceeding” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code (Chapter 11
of Title 11 of the United States Code) or under any other bankruptcy or insolvency law, assignments for the benefit of creditors,
formal or informal moratoria, compositions, or extensions generally with creditors, or proceedings seeking reorganization, arrangement,
or other similar relief.

 

    -16-

     

    

 

“Intellectual
Property” means the Copyrights, Trademarks, Patents and Other Proprietary Rights.

 

“Licenses”
means the Copyright Licenses, the Trademark Licenses, the Patent Licenses and all licenses, contracts or other agreements, whether
written or oral, naming any Grantor as licensee or licensor and providing for the grant of any rights with respect to any Other
Proprietary Rights.

 

“Lien”
means any mortgage, deed of trust, pledge, lien (statutory or otherwise), security interest, charge or other encumbrance or security
or preferential arrangement of any nature, including, without limitation, any conditional sale or title retention arrangement,
any capitalized lease and any assignment, deposit arrangement or financing lease intended as, or having the effect of, security.

 

“Obligations”
shall have the meaning set forth in Section 3 hereof.

 

“Other
Proprietary Rights” means all inventions, trade secrets, ideas, concepts, methods, techniques, processes, proprietary
information, technology, know-how and formulae, and all other intellectual or proprietary rights, in any jurisdiction through
the world, of any Grantor, now or hereafter owned, acquired, licensed, used or held for use.

 

“Patent
Licenses” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee
or licensor and providing for the grant of any right to make, use, offer for sale, sell or import any invention covered by any
Patent.

 

“Patents”
means all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, and other general
intangibles of like nature, of any Grantor, now or hereafter owned, acquired, licensed, used or held for use, all applications,
registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United
States Patent and Trademark Office, or in any similar office or agency of the United States or any other country or any political
subdivision thereof), and all reissues, divisionals, continuations, continuations in part, reexaminations, or extensions thereof.

 

“Perfection
Certificate” means that certain Perfection Certificate, dated as of the date hereof, by the Company on behalf of itself
and its Subsidiaries, and together with any supplement thereto.

 

“Perfection
Requirements” shall have the meaning set forth in Section 4(i) hereof.

 

“Permitted
Liens” shall have the meaning set forth in the Notes.

 

“Pledged
Debt” means the indebtedness described in Schedule VII hereto and all indebtedness from time to time owned or acquired
by a Grantor, the Promissory Notes and other Instruments evidencing any or all of such indebtedness, and all interest, cash, Instruments,
Investment Property, financial assets, securities, capital stock, other equity interests, stock options and Commodity Contracts,
notes, debentures, bonds, Promissory Notes or other evidences of indebtedness and all other property from time to time received,
receivable or otherwise distributed in respect of or in exchange for any or all of such indebtedness.

 

    -17-

     

    

 

“Pledged
Interests” means, collectively, (a) the Pledged Debt, (b) the Pledged Shares and (c) all security entitlements in any
and all of the foregoing.

 

“Pledged
Issuer” has the meaning specified therefor in the definition of the term “Pledged Shares”.

 

“Pledged
Shares” means (a) the shares of capital stock or other equity interests described in Schedule VIII hereto, whether or
not evidenced or represented by any stock certificate, certificated security or other Instrument, issued by the Persons described
in such Schedule VIII (the “Existing Issuers”), (b) the shares of capital stock or other equity interests at
any time and from time to time acquired by a Grantor of any and all Persons now or hereafter existing (such Persons, together
with the Existing Issuers, being hereinafter referred to collectively as the “Pledged Issuers” and each individually
as a “Pledged Issuer”), whether or not evidenced or represented by any stock certificate, certificated security
or other Instrument, and (c) the certificates representing such shares of capital stock, all options and other rights, contractual
or otherwise, in respect thereof and all dividends, distributions, cash, Instruments, Investment Property, financial assets, securities,
capital stock, other equity interests, stock options and commodity contracts, notes, debentures, bonds, Promissory Notes or other
evidences of indebtedness and all other property (including, without limitation, any stock dividend and any distribution in connection
with a stock split) from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all
of such capital stock.

 

“Trademark
Licenses” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensor
or licensee and providing for the grant of any right with respect to any Trademark.

 

“Trademarks”
means all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names,
d/b/a’s, Internet domain names, trade styles, designs, logos and other source or business identifiers and all general intangibles
of like nature, now or hereafter owned, adopted, acquired, licensed, used or held for use by any Grantor, all applications, registrations
and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Patent
and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political
subdivision thereof), and all renewals thereof, together with all goodwill of the business symbolized by any of the foregoing
and all customer lists, formulae and other Records of any Grantor relating to the distribution of products and services in connection
with which any of the foregoing are used.

 

    -18-

     

    

 

●
Grant of Security Interest. As collateral security for the payment, performance and observance of all of the Obligations,
each Grantor hereby pledges and assigns to the Collateral Agent (and its agents and designees) for the benefit of the Buyers,
and grants to the Collateral Agent (and its agents and designees) for the benefit of the Buyers a continuing security interest
in, all personal property of such Grantor, wherever located and whether now or hereafter existing and whether now owned or hereafter
acquired, of every kind and description, tangible or intangible, including, without limitation, the following (all being collectively
referred to herein as the “Collateral”):

 

		●	all
                                         Accounts;

 

		●	all
                                         Chattel Paper (whether tangible or electronic);

 

		●	the
                                         Commercial Tort Claims specified on Schedule VI hereto;

 

		●	all
                                         Deposit Accounts (including, without limitation, all cash, and all other property from
                                         time to time deposited therein or otherwise credited thereto and the monies and property
                                         in the possession or under the control of the Collateral Agent or a Buyer or any affiliate,
                                         representative, agent or correspondent of the Collateral Agent or a Buyer;

 

		●	all
                                         Documents;

 

		●	all
                                         Equipment;

 

		●	all
                                         Fixtures;

 

		●	all
                                         General Intangibles (including, without limitation, all Payment Intangibles);

 

		●	all
                                         Goods;

 

		●	all
                                         Instruments (including, without limitation, Promissory Notes and each certificated Security);

 

		●	all
                                         Inventory;

 

		●	all
                                         Investment Property;

 

		●	all
                                         Intellectual Property and all Licenses;

 

		●	all
                                         Letter-of-Credit Rights;

 

		●	all
                                         Supporting Obligations;

 

		●	all
                                         Pledged Interests;

 

		●	all
                                         other tangible and intangible personal property of such Grantor (whether or not subject
                                         to the Code), including, without limitation, all bank and other accounts and all cash
                                         and all investments therein, all proceeds, products, offspring, accessions, rents, profits,
                                         income, benefits, substitutions and replacements of and to any of the property of such
                                         Grantor described in the preceding clauses of this Section 2 (including, without
                                         limitation, any proceeds of insurance thereon and all causes of action, claims and warranties
                                         now or hereafter held by such Grantor in respect of any of the items listed above), and
                                         all books, correspondence, files and other Records, including, without limitation, all
                                         tapes, disks, cards, Software, data and computer programs in the possession or under
                                         the control of such Grantor or any other Person from time to time acting for such Grantor
                                         that at any time evidence or contain information relating to any of the property described
                                         in the preceding clauses of this Section 2 or are otherwise necessary or helpful
                                         in the collection or realization thereof; and

 

    -19-

     

    

 

		●	all
                                         Proceeds, including all Cash Proceeds and Noncash Proceeds, and products of any and all
                                         of the foregoing Collateral;

 

in
each case, howsoever such Grantor’s interest therein may arise or appear (whether by ownership, security interest, claim
or otherwise). Notwithstanding anything to the contrary herein, the security interest granted herein shall not attach to, and
no security interest is granted hereunder in, any Excluded Assets.

 

●
Security for Obligations. The security interest created hereby in the Collateral constitutes continuing collateral security
for all of the following obligations, whether now existing or hereafter incurred (collectively, the “Obligations”):

 

		●	the
                                         prompt payment by each Grantor, as and when due and payable (by scheduled maturity, required
                                         prepayment, acceleration, demand or otherwise), of all amounts from time to time owing
                                         by it in respect of the Securities Purchase Agreement, the Notes, the Guarantee Agreement
                                         and the other Transaction Documents, including, without limitation, (A) all principal
                                         of and interest on the Notes (including, without limitation, all interest that accrues
                                         after the commencement of any Insolvency Proceeding of any Grantor, whether or not the
                                         payment of such interest is unenforceable or is not allowable due to the existence of
                                         such Insolvency Proceeding), (B) all amounts from time to time owing by such Grantor
                                         under the Guarantee Agreement, and (C) all fees, commissions, expense reimbursements,
                                         indemnifications and all other amounts due or to become due under any of the Transaction
                                         Documents; and

 

		●	the
                                         due performance and observance by each Grantor of all of its other obligations from time
                                         to time existing in respect of any of the Transaction Documents for so long as the Notes
                                         are outstanding.

 

●
Representations and Warranties. Each Grantor represents and warrants as follows:

 

		●	Schedule
                                         I hereto sets forth (i) the exact legal name of such Grantor, and (ii) the jurisdiction
                                         of organization and organizational identification number of such Grantor, or states that
                                         no such organizational identification number exists.

 

		●	There
                                         is no pending or written notice threatening any action, suit, proceeding or claim affecting
                                         such Grantor before any governmental authority or any arbitrator, or any order, judgment
                                         or award by any governmental authority or arbitrator, that could reasonably be expected
                                         to adversely affect the grant by such Grantor, or the perfection, of the security interest
                                         purported to be created hereby in the Collateral, or the exercise by the Collateral Agent
                                         of any of its rights or remedies hereunder.

 

    -20-

     

    

 

		●	Each
                                         Grantor (i) has timely filed all foreign, federal and state income and all other tax
                                         returns, reports and declarations required by any jurisdiction to which it is subject,
                                         (ii) has timely paid all taxes and other governmental assessments and charges that are
                                         material in amount, shown or determined to be due on such returns, reports and declarations,
                                         except those being contested in good faith and (iii) has set aside on its books provision
                                         reasonably adequate for the payment of all taxes for periods subsequent to the periods
                                         to which such returns, reports or declarations apply. There are no unpaid taxes in any
                                         material amount claimed to be due by the taxing authority of any jurisdiction, and the
                                         officers of each Grantor know of no basis for any such claim.

 

		●	All
                                         Equipment, Fixtures, Goods and Inventory of such Grantor now existing are, and all Equipment,
                                         Fixtures, Goods and Inventory of such Grantor hereafter existing will be, located and/or
                                         based at the addresses specified therefor in Schedule III hereto, except that
                                         such Grantor will give the Collateral Agent not less than 30 days’ prior written
                                         notice of any change of the location of any such Collateral, other than to locations
                                         set forth on Schedule III and with respect to which the Collateral Agent has filed
                                         financing statements and otherwise fully perfected its Liens thereon. Such Grantor’s
                                         chief place of business and chief executive office, the place where such Grantor keeps
                                         its Records concerning Accounts and all originals of all Chattel Paper are located at
                                         the addresses specified therefor in Schedule III hereto. None of the Accounts
                                         is evidenced by Promissory Notes or other Instruments. Set forth in Schedule IV
                                         hereto is a complete and accurate list, as of the date of this Agreement, of (i) each
                                         Promissory Note, Security and other Instrument owned by each Grantor and (ii) each Deposit
                                         Account, Securities Account and Commodities Account of each Grantor, together with the
                                         name and address of each institution at which each such Account is maintained, the account
                                         number for each such Account and a description of the purpose of each such Account.

 

		●	Each
                                         License sets forth the entire agreement and understanding of the parties thereto relating
                                         to the subject matter thereof, and there are no other agreements, arrangements or understandings,
                                         written or oral, relating to the matters covered thereby or the rights of such Grantor
                                         or any of its affiliates in respect thereof. Each material License now existing is, and
                                         any material License entered into in the future will be, the legal, valid and binding
                                         obligation of the parties thereto, enforceable against such parties in accordance with
                                         its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization,
                                         moratorium, fraudulent conveyance, suretyship or other similar laws and equitable principles
                                         (regardless of whether enforcement is sought in equity or in law). No default under any
                                         material License by any such party has occurred, nor does any defense, offset, deduction
                                         or counterclaim exist thereunder in favor of any such party.

 

    -21-

     

    

 

		●	Each
                                         Grantor owns (free and clear of all liens, encumbrances and defects except for Permitted
                                         Liens) or possesses a valid license or other lawful right to use all Intellectual Property
                                         necessary, used or held for use, to conduct its business as presently conducted and as
                                         presently proposed to be conducted. Each of the registrations or applications for registration
                                         of Intellectual Property (including issued patents and applications for patent) owned
                                         or licensed to such Grantor is listed on Schedule II hereto, and each item of such Intellectual
                                         Property is valid and enforceable. Each of the Licenses or other contracts (including
                                         settlement agreements) with respect to the use, ownership or enforcement of Intellectual
                                         Property to which any Grantor is a party is listed on Schedule II hereto, each such contract
                                         is valid and enforceable, and none of the Grantors and, to the knowledge of the Grantors,
                                         none of the counterparties to any such contract, is in default or breach thereunder or
                                         thereof. Except as set forth in Schedule II hereto, none of the Grantors’ Intellectual
                                         Property has expired or terminated, has been abandoned or canceled, or adjudged invalid
                                         or unenforceable or are scheduled or expected to expire or terminate or are scheduled
                                         or expected to be abandoned or canceled, or adjudged invalid or unenforceable, within
                                         three (3) months from the date hereof. The conduct of the business of the Grantors does
                                         not infringe, misappropriate or otherwise violate or conflict with the Intellectual Property
                                         of others, and in the past six (6) years, no claim, action or proceeding (including in
                                         the U.S. Patent and Trademark Office, or any corresponding non-U.S. authority, or before
                                         any other governmental authority) has been made or brought alleging the foregoing. There
                                         is no claim, action or proceeding that has been made or brought in the past six (6) years
                                         by or against, being threatened by or, to the knowledge of any Grantor, being threatened
                                         against, any Grantor regarding Intellectual Property, including any challenging the validity,
                                         enforceability, ownership, enforcement, patentability or registrability of such Intellectual
                                         Property. To the knowledge of the Grantors, no third party is infringing, misappropriating
                                         or otherwise conflicting with its Intellectual Property. None of the Grantors are aware
                                         of any facts or circumstances which might give rise to any of the foregoing infringements,
                                         misappropriations or other conflicts, or claims, actions or proceedings. Each Grantor
                                         has taken reasonable security measures to protect the secrecy, confidentiality
                                         and value of all of its Intellectual Property and, to its knowledge, no unauthorized
                                         disclosure of any information comprising any Intellectual Property has occurred. All
                                         present and former employees, consultants and independent contractors of each Grantor
                                         that have been involved in the development of any material Intellectual Property have
                                         entered into written agreements under which such Persons (A) agree to protect the trade
                                         secrets, know-how and other confidential information of the Grantors, as applicable,
                                         and (B) assign to one of the Grantors all right, title and interest in and to all Intellectual
                                         Property created by such Person in the course of his, her or its employment or other
                                         engagement by one of the Grantors. Except as set forth on Schedule II hereto, no United
                                         States federal or state agency or any other government or governmental agency, university,
                                         research institute or other similar organization has sponsored any research by any Grantor
                                         or been involved with or otherwise sponsored any development of any Intellectual Property
                                         claimed by any Grantor.

 

		●	Such
                                         Grantor is and will be at all times the sole and exclusive owner of, or otherwise has
                                         and will have adequate rights in, the Collateral free and clear of any Liens, except
                                         for Permitted Liens. No effective financing statement or other instrument similar in
                                         effect covering all or any part of the Collateral is on file in any recording or filing
                                         office except (A) such as may have been filed in favor of the Collateral Agent relating
                                         to this Agreement, and (B) such as may have been filed to perfect any Permitted
                                         Liens.

 

		●	The
                                         exercise by the Collateral Agent of any of its rights and remedies hereunder will not
                                         contravene any law or any contractual restriction binding on or otherwise affecting such
                                         Grantor or any of its properties and will not result in or require the creation of any
                                         Lien, upon or with respect to any of its properties.

 

    -22-

     

    

 

		●	No
                                         authorization or approval or other action by, and no notice to or filing with, any governmental
                                         authority or other regulatory body, or any other Person, is required for (i) the
                                         grant by such Grantor, or the perfection, of the security interest purported to be created
                                         hereby in the Collateral, or (ii) the exercise by the Collateral Agent of any of
                                         its rights and remedies hereunder, except (A) for the filing under the Uniform Commercial
                                         Code as in effect in the applicable jurisdiction of the financing statements, all of
                                         which financing statements have been duly filed and are in full force and effect, (B)
                                         with respect to the perfection of the security interest created hereby in the Intellectual
                                         Property, for the recording of the appropriate Intellectual Property Security Agreement,
                                         substantially in the form of Exhibit A hereto, as applicable, in the United States
                                         Patent and Trademark Office or the United States Copyright Office, as applicable, (C) delivery
                                         of Collateral consisting of certificates (if any) evidencing instruments, notes and debt
                                         securities required to be pledged hereunder, (D) delivery of Collateral consisting
                                         of certificates (if any) evidencing equity interests required to be pledged hereunder,
                                         (E) solely with respect to any fee-owned facility required to be subject to a mortgage,
                                         fixture filings pursuant to the Uniform Commercial Code in the applicable county filing
                                         office of the relevant State(s) in which such fee-owned facility is located, (F) the
                                         recording of any mortgage on any fee-owned facility in the applicable county office and
                                         the delivery of other real property deliverables to be mutually agreed in respect thereof,
                                         and (G) entering into account control agreements with respect to any Cash Management
                                         Accounts (excluding any Excluded Accounts) (subclauses (A) through (G), each a “Perfection
                                         Requirement” and collectively, the “Perfection Requirements”).
                                         Notwithstanding anything to the contrary contained herein, no Perfection Requirement
                                         shall be required to be undertaken with respect to the laws of any non-U.S. jurisdiction
                                         to create or perfect a security interest in the Collateral (and no security agreements
                                         or pledge agreements governed by the laws of any non-U.S. jurisdiction shall be required
                                         in respect of such assets) to the extent (i) it would reasonably be expected to cause
                                         any material adverse tax consequences to any Grantor or (ii) the Collateral Agent and
                                         the Company reasonably determine that the cost of creating or perfecting such security
                                         interest is excessive in relation to the benefits to the Collateral Agent and the Buyers
                                         therefrom.

 

		●	This
                                         Agreement creates in favor of the Collateral Agent a legal, valid and enforceable security
                                         interest in the Collateral, as security for the Obligations. The compliance with the
                                         Perfection Requirements will result in the perfection of such security interests. Such
                                         security interests are, or in the case of Collateral in which such Grantor obtains rights
                                         after the date hereof, will be, perfected first-priority security interests, subject
                                         only to completion of the Perfection Requirements and Permitted Liens. Such Perfection
                                         Requirements and all other action necessary to perfect and protect such security interest
                                         have been or will be duly taken, except for the Collateral Agent’s having possession
                                         of Documents, Chattel Paper, Instruments and cash constituting Collateral after the date
                                         hereof and the other filings and recordations described in Section 4(i) hereof.

 

		●	As
                                         of the date hereof, such Grantor does not hold any Commercial Tort Claims nor is such
                                         Grantor aware of any such pending claims, except for such claims described in Schedule
                                         VI.

 

		●	Each
                                         of the Grantors (other than the Company) is a wholly-owned Subsidiary of the Company
                                         and are the only Subsidiaries of the Company, as of the date hereof.

 

    -23-

     

    

 

●Covenants
as to the Collateral. So long as any of the Obligations shall remain outstanding, unless the Collateral Agent shall otherwise
consent in writing:

 

		●	Further
                                         Assurances. Each Grantor will at its expense, at any time and from time to time,
                                         promptly execute and deliver all further instruments and documents and take all further
                                         action that the Collateral Agent may reasonably request in order to: (i) perfect
                                         and protect the security interest purported to be created hereby; (ii) enable the
                                         Collateral Agent to exercise and enforce its rights and remedies hereunder in respect
                                         of the Collateral; or (iii) otherwise effect the purposes of this Agreement, including,
                                         without limitation: (A) marking conspicuously all Chattel Paper and, at the request
                                         of the Collateral Agent, each of its Records pertaining to the Collateral with a legend,
                                         in form and substance satisfactory to the Collateral Agent, indicating that such Chattel
                                         Paper or other Collateral is subject to the security interest created hereby, (B) 
                                         delivering and pledging to the Collateral Agent hereunder each Promissory Note, Security,
                                         Chattel Paper or other Instrument, now or hereafter owned by such Grantor, duly endorsed
                                         and accompanied by executed instruments of transfer or assignment, all in form and substance
                                         satisfactory to the Collateral Agent, (C) executing and filing (to the extent, if
                                         any, that such Grantor’s signature is required thereon) or authenticating the filing
                                         of, such financing or continuation statements, or amendments thereto, as may be necessary
                                         or that the Collateral Agent may request in order to perfect and preserve the security
                                         interest purported to be created hereby, (D) furnishing to the Collateral Agent
                                         from time to time statements and schedules further identifying and describing the Collateral
                                         and such other reports in connection with the Collateral in each case as the Collateral
                                         Agent may reasonably request, all in reasonable detail, (E) if any Collateral shall
                                         be in the possession of a third party, notifying such Person of the Collateral Agent’s
                                         security interest created hereby and obtaining a written acknowledgment from such Person
                                         that such Person holds possession of the Collateral for the benefit of the Collateral
                                         Agent, which such written acknowledgement shall be in form and substance satisfactory
                                         to the Collateral Agent, (F) if at any time after the date hereof, such Grantor
                                         acquires or holds any Commercial Tort Claim, promptly notifying the Collateral Agent
                                         in a writing signed by such Grantor setting forth a brief description of such Commercial
                                         Tort Claim and granting to the Collateral Agent a security interest therein and in the
                                         proceeds thereof, which writing shall incorporate the provisions hereof and shall be
                                         in form and substance satisfactory to the Collateral Agent, (G)  upon the acquisition
                                         after the date hereof by such Grantor of any motor vehicle or other Equipment subject
                                         to a certificate of title or ownership (other than a Motor Vehicle or Equipment that
                                         is subject to a purchase money security interest), causing the Collateral Agent to be
                                         listed as the lienholder on such certificate of title or ownership and delivering evidence
                                         of the same to the Collateral Agent in accordance with the Securities Purchase Agreement;
                                         and (H) taking all actions required by any earlier versions of the Uniform Commercial
                                         Code or by other law, as applicable, in any relevant Uniform Commercial Code jurisdiction,
                                         or by other law as applicable in any foreign jurisdiction.

 

		●	Location
                                         of Equipment and Inventory. Each Grantor will keep the Equipment and Inventory at
                                         the locations specified therefor in Section 4(d) hereof or, upon not less
                                         than thirty (30) days’ prior written notice to the Collateral Agent accompanied
                                         by a new Schedule III hereto indicating each new location of the Equipment and
                                         Inventory, at such other locations in the United States.

 

		●	Condition
                                         of Equipment. Each Grantor will maintain or cause the Equipment (necessary or useful
                                         to its business) to be maintained and preserved in good condition, repair and working
                                         order, ordinary wear and tear excepted, and will forthwith, or in the case of any loss
                                         or damage to any material Equipment of such Grantor within a commercially reasonable
                                         time after the occurrence thereof, make or cause to be made all repairs, replacements
                                         and other improvements in connection therewith which are necessary, consistent with past
                                         practice, or which the Collateral Agent may reasonably request to such end. Such Grantor
                                         will promptly furnish to the Collateral Agent a statement describing in reasonable detail
                                         any such loss or damage to any such Equipment.

 

    -24-

     

    

 

		●	Taxes,
                                         Etc. Each Grantor agrees to pay promptly when due all property and other taxes, assessments
                                         and governmental charges or levies imposed upon, and all claims (including claims for
                                         labor, materials and supplies) against, the Equipment and Inventory, except to the extent
                                         the validity thereof is being contested in good faith by proper proceedings which stay
                                         the imposition of any penalty, fine or Lien resulting from the non-payment thereof and
                                         with respect to which adequate reserves in accordance with GAAP have been set aside for
                                         the payment thereof.

 

		●	Insurance.

 

		●	Each
                                         Grantor will maintain insurance with responsible and reputable insurance companies or
                                         associations (including, without limitation, comprehensive general liability, hazard,
                                         rent and business interruption insurance) with respect to its properties (including all
                                         real properties leased or owned by it) and business, in such amounts and covering such
                                         risks as is required by any governmental authority having jurisdiction with respect thereto
                                         or as is carried generally in accordance with sound business practice by companies in
                                         similar businesses similarly situated. Unless otherwise agreed to by the
                                         Collateral Agent, each such policy for liability insurance shall provide for all losses
                                         to be paid on behalf of the Collateral Agent and such Grantor as their respective interests
                                         may appear, and each policy for property damage insurance shall provide for all losses
                                         to be adjusted with, and paid directly to, the Collateral Agent. Unless otherwise agreed
                                         to by the Collateral Agent, each such policy shall in addition (A) name the Collateral
                                         Agent as an additional insured party thereunder (without any representation or warranty
                                         by or obligation upon the Collateral Agent) as their interests may appear, (B) contain
                                         an agreement by the insurer that any loss thereunder shall be payable to the Collateral
                                         Agent on its own account notwithstanding any action, inaction or breach of representation
                                         or warranty by such Grantor, (C) provide that there shall be no recourse against the
                                         Collateral Agent for payment of premiums or other amounts with respect thereto, and (D)
                                         provide that at least 30 days’ prior written notice of cancellation, lapse, expiration
                                         or other adverse change shall be given to the Collateral Agent by the insurer. Such Grantor
                                         will, if so requested by the Collateral Agent, deliver to the Collateral Agent original
                                         or duplicate policies of such insurance and, as often as the Collateral Agent may reasonably
                                         request, a report of a reputable insurance broker with respect to such insurance. Such
                                         Grantor will also, at the request of the Collateral Agent, execute and deliver instruments
                                         of assignment of such insurance policies and cause the respective insurers to acknowledge
                                         notice of such assignment.

 

		●	Reimbursement
                                         under any liability insurance maintained by a Grantor pursuant to this Section 5(e)
                                         may be paid directly to the Person who shall have incurred liability covered by such
                                         insurance. In the case of any loss involving damage to Equipment or Inventory, any proceeds
                                         of insurance maintained by a Grantor pursuant to this Section 5(e) shall be paid
                                         to the Collateral Agent (except as to which paragraph (iii) of this Section 5(e)
                                         is not applicable), such Grantor will make or cause to be made the necessary repairs
                                         to or replacements of such Equipment or Inventory, and any proceeds of insurance maintained
                                         by such Grantor pursuant to this Section 5(e) shall be paid by the Collateral
                                         Agent to such Grantor as reimbursement for the costs of such repairs or replacements.

 

    -25-

     

    

 

		●	All
                                         insurance payments in respect of such Equipment or Inventory shall be paid to the Collateral
                                         Agent and applied as specified in Section 7(b) hereof.

 

		●	Provisions
                                         Concerning the Accounts.

 

		●	Each
                                         Grantor will (A) give the Collateral Agent at least 30 days’ prior written notice
                                         of any change in such Grantor’s name, identity or organizational structure, (B)
                                         maintain its jurisdiction of incorporation as set forth in Section 4(a) hereto,
                                         (C) immediately notify the Collateral Agent upon obtaining an organizational identification
                                         number, if on the date hereof such Grantor did not have such identification number, and
                                         (D) keep adequate records concerning the Accounts and Chattel Paper and permit representatives
                                         of the Collateral Agent during normal business hours on reasonable notice to such Grantor,
                                         to inspect and make abstracts from such Records and Chattel Paper.

 

		●	Each
                                         Grantor will, except as otherwise provided in this subsection (f), continue to collect,
                                         at its own expense, all amounts due or to become due under the Accounts. In connection
                                         with such collections, such Grantor may (and, at the Collateral Agent’s direction,
                                         will) take such action as such Grantor or the Collateral Agent may deem necessary or
                                         advisable to enforce collection or performance of the Accounts; provided, however,
                                         that the Collateral Agent shall have the right at any time, upon the occurrence and during
                                         the continuance of an Event of Default, to notify the Account Debtors or obligors under
                                         any Accounts of the assignment of such Accounts to the Collateral Agent and to direct
                                         such Account Debtors or obligors to make payment of all amounts due or to become due
                                         to such Grantor thereunder directly to the Collateral Agent or its designated agent and,
                                         upon such notification and at the expense of such Grantor and to the extent permitted
                                         by law, to enforce collection of any such Accounts and to adjust, settle or compromise
                                         the amount or payment thereof, in the same manner and to the same extent as such Grantor
                                         might have done. After receipt by a Grantor of a notice from the Collateral Agent that
                                         the Collateral Agent has notified, intends to notify, or has enforced or intends to enforce
                                         a Grantor’s rights against the Account Debtors or obligors under any Accounts as
                                         referred to in the proviso to the immediately preceding sentence, (A) all amounts
                                         and proceeds (including Instruments) received by such Grantor in respect of the Accounts
                                         shall be received in trust for the benefit of the Collateral Agent hereunder, shall be
                                         segregated from other funds of such Grantor and shall be forthwith paid over to the Collateral
                                         Agent in the same form as so received (with any necessary endorsement) to be held as
                                         cash collateral and applied as specified in Section 7(b) hereof, and (B) such
                                         Grantor will not adjust, settle or compromise the amount or payment of any Account or
                                         release wholly or partly any Account Debtors or obligor thereof or allow any credit or
                                         discount thereon. In addition, upon the occurrence and during the continuance of an Event
                                         of Default, the Collateral Agent may (in its sole and absolute discretion) direct any
                                         or all of the banks and financial institutions with which such Grantor either maintains
                                         a Deposit Account or a lockbox or deposits the proceeds of any Accounts to send immediately
                                         to the Collateral Agent by wire transfer (to such account as the Collateral Agent shall
                                         specify, or in such other manner as the Collateral Agent shall direct) all or a portion
                                         of such securities, cash, investments and other items held by such institution. Any such
                                         securities, cash, investments and other items so received by the Collateral Agent shall
                                         (in the sole and absolute discretion of the Collateral Agent) be held as additional Collateral
                                         for the Obligations or distributed in accordance with Section 7 hereof.

 

    -26-

     

    

 

		●	Transfers
                                         and Other Liens. No Grantor will create, suffer to exist or grant any Lien upon or
                                         with respect to any Collateral other than a Permitted Lien.

 

		●	Intellectual
                                         Property.

 

		●	If
                                         applicable, each Grantor shall, upon the Collateral Agent’s written request, duly
                                         execute and deliver the applicable Intellectual Property Security Agreement in the form
                                         attached hereto as Exhibit A. Each Grantor (either itself or through licensees)
                                         will, and will cause each licensee thereof to, take all action necessary to maintain
                                         all of the Intellectual Property in full force and effect, including, without limitation,
                                         using the proper statutory notices and markings and using the Trademarks on each applicable
                                         trademark class of goods in order to so maintain the Trademarks in full force and free
                                         from any claim of abandonment for non-use, and such Grantor will not (nor permit any
                                         licensee thereof to) do any act or knowingly omit to do any act whereby any Intellectual
                                         Property may become invalidated. Each Grantor will (A) cause to be taken all necessary
                                         steps in any proceeding before the United States Patent and Trademark Office and the
                                         United States Copyright Office or any similar office or agency in any other country or
                                         political subdivision thereof to maintain each registration of the Intellectual Property,
                                         including, without limitation, filing of renewals, affidavits of use, affidavits of incontestability
                                         and opposition, interference and cancellation proceedings and payment of maintenance
                                         fees, filing fees, taxes or other governmental fees in the ordinary course of business
                                         and (B) take commercially reasonable steps to protect, maintain and enforce all other
                                         Intellectual Property. If any Intellectual Property is infringed, misappropriated, diluted
                                         or otherwise violated in any material respect by a third party, such Grantor shall (x)
                                         upon learning of such infringement, misappropriation, dilution or other violation, promptly
                                         notify the Collateral Agent and (y) to the extent such Grantor shall deem appropriate
                                         under the circumstances, in the exercise of its reasonable judgment, promptly sue for
                                         infringement, misappropriation, dilution or other violation, seek injunctive relief where
                                         appropriate and recover any and all damages for such infringement, misappropriation,
                                         dilution or other violation, or take such other actions as such Grantor shall deem appropriate
                                         under the circumstances, in the exercise of its reasonable judgment, to maintain, enforce
                                         and protect such Intellectual Property. Each Grantor shall furnish to the Collateral
                                         Agent from time to time upon its request statements and schedules further identifying
                                         and describing the Intellectual Property and Licenses and such other reports in connection
                                         with the Intellectual Property and Licenses as the Collateral Agent may reasonably request,
                                         all in reasonable detail and promptly upon request of the Collateral Agent, following
                                         receipt by the Collateral Agent of any such statements, schedules or reports, such Grantor
                                         shall modify this Agreement by amending Schedule II hereto, as the case may be,
                                         to include any Intellectual Property and License, as the case may be, which becomes part
                                         of the Collateral under this Agreement and shall execute and authenticate such documents,
                                         including, without limitation, the applicable Intellectual Property Security Agreements,
                                         and do such acts as shall be necessary to subject such Intellectual Property and Licenses
                                         to the Lien and security interest created by this Agreement. Notwithstanding anything
                                         herein to the contrary, upon the occurrence and during the continuance of an Event of
                                         Default, such Grantor may not abandon or otherwise permit any Intellectual Property to
                                         become invalid without the prior written consent of the Collateral Agent, and if any
                                         Intellectual Property is infringed, misappropriated, diluted or otherwise violated by
                                         a third party, such Grantor will take such action as the Collateral Agent shall deem
                                         appropriate under the circumstances to maintain, enforce and protect such Intellectual
                                         Property.

 

    -27-

     

    

 

		●	In
                                         no event shall a Grantor, either itself or through any agent, employee, licensee or designee,
                                         file an application for the registration of any Trademark or Copyright or the issuance
                                         of any Patent with the United States Patent and Trademark Office or the United States
                                         Copyright Office, as applicable, or in any similar office or agency of the United States
                                         or any country or any political subdivision thereof unless it gives the Collateral Agent
                                         prior written notice thereof. In the event that, after the date hereof, a Grantor acquires
                                         any registration, or application for the registration, of any Trademark or Copyright,
                                         or any issued Patent, or application for any Patent, such Grantor shall provide the Collateral
                                         Agent written notice thereof with thirty (30) days of acquiring such Trademark, Copyright
                                         or Patent, as applicable. Upon request of the Collateral Agent, each Grantor shall execute,
                                         authenticate and deliver any and all assignments, agreements, instruments, documents
                                         and papers, including, without limitation, the applicable Intellectual Property Security
                                         Agreements, as the Collateral Agent may reasonably request to evidence the Collateral
                                         Agent’s security interest hereunder in the foregoing Intellectual Property and
                                         the General Intangibles of such Grantor relating thereto or represented thereby, and
                                         such Grantor hereby appoints the Collateral Agent its attorney-in-fact to execute and/or
                                         authenticate and file all such writings for the foregoing purposes, all acts of such
                                         attorney being hereby ratified and confirmed, and such power (being coupled with an interest)
                                         shall be irrevocable until the indefeasible payment in full in cash of all obligations
                                         under the Notes (together with any matured indemnification obligations as of the date
                                         of such payment, but excluding any inchoate or unmatured contingent indemnification obligations).

 

		●	Upon
                                         the Collateral Agent’s request, each Grantor shall cause each domain registrar
                                         where any of such Grantor’s Internet domain names are registered, whether as of
                                         the date of this Agreement or at any time hereafter, to execute and deliver to the Collateral
                                         Agent a domain name control agreement, in form and substance reasonably satisfactory
                                         to the Collateral Agent, duly executed by such Grantor and such domain registrar, or
                                         enter into other arrangements in form and substance satisfactory to the Collateral Agent,
                                         pursuant to which such domain registrar shall irrevocably agree, inter alia, that
                                         it will comply at any time with the instructions originated by the Collateral Agent to
                                         such domain registrar directing substitution of the Collateral Agent or its designee
                                         as the registered owner of such Internet domain names, without further consent of such
                                         Grantor, which instructions the Collateral Agent will not give to such domain registrar
                                         in the absence of a continuing Event of Default.

 

    -28-

     

    

 

		●	Deposit,
                                         Commodities and Securities Accounts. Upon the Collateral Agent’s request and
                                         unless otherwise agreed by Agent, each Grantor shall cause each bank and other financial
                                         institution with an account referred to in Schedule IV hereto to execute and deliver
                                         to the Collateral Agent a control agreement, in form and substance reasonably satisfactory
                                         to the Collateral Agent, duly executed by such Grantor and such bank or financial institution,
                                         or enter into other arrangements in form and substance satisfactory to the Collateral
                                         Agent, pursuant to which such institution shall irrevocably agree, inter alia,
                                         that (i) it will comply at any time with the instructions originated by the Collateral
                                         Agent to such bank or financial institution directing the disposition of cash, Commodity
                                         Contracts, securities, Investment Property and other items from time to time credited
                                         to such account, without further consent of such Grantor, which instructions the Collateral
                                         Agent will not give to such bank or other financial institution in the absence of a continuing
                                         Event of Default, (ii) all cash, Commodity Contracts, securities, Investment Property
                                         and other items of such Grantor deposited with such institution shall be subject to a
                                         perfected, first-priority security interest in favor of the Collateral Agent, (iii) any
                                         right of set off, banker’s Lien or other similar Lien, security interest or encumbrance
                                         shall be fully waived as against the Collateral Agent, and (iv) upon receipt of
                                         written notice from the Collateral Agent during the continuance of an Event of Default,
                                         such bank or financial institution shall immediately send to the Collateral Agent by
                                         wire transfer (to such account as the Collateral Agent shall specify, or in such other
                                         manner as the Collateral Agent shall direct) all such cash, the value of any Commodity
                                         Contracts, securities, Investment Property and other items held by it. Without the prior
                                         written consent of the Collateral Agent, such Grantor shall not make or maintain any
                                         Deposit Account, Commodity Account or Securities Account except for the accounts set
                                         forth in Schedule IV hereto. The provisions of this paragraph 5(i) shall not apply
                                         to (i) Deposit Accounts for which the Collateral Agent is the depositary, (ii) accounts
                                         specially and exclusively used for escrow, payroll, withholding, payroll taxes and other
                                         employee wage and benefit payments to or for the benefit of a Grantor’s salaried
                                         employees, trust or other similar accounts, (iii) zero balance accounts and (iv) such
                                         other accounts as may be agreed to by the Collateral Agent in writing (the foregoing,
                                         “Excluded Accounts”).

 

		●	Motor
                                         Vehicles.

 

		●	Each
                                         Grantor shall deliver to the Collateral Agent originals of the certificates of title
                                         or ownership for all motor vehicles owned by it with the Collateral Agent listed as lienholder,
                                         for the benefit of the Buyers.

 

		●	Each
                                         Grantor hereby appoints the Collateral Agent as its attorney-in-fact, effective the date
                                         hereof and terminating upon the termination of this Agreement, for the purpose of (A)
                                         executing on behalf of such Grantor title or ownership applications for filing with appropriate
                                         state agencies to enable motor vehicles now owned or hereafter acquired by such Grantor
                                         to be retitled and the Collateral Agent listed as lienholder thereof, (B) filing such
                                         applications with such state agencies, and (C) executing such other documents and instruments
                                         on behalf of, and taking such other action in the name of, such Grantor as the Collateral
                                         Agent may deem necessary or advisable to accomplish the purposes hereof (including, without
                                         limitation, for the purpose of creating in favor of the Collateral Agent a perfected
                                         Lien on the motor vehicles and exercising the rights and remedies of the Collateral Agent
                                         hereunder). This appointment as attorney-in-fact is coupled with an interest and is irrevocable
                                         until the indefeasible payment in full in cash of all obligations under the Notes (together
                                         with any matured indemnification obligations as of the date of such payment, but excluding
                                         any inchoate or unmatured contingent indemnification obligations).

 

		●	Any
                                         certificates of title or ownership delivered pursuant to the terms hereof shall be accompanied
                                         by odometer statements for each motor vehicle covered thereby.

 

		●	So
                                         long as no Event of Default shall have occurred and be continuing, upon the request of
                                         such Grantor, the Collateral Agent shall execute and deliver to such Grantor such instruments
                                         as such Grantor shall reasonably request to remove the notation of the Collateral Agent
                                         as lienholder on any certificate of title for any motor vehicle; provided, however,
                                         that any such instruments shall be delivered, and the release effective, only upon receipt
                                         by the Collateral Agent of a certificate from such Grantor stating that such motor vehicle
                                         is to be sold or has suffered a casualty loss (with title thereto passing to the casualty
                                         insurance company therefor in settlement of the claim for such loss) and the amount that
                                         such Grantor will receive as sale proceeds or insurance proceeds. Any proceeds of such
                                         sale or casualty loss shall be paid to the Collateral Agent hereunder immediately upon
                                         receipt, to be applied to the Obligations then outstanding.

 

    -29-

     

    

 

		●	Control.
                                         Each Grantor hereby agrees to take any or all action that may be necessary or that the
                                         Collateral Agent may request in order for the Collateral Agent to obtain control in accordance
                                         with Sections 9-105 – 9-107 of the Code with respect to the following Collateral:
                                         (i) Electronic Chattel Paper, (ii) Investment Property, (iii) Pledged Interests
                                         and (iv) Letter-of-Credit Rights.

 

		●	Inspection
                                         and Reporting. Each Grantor shall permit the Collateral Agent, or any agent or representatives
                                         thereof or such professionals or other Persons as the Collateral Agent may designate,
                                         not more than once a year in the absence of an Event of Default, (i) to examine
                                         and make copies of and abstracts from such Grantor’s records and books of account,
                                         (ii) to visit and inspect its properties, (iii) to verify materials, leases, Instruments,
                                         Accounts, Inventory and other assets of such Grantor from time to time, (iii) to
                                         conduct audits, physical counts, appraisals and/or valuations, examinations at the locations
                                         of such Grantor. Each Grantor shall also permit the Collateral Agent, or any agent or
                                         representatives thereof or such professionals or other Persons as the Collateral Agent
                                         may designate to discuss such Grantor’s affairs, finances and accounts with any
                                         of its officers subject to the execution by the Collateral Agent or its designee(s) of
                                         a mutually agreeable confidentiality agreement.

 

		●	Future
                                         Subsidiaries. If any Grantor shall hereafter create or acquire any Subsidiary, simultaneously
                                         with the creation of acquisition of such Subsidiary, such Grantor shall cause such Subsidiary
                                         to become a party to this Agreement as an additional “Grantor” hereunder
                                         and to become a party to the Guarantee Agreement as an additional “Guarantor”
                                         thereunder, and to duly execute and/or deliver such opinions of counsel and other documents,
                                         in form and substance acceptable to the Collateral Agent, as the Collateral Agent shall
                                         reasonably request with respect thereto.

 

●Additional
Provisions Concerning the Collateral.

 

		●	Each
                                         Grantor hereby (i) authorizes the Collateral Agent to file one or more Uniform Commercial
                                         Code financing or continuation statements, and amendments thereto, relating to the Collateral
                                         (including, without limitation, financing statements describing the Collateral as “all
                                         assets” or “all personal property” or words of similar effect) and
                                         (ii) ratifies such authorization to the extent that the Collateral Agent has filed
                                         any such financing or continuation statements, or amendments thereto, prior to the date
                                         hereof. A photocopy or other reproduction of this Agreement or any financing statement
                                         covering the Collateral or any part thereof shall be sufficient as a financing statement
                                         where permitted by law.

 

		●	Each
                                         Grantor hereby irrevocably appoints the Collateral Agent as its attorney-in-fact and
                                         proxy, with full authority in the place and stead of such Grantor and in the name of
                                         such Grantor or otherwise, from time to time in the Collateral Agent’s discretion,
                                         so long as an Event of Default shall have occurred and be continuing, to take any action
                                         and to execute any instrument which the Collateral Agent may deem necessary or advisable
                                         to accomplish the purposes of this Agreement (subject to the rights of such Grantor under
                                         Section 5 hereof), including, without limitation, (i) to obtain and adjust insurance
                                         required to be paid to the Collateral Agent pursuant to Section 5(e) hereof, (ii)
                                         to ask, demand, collect, sue for, recover, compound, receive and give acquittance and
                                         receipts for moneys due and to become due under or in respect of any Collateral, (iii)
                                         to receive, endorse, and collect any drafts or other instruments, documents and chattel
                                         paper in connection with clause (i) or (ii) above, (iv) to file any claims or take any
                                         action or institute any proceedings which the Collateral Agent may deem necessary for
                                         the collection of any Collateral or otherwise to enforce the rights of the Collateral
                                         Agent and the Buyers with respect to any Collateral, and (v) to execute assignments,
                                         licenses and other documents to enforce the rights of the Collateral Agent and the Buyers
                                         with respect to any Collateral. This power is coupled with an interest and is irrevocable
                                         until the indefeasible payment in full in cash of all obligations under the Notes (together
                                         with any matured indemnification obligations as of the date of such payment, but excluding
                                         any inchoate or unmatured contingent indemnification obligations).

 

    -30-

     

    

 

		●	Each
                                         Grantor hereby releases the Collateral Agent from any claims, causes of action and demands
                                         at any time arising out of or with respect to any actions taken or omitted to be taken
                                         by the Collateral Agent under the powers of attorney granted herein other than actions
                                         taken or omitted to be taken through the Collateral Agent’s gross negligence or
                                         willful misconduct, as determined by a final determination of a court of competent jurisdiction.

 

		●	For
                                         the purpose of enabling the Collateral Agent to exercise rights and remedies hereunder,
                                         at such time as the Collateral Agent shall be lawfully entitled to exercise such rights
                                         and remedies upon and during an Event of Default, and for no other purpose, each Grantor
                                         hereby grants to the Collateral Agent, to the extent assignable, an irrevocable, non-exclusive
                                         license (exercisable without payment of royalty or other compensation to such Grantor)
                                         to use, assign, license or sublicense any Intellectual Property now owned or hereafter
                                         acquired by such Grantor, wherever the same may be located, including in such license
                                         reasonable access to all media in which any of the licensed items may be recorded or
                                         stored and to all computer programs used for the compilation or printout thereof. Notwithstanding
                                         anything contained herein to the contrary, but subject to the provisions of the Securities
                                         Purchase Agreement that limit the right of such Grantor to dispose of its property and
                                         Section 5(h) hereof, so long as no Event of Default shall have occurred and be
                                         continuing, such Grantor may exploit, use, enjoy, protect, license, sublicense, assign,
                                         sell, dispose of or take other actions with respect to the Intellectual Property in the
                                         ordinary course of its business. In furtherance of the foregoing, unless an Event of
                                         Default shall have occurred and be continuing, the Collateral Agent shall from time to
                                         time, upon the request of a Grantor, execute and deliver any instruments, certificates
                                         or other documents, in the form so requested, which such Grantor shall have certified
                                         are appropriate (in such Grantor’s judgment) to allow it to take any action permitted
                                         above (including relinquishment of the license provided pursuant to this clause (c) as
                                         to any Intellectual Property). Further, upon the indefeasible payment in full in cash
                                         of all obligations under the Notes (together with any matured indemnification obligations
                                         as of the date of such payment, but excluding any inchoate or unmatured contingent indemnification
                                         obligations), the Collateral Agent (subject to Section 10(e) hereof) shall release
                                         and reassign to such Grantor all of the Collateral Agent’s right, title and interest
                                         in and to the Intellectual Property, all without recourse, representation or warranty
                                         whatsoever. The exercise of rights and remedies hereunder by the Collateral Agent shall
                                         not terminate the rights of the holders of any licenses or sublicenses theretofore granted
                                         by such Grantor in accordance with the second sentence of this clause (c). Each Grantor
                                         hereby releases the Collateral Agent from any claims, causes of action and demands at
                                         any time arising out of or with respect to any actions taken or omitted to be taken by
                                         the Collateral Agent under the powers of attorney granted herein other than actions taken
                                         or omitted to be taken through the Collateral Agent’s gross negligence or willful
                                         misconduct, as determined by a final determination of a court of competent jurisdiction.

 

		●	The
                                         powers conferred on the Collateral Agent hereunder are solely to protect its interest
                                         in the Collateral and shall not impose any duty upon it to exercise any such powers.
                                         Except for the safe custody of any Collateral in its possession and the accounting for
                                         moneys actually received by it hereunder, the Collateral Agent shall have no duty as
                                         to any Collateral or as to the taking of any necessary steps to preserve rights against
                                         prior parties or any other rights pertaining to any Collateral.

 

    -31-

     

    

 

●Remedies
Upon Event of Default. If any Event of Default shall have occurred and be continuing:

 

		●	The
                                         Collateral Agent may exercise in respect of the Collateral, in addition to any other
                                         rights and remedies provided for herein or otherwise available to it, all of the rights
                                         and remedies of a secured party upon default under the Code (whether or not the Code
                                         applies to the affected Collateral), and also may (i) take absolute control of the
                                         Collateral, including, without limitation, transfer into the Collateral Agent’s
                                         name or into the name of its nominee or nominees (to the extent the Collateral Agent
                                         has not theretofore done so) and thereafter receive, for the benefit of the Collateral
                                         Agent, all payments made thereon, give all consents, waivers and ratifications in respect
                                         thereof and otherwise act with respect thereto as though it were the outright owner thereof,
                                         (ii) require each Grantor to, and each Grantor hereby agrees that it will at its
                                         expense and upon request of the Collateral Agent forthwith, assemble all or part of its
                                         respective Collateral as directed by the Collateral Agent and make it available to the
                                         Collateral Agent at a place or places to be designated by the Collateral Agent that is
                                         reasonably convenient to both parties, and the Collateral Agent may enter into and occupy
                                         any premises owned or leased by such Grantor where the Collateral or any part thereof
                                         is located or assembled for a reasonable period in order to effectuate the Collateral
                                         Agent’s rights and remedies hereunder or under law, without obligation to such
                                         Grantor in respect of such occupation, and (iii) without notice except as specified
                                         below and without any obligation to prepare or process the Collateral for sale, (A) sell
                                         the Collateral or any part thereof in one or more parcels at public or private sale,
                                         at any of the Collateral Agent’s offices or elsewhere, for cash, on credit or for
                                         future delivery, and at such price or prices and upon such other terms as the Collateral
                                         Agent may deem commercially reasonable and/or (B) lease, license or dispose of the
                                         Collateral or any part thereof upon such terms as the Collateral Agent may deem commercially
                                         reasonable. Each Grantor agrees that, to the extent notice of sale or any other disposition
                                         of its respective Collateral shall be required by law, at least ten (10) days’
                                         notice to such Grantor of the time and place of any public sale or the time after which
                                         any private sale or other disposition of its respective Collateral is to be made shall
                                         constitute reasonable notification. The Collateral Agent shall not be obligated to make
                                         any sale or other disposition of any Collateral regardless of notice of sale having been
                                         given. The Collateral Agent may adjourn any public or private sale from time to time
                                         by announcement at the time and place fixed therefor, and such sale may, without further
                                         notice, be made at the time and place to which it was so adjourned. Each Grantor hereby
                                         waives any claims against the Collateral Agent and the Buyers arising by reason of the
                                         fact that the price at which its respective Collateral may have been sold at a private
                                         sale was less than the price which might have been obtained at a public sale or was less
                                         than the aggregate amount of the Obligations, even if the Collateral Agent accepts the
                                         first offer received and does not offer such Collateral to more than one offeree, and
                                         waives all rights that such Grantor may have to require that all or any part of such
                                         Collateral be marshalled upon any sale (public or private) thereof. Each Grantor hereby
                                         acknowledges that (i) any such sale of its respective Collateral by the Collateral
                                         Agent shall be made without warranty, (ii) the Collateral Agent may specifically
                                         disclaim any warranties of title, possession, quiet enjoyment or the like, and (iii) such
                                         actions set forth in clauses (i) and (ii) above shall not adversely affect the commercial
                                         reasonableness of any such sale of Collateral. In addition to the foregoing, (1) upon
                                         written notice to any Grantor from the Collateral Agent, such Grantor shall cease any
                                         use of the Intellectual Property or any Trademark similar to any Trademark contained
                                         in the Collateral for any purpose described in such notice; (2) the Collateral Agent
                                         may, at any time and from time to time, upon 10 days’ prior notice to such Grantor,
                                         license, whether general, special or otherwise, and whether on an exclusive or non-exclusive
                                         basis, any of the Intellectual Property, throughout the universe for such term or terms,
                                         on such conditions, and in such manner, as the Collateral Agent shall in its sole discretion
                                         determine to the extent consistent with any restrictions or conditions imposed upon such
                                         Grantor with respect to such Intellectual Property by license or other contractual arrangement;
                                         and (2) the Collateral Agent may, at any time, pursuant to the authority granted in Section
                                         6 hereof (such authority being effective upon the occurrence and during the continuance
                                         of an Event of Default), execute and deliver on behalf of such Grantor, one or more instruments
                                         of assignment of the Intellectual Property (or any application or registration thereof),
                                         in form suitable for filing, recording or registration in any country.

 

    -32-

     

    

 

		●	Any
                                         cash held by the Collateral Agent as Collateral and all Cash Proceeds received by the
                                         Collateral Agent in respect of any sale of or collection from, or other realization upon,
                                         all or any part of the Collateral may, in the discretion of the Collateral Agent, be
                                         held by the Collateral Agent as collateral for, and/or then or at any time thereafter
                                         applied (after payment of any amounts payable to the Collateral Agent pursuant to Section
                                         8 hereof) in whole or in part by the Collateral Agent against, all or any part of
                                         the Obligations in such order as the Collateral Agent shall elect, consistent with the
                                         provisions of the Securities Purchase Agreement. Any surplus of such cash or Cash Proceeds
                                         held by the Collateral Agent and remaining after the indefeasible payment in full in
                                         cash of all obligations under the Notes (together with any matured indemnification obligations
                                         as of the date of such payment, but excluding any inchoate or unmatured contingent indemnification
                                         obligations) shall be paid over to whomsoever shall be lawfully entitled to receive the
                                         same or as a court of competent jurisdiction shall direct.

 

		●	In
                                         the event that the proceeds of any such sale, collection or realization are insufficient
                                         to pay all amounts to which the Collateral Agent and the Buyers are legally entitled,
                                         each Grantor shall be liable for the deficiency, together with interest thereon at the
                                         highest rate specified in any of the applicable Transaction Documents for interest on
                                         overdue principal thereof or such other rate as shall be fixed by applicable law, together
                                         with the costs of collection and the reasonable fees, costs, expenses and other client
                                         charges of any attorneys employed by the Collateral Agent to collect such deficiency.

 

		●	Each
                                         Grantor hereby acknowledges that if the Collateral Agent complies with any applicable
                                         state, provincial, or federal law requirements in connection with a disposition of the
                                         Collateral, such compliance will not adversely affect the commercial reasonableness of
                                         any sale or other disposition of the Collateral.

 

		●	The
                                         Collateral Agent shall not be required to marshal any present or future collateral security
                                         (including, but not limited to, this Agreement and the Collateral) for, or other assurances
                                         of payment of, the Obligations or any of them or to resort to such collateral security
                                         or other assurances of payment in any particular order, and all of the Collateral Agent’s
                                         rights hereunder and in respect of such collateral security and other assurances of payment
                                         shall be cumulative and in addition to all other rights, however existing or arising.
                                         To the extent that each Grantor lawfully may, such Grantor hereby agrees that it will
                                         not invoke any law relating to the marshalling of collateral which might cause delay
                                         in or impede the enforcement of the Collateral Agent’s rights under this Agreement
                                         or under any other instrument creating or evidencing any of the Obligations or under
                                         which any of the Obligations is outstanding or by which any of the Obligations is secured
                                         or payment thereof is otherwise assured, and, to the extent that it lawfully may, such
                                         Grantor hereby irrevocably waives the benefits of all such laws.

 

    -33-

     

    

 

●Indemnity
and Expenses.

 

		●	Each
                                         Grantor agrees, jointly and severally, to defend, protect, indemnify and hold the Collateral
                                         Agent and each of the Buyers, jointly and severally, harmless from and against any and
                                         all claims, damages, losses, liabilities, obligations, penalties, fees, costs and expenses
                                         (including, without limitation, reasonable legal fees, costs, expenses, and disbursements
                                         of such Person’s counsel) to the extent that they arise out of or otherwise result
                                         from this Agreement (including, without limitation, enforcement of this Agreement), except
                                         claims, losses or liabilities resulting solely and directly from such Person’s
                                         gross negligence or willful misconduct, as determined by a final judgment of a court
                                         of competent jurisdiction.

 

		●	Each
                                         Grantor agrees, jointly and severally, to, upon demand, pay to the Collateral Agent the
                                         amount of any and all costs and expenses, including the reasonable fees, costs, expenses
                                         and disbursements of counsel for the Collateral Agent and of any experts and agents (including,
                                         without limitation, any collateral trustee which may act as agent of the Collateral Agent),
                                         which the Collateral Agent may incur in connection with (i) the preparation, negotiation,
                                         execution, delivery, recordation, administration, amendment, waiver or other modification
                                         or termination of this Agreement subject to, and to the extent of, Section 4(d) of the
                                         Securities Purchase Agreement, (ii) the custody, preservation, use or operation
                                         of, or the sale of, collection from, or other realization upon, any Collateral, (iii) the
                                         exercise or enforcement of any of the rights of the Collateral Agent hereunder, or (iv) the
                                         failure by any Grantor to perform or observe any of the provisions hereof.

 

●Notices,
Etc. All notices and other communications provided for hereunder shall be served in accordance with Section 9(f) of the Securities
Purchase Agreement.

 

●Miscellaneous.

 

		●	No
                                         amendment of any provision of this Agreement shall be effective unless it is in writing
                                         and signed by each Grantor and the Collateral Agent, and no waiver of any provision of
                                         this Agreement, and no consent to any departure by a Grantor therefrom, shall be effective
                                         unless it is in writing and signed by the Collateral Agent, and then such waiver or consent
                                         shall be effective only in the specific instance and for the specific purpose for which
                                         given.

 

		●	No
                                         failure on the part of the Collateral Agent to exercise, and no delay in exercising,
                                         any right hereunder or under any of the other Transaction Documents shall operate as
                                         a waiver thereof; nor shall any single or partial exercise of any such right preclude
                                         any other or further exercise thereof or the exercise of any other right. The rights
                                         and remedies of the Collateral Agent or any Buyer provided herein and in the other Transaction
                                         Documents are cumulative and are in addition to, and not exclusive of, any rights or
                                         remedies provided by law. The rights of the Collateral Agent or any Buyer under any of
                                         the other Transaction Documents against any party thereto are not conditional or contingent
                                         on any attempt by such Person to exercise any of its rights under any of the other Transaction
                                         Documents against such party or against any other Person, including but not limited to,
                                         any Grantor.

 

    -34-

     

    

 

		●	To
                                         the extent permitted by applicable law, each Grantor hereby waives promptness, diligence,
                                         notice of acceptance and any other notice with respect to any of the Obligations and
                                         this Agreement and any requirement that the Collateral Agent exhaust any right or take
                                         any action against any other Person or any Collateral. Each Grantor acknowledges that
                                         it will receive direct and indirect benefits from the financing arrangements contemplated
                                         herein and that the waiver set forth in this Section 10(c) is knowingly made
                                         in contemplation of such benefits. The Grantors hereby waive any right to revoke this
                                         Agreement, and acknowledge that this Agreement is continuing in nature and applies to
                                         all Obligations, whether existing now or in the future.

 

		●	No
                                         Grantor may exercise any rights that it may now or hereafter acquire against any other
                                         Grantor that arise from the existence, payment, performance or enforcement of any Grantor’s
                                         obligations under this Agreement, including, without limitation, any right of subrogation,
                                         reimbursement, exoneration, contribution or indemnification and any right to participate
                                         in any claim or remedy of the Collateral Agent against any Grantor or any Collateral,
                                         whether or not such claim, remedy or right arises in equity or under contract, statute
                                         or common law, including, without limitation, the right to take or receive from any Grantor,
                                         directly or indirectly, in cash or other property or by set-off or in any other manner,
                                         payment or security solely on account of such claim, remedy or right, unless and until
                                         the indefeasible payment in full in cash of all obligations under the Notes (together
                                         with any matured indemnification obligations as of the date of such payment, but excluding
                                         any inchoate or unmatured contingent indemnification obligations). If any amount shall
                                         be paid to a Grantor in violation of the immediately preceding sentence at any time prior
                                         to the indefeasible payment in full in cash of all obligations under the Notes (together
                                         with any matured indemnification obligations as of the date of such payment, but excluding
                                         any inchoate or unmatured contingent indemnification obligations), such amount shall
                                         be held in trust for the benefit of the Collateral Agent and shall forthwith be paid
                                         to the Collateral Agent to be credited and applied to the Obligations and all other amounts
                                         payable under the Transaction Documents, whether matured or unmatured, in accordance
                                         with the terms of the Transaction Documents, or to be held as Collateral for any Obligations
                                         or other amounts payable under the Transaction Documents thereafter arising.

 

		●	Any
                                         provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall,
                                         as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
                                         without invalidating the remaining portions hereof or thereof or affecting the validity
                                         or enforceability of such provision in any other jurisdiction.

 

    -35-

     

    

 

		●	This
                                         Agreement shall create a continuing security interest in the Collateral and shall (i)
                                         remain in full force and effect until the indefeasible payment in full in cash of all
                                         obligations under the Notes (together with any matured indemnification obligations as
                                         of the date of such payment, but excluding any inchoate or unmatured contingent indemnification
                                         obligations), and (ii) be binding on each Grantor and all other Persons who become bound
                                         as debtor to this Agreement in accordance with Section 9-203(d) of the Code and shall
                                         inure, together with all rights and remedies of the Collateral Agent and the Buyers hereunder,
                                         to the benefit of the Collateral Agent and the Buyers and their respective permitted
                                         successors, transferees and assigns. Without limiting the generality of clause (ii) of
                                         the immediately preceding sentence, without notice to any Grantor, the Collateral Agent
                                         and the Buyers may assign or otherwise transfer their rights and obligations under this
                                         Agreement and any of the other Transaction Documents, to any other Person and such other
                                         Person shall thereupon become vested with all of the benefits in respect thereof granted
                                         to the Collateral Agent and the Buyers herein or otherwise. Upon any such assignment
                                         or transfer, all references in this Agreement to the Collateral Agent or any such Buyer
                                         shall mean the assignee of the Collateral Agent or such Buyer. None of the rights or
                                         obligations of any Grantor hereunder may be assigned or otherwise transferred without
                                         the prior written consent of the Collateral Agent, and any such assignment or transfer
                                         without the consent of the Collateral Agent shall be null and void.

 

		●	Upon
                                         the indefeasible payment in full in cash of all obligations under the Notes (together
                                         with any matured indemnification obligations as of the date of such payment, but excluding
                                         any inchoate or unmatured contingent indemnification obligations), (i) this Agreement
                                         and the security interests created hereby shall terminate and all rights to the Collateral
                                         shall revert to the respective Grantor that granted such security interests hereunder,
                                         and (ii) the Collateral Agent will, upon such Grantor’s request and at such Grantor’s
                                         expense, (A) return to such Grantor such of the Collateral as shall not have been sold
                                         or otherwise disposed of or applied pursuant to the terms hereof, and (B) execute and
                                         deliver to such Grantor such documents as such Grantor shall reasonably request to evidence
                                         such termination, all without any representation, warranty or recourse whatsoever.

 

		●	THIS
                                         AGREEMENT SHALL BE GOVERNED BY, CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE LAWS
                                         OF THE STATE OF NEW YORK, EXCEPT AS REQUIRED BY MANDATORY PROVISIONS OF LAW AND EXCEPT
                                         TO THE EXTENT THAT THE VALIDITY AND PERFECTION OR THE PERFECTION AND THE EFFECT OF PERFECTION
                                         OR NON-PERFECTION OF THE SECURITY INTEREST CREATED HEREBY, OR REMEDIES HEREUNDER, IN
                                         RESPECT OF ANY PARTICULAR COLLATERAL ARE GOVERNED BY THE LAW OF A JURISDICTION OTHER
                                         THAN THE STATE OF NEW YORK.

 

		●	ANY
                                         LEGAL ACTION, SUIT OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY DOCUMENT RELATED
                                         THERETO MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK IN THE COUNTY OF NEW YORK
                                         OR THE UNITED STATES OF AMERICA FOR THE SOUTHERN DISTRICT OF NEW YORK, AND APPELLATE
                                         COURTS THEREOF, AND, BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH GRANTOR HEREBY
                                         ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE
                                         JURISDICTION OF THE AFORESAID COURTS. EACH GRANTOR HEREBY EXPRESSLY AND IRREVOCABLY WAIVES,
                                         TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION, INCLUDING, WITHOUT LIMITATION,
                                         ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS,
                                         WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY SUCH ACTION, SUIT OR PROCEEDING
                                         IN SUCH RESPECTIVE JURISDICTIONS AND CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE
                                         RELIEF AS IS DEEMED APPROPRIATE BY THE COURT.

 

    -36-

     

    

 

		●	EACH
                                         GRANTOR AND (BY ITS ACCEPTANCE OF THE BENEFITS OF THIS AGREEMENT) THE COLLATERAL AGENT
                                         WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED ON,
                                         ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE OTHER TRANSACTION
                                         DOCUMENTS, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, VERBAL OR WRITTEN STATEMENT OR
                                         OTHER ACTION OF THE PARTIES HERETO.

 

		●	Nothing
                                         contained herein shall affect the right of the Collateral Agent to serve process in any
                                         other manner permitted by law or commence legal proceedings or otherwise proceed against
                                         any Grantor or any property of such Grantor in any other jurisdiction.

 

		●	Each
                                         Grantor irrevocably and unconditionally waives any right it may have to claim or recover
                                         in any legal action, suit or proceeding referred to in this Section any special, exemplary,
                                         punitive or consequential damages.

 

		●	Section
                                         headings herein are included for convenience of reference only and shall not constitute
                                         a part of this Agreement for any other purpose.

 

		●	This
                                         Agreement may be executed in any number of counterparts and by different parties hereto
                                         in separate counterparts, each of which shall be deemed to be an original, but all of
                                         which taken together constitute one in the same Agreement.

 

[REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

    -37-

     

    

 

IN
WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its officer thereunto duly authorized,
as of the date first above written.

 

	 	QUOIN
    PHARMACEUTICALS, INC.
	 	
	 	By:	                                
	 	Name:
	 	Title:

 

	 	Address
    for Notices:
	 	42127
    Pleasant Forest Court
	 	Ashburn,
    VA 20148
	 	Attention:
    Michael Myers, Ph.D.
	 	Email:
    mmyers@quoinpharma.com

 

Pledge
and Security Agreement

 

     

     

    

 

	ACCEPTED BY:
	 
	Altium Growth Fund, LP,
	as Collateral Agent
	 
	By:	 	 
	 	Name:  	 
	 	Title:	 
	 	Address:  	 

 

Pledge
and Security Agreement 

 

     

     

    

 

SCHEDULE
I

LEGAL NAMES; ORGANIZATIONAL IDENTIFICATION NUMBERS; STATES OR JURISDICTION OF ORGANIZATION

 

	Legal
    Name	State
                                         of

                                                                                Organization
	Type
                                         of

                                                                                Organization
	Organizational

                                                                                                                                                                                      Identification

                                                                                Number

	Quoin
    Pharmaceuticals, Inc.	Delaware	Corporation	6782497

 

    Sched. I-1

     

    

 

SCHEDULE
II

 

INTELLECTUAL
PROPERTY AND LICENSES; TRADE NAMES

 

		A.	COPYRIGHTS

 

None.

 

		B.	PATENTS

 

See
D. below regarding patent rights licensed from Skinvisible Pharmaceuticals, Inc.

 

		C.	TRADEMARKS

 

None.

 

		D.	OTHER
                                         PROPRIETARY RIGHTS

 

The
company has an exclusive license to the patents below, pursuant to an Exclusive Licensing Agreement, dated October 2019, with
Skinvisible Pharmaceuticals, Inc.

 

	Jurisdiction	 	Patent
    Number	 	Grant
    Date	 	Estimated.
    Expiration Date	 	Title
	Australia	 	2002355964	 	9/8/2008	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	Canada	 	2457124	 	10/11/2011	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	China
    P.R.	 	028163249	 	7/1/2009	 	8/15/2022	 	MANUFACTURING
    AND USING
	India	 	208399	 	7/27/2007	 	8/16/2022	 	METHODS
    FOR MANUFACTURING AND USING
	Republic
    of Korea	 	0942859	 	2/9/2010	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	Hong
    Kong	 	HK1066971	 	2/5/2010	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	Great
    Britain	 	1425044	 	2/15/2012	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	France	 	1425044	 	2/15/2012	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	Germany	 	60242220.5	 	2/15/2012	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	Switzerland	 	1425044	 	2/15/2012	 	8/16/2022	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	United
    States	 	6756059	 	6/29/2004	 	8/20/2021	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR
	United
    States	 	7674471	 	3/9/2010	 	2/27/2024	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	United
    States	 	8318818	 	11/27/2012	 	2/1/2029	 	TOPICAL
    COMPOSITION, TOPICAL COMPOSITION PRECURSOR, AND METHODS FOR MANUFACTURING AND USING
	United
    States	 	8128913	 	3/6/2012	 	11/1/2029	 	Sunscreen
    composition with enhanced UV-A absorber stability and methods
	United
    States	 	8299122	 	10/30/2012	 	4/14/2029	 	Method
    for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
	United
    States	 	9149490	 	10/6/2015	 	2/17/2029	 	Acne
    treatment composition and methods for using
	United
    States	 	8735422	 	5/27/2014	 	4/10/2030	 	Cationic
    pharmaceutically active ingredient containing composition, and methods for manufacturing and using

 

		E.	TRADE
                                         NAMES

 

None.

 

		F.	NAME
                                         OF, AND EACH TRADE NAME USED BY, EACH PERSON FROM WHICH A GRANTOR HAS ACQUIRED ANY SUBSTANTIAL
                                         PART OF THE COLLATERAL WITHIN THE PRECEDING FIVE YEARS

 

Skinvisible
Pharmaceuticals, Inc.

 

    Sched. II-1

     

    

 

SCHEDULE
III

 

LOCATIONS

 

	Grantor	Location	Description
	Quoin
    Pharmaceuticals, Inc.	42127
    Pleasant Forest Court Ashburn, VA 20148	Chief
    executive office

 

    Sched. III-1

     

    

 

SCHEDULE
IV

 

PROMISSORY NOTES, SECURITIES, DEPOSIT ACCOUNTS, SECURITIES ACCOUNTS AND COMMODITIES ACCOUNTS

 

A.
Promissory Notes:

 

$666,666.67
Promissory Note, issued in October 2020 to Tony Wild

 

$146,666.67
Promissory Note, issued in October 2020 to Dennis Langer

 

$133,333.33
Promissory Note, issued in October 2020 to James Culverwell

 

$133,333.33
Promissory Note, issued in October 2020 to Mark Woloshyn

 

$133,333.33
Promissory Note, issued in October 2020 to Hugh Betts

 

B.
Securities and Other Instruments:

 

None.

 

C.
Deposit Accounts, Securities Accounts and Commodities Accounts:

 

	Grantor	Name
                                         and Address of

                                                                                Institution
                                         Maintaining

                                                                                Account
	Account
    Number	Type
    of Account
	Quoin
    Pharmaceuticals, Inc.	Wells
        Fargo Bank

        420
        Montgomery St

        San
        Francisco, CA 94104

         
	5891586058	Checking
	 	 	 	 

 

    Sched. IV-1

     

    

 

SCHEDULE
V

 

[RESERVED]

 

    Sched. V-1

     

    

 

SCHEDULE
VI

 

COMMERCIAL
TORT CLAIMS

 

None.

 

    Sched. VI-1

     

    

 

SCHEDULE
VII

 

PLEDGED
DEBT

 

Promissory
Notes described in Schedule IV.

 

    Sched. VII-1

     

    

 

SCHEDULE
VIII

 

PLEDGED
SHARES

 

None.

 

    Sched. VIII-1

     

    

 

EXHIBIT
A

 

[TRADEMARK]
[PATENT] [COPYRIGHT] SECURITY AGREEMENT

 

WHEREAS,
______________________________ (the “Assignor”) [has adopted, used and is using, and holds all right,
title and interest in and to, the trademarks and service marks listed on the annexed Schedule 1A, which trademarks
and service marks are registered or applied for in the United States Patent and Trademark Office (the “Trademarks”)]
[holds all right, title and interest in the letter patents, design patents and utility patents, and all applications therefor,
listed on the annexed Schedule 1A, which patents are issued or applied for in the United States Patent and Trademark
Office (the “Patents”)] [holds all right, title and interest in the copyrights listed on the annexed Schedule
1A, which copyrights are registered or applied for in the United States Copyright Office (the “Copyrights”)];

 

WHEREAS,
the Assignor has entered into a Pledge and Security Agreement, dated as of March 25, 2021 (as amended, restated or otherwise modified
from time to time the “Security Agreement”), in favor of Empery Debt Opportunity Fund, LP, as collateral agent
for certain buyers (the “Assignee”);

 

WHEREAS,
pursuant to the Security Agreement, the Assignor has assigned and granted to the Assignee for the benefit of the Buyers (as defined
in the Security Agreement) a continuing security interest in all right, title and interest of the Assignor in, to and under the
[Trademarks, together with, among other things, the good-will of the business symbolized by the Trademarks] [Patents] [Copyrights],
including, without limitation, all applications, registrations and recordings thereof, as applicable, and all proceeds thereof,
including, without limitation, any and all causes of action which may exist by reason of infringement, misappropriation or other
violation thereof and any and all damages arising from past, present and future infringements, misappropriations or other violations
thereof (the “Collateral”), to secure the payment, performance and observance of the “Obligations”
(as defined in the Security Agreement);

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor does
hereby pledge, convey, sell, assign, transfer and set over unto the Assignee and grants to the Assignee for the benefit of the
Buyers a continuing security interest in the Collateral.

 

The
Assignor does hereby further acknowledge and affirm that the rights and remedies of the Assignee with respect to the Collateral
are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference
as if fully set forth herein. In the event of a conflict between any provision of this [Trademark][Patent][Copyright] Security
and the Security Agreement, the terms of the Security Agreement shall govern.

 

    Exh. A-1

     

    

 

IN
WITNESS WHEREOF, the Assignor has caused this [Trademark][Patent][Copyright] Security Agreement to be duly executed by its officer
thereunto duly authorized as of _____________, 20__

 

	 	[GRANTOR]
	 	 
	 	By:	
	 		Name:
	 		Title:

 

    Exh. A-2

     

    

 

SCHEDULE
1A TO [TRADEMARK][PATENT][COPYRIGHT] SECURITY AGREEMENT

 

[Trademarks
and Trademark Applications]

[Patent
and Patent Applications]

[Copyright
and Copyright Applications]

Owned
by ______________________________

 

     

     

    

 

EXHIBIT
E

 

Private
Placement Memorandum

 

[Redacted.]

 

     

     

    

 

EXHIBIT
F

 

Form
of Opinion of Company Outside Counsel

 

March
__, 2021

 

Buyers
under the

Securities
Purchase Agreement

 

Re:Securities
Purchase Agreement dated March 24, 2021 by and among Quoin Pharmaceuticals, Inc. and Altium Growth Fund, LP

 

Ladies
and Gentlemen:

 

We
have acted as counsel to Quoin Pharmaceutics, Inc., a Delaware corporation (the “Company”) in connection
with the offer and sale by the Company of Senior Secured Notes (the “Notes”) and Warrants to purchase
shares of the Company’s Common Stock (the “Warrants”), pursuant to the Securities Purchase Agreement
dated as of the date hereof (the “Purchase Agreement”), by and among the Company and the investors set
forth on the Schedule of Buyers to the Purchase Agreement. This opinion is being delivered to you pursuant to Section 7(ii) of
the Purchase Agreement All capitalized terms used herein and not otherwise defined herein have definitions specified in the Purchase
Agreement.

 

In
connection with rendering this opinion, we have examined originals, certified copies or copies otherwise identified as being true
copies of the following:

 

(a)
the Purchase Agreement.

 

(b)
the Notes;

 

(c)
the Warrants;

 

(d)
the Pledge and Security Agreement (together with the Purchase Agreement, the Notes, and the Warrants, the “Transaction
Agreements”);

 

(e)
The certificate of Michael Myers, Chief Executive Officer of the Company, dated the date hereof, a copy of which is attached as
Exhibit A hereto (the “Company Certificate”);

 

(f)
An unfiled copy of the UCC-1 financing statement naming the Company, as debtor, and the Collateral Agent, as secured party, together
with all schedules and exhibits thereto, to be filed in the Office of the Secretary of State of the State of Delaware (the “DE
Filing Office”), a copy of which is attached hereto (the “Financing Statement”);

 

(g)
Such other documents as we have deemed necessary or appropriate as a basis for the opinions set forth below.

 

Except
as otherwise stated herein, as to factual matters we have, with your consent, relied upon the foregoing, and upon oral and written
statements and representations of officers and other representatives of the Company, and others, including the factual representations
and warranties of the Company in the Transaction Agreements. We have not independently verified such factual matters.

 

     

     

    

 

We
are opining as to the effect on the subject transaction only of the federal laws of the United States, the internal laws of the
State of New York, the Delaware General Corporation Law and in paragraph 12 of this letter, the DE-UCC (as defined below), and
we express no opinion with respect to the applicability to the opinions expressed herein, or the effect thereon, of the laws of
any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any local
agencies within any state. “UCC Collateral” shall mean that portion of the Collateral that can be perfected
by filing the Financing Statement in the DE Filing Office and in which the Company has rights and in which a valid security interest
may be created under Article 9 of the Uniform Commercial Code as now in effect in the State of New York (the “NY UCC”).
With your permission, we have based our opinions set forth in paragraph 2 exclusively upon our review of Article 9 of the Uniform
Commercial Code of the State of Delaware as set forth in the CCH Secured Transactions
Guide without regard to judicial interpretations thereof or any regulations promulgated thereunder or any other laws
of the State of Delaware (the “DE UCC” and, together with the NY UCC, the “Applicable UCC”).
Except as otherwise stated herein, our opinions herein are based upon our consideration of only those statutes, rules and regulations
which, in our experience, are normally applicable to borrowers in secured loan transactions. We express no opinion as to any state
or federal laws or regulations applicable to the subject transactions because of the legal or regulatory status of any parties
to the Transaction Agreements or the legal or regulatory status of any of their affiliates.

 

In
addition, we have examined originals or copies authenticated to our satisfaction of such corporate records, certificates of officers
of the Company and public officials, and other documents as we have deemed relevant or necessary in connection with our opinions
set forth herein. We have relied, without independent verification, on certificates of public officials and, as to questions of
fact material to such opinions, upon the representations of the Company set forth in the Transaction Agreements, certificates
of officers and other representatives of the Company and factual information we have obtained from such other sources as we have
deemed reasonable. We have assumed without investigation that there has been no relevant change or development between the dates
as of which the information cited in the preceding sentence was given and the date of this letter. We have not independently verified
the accuracy of the matters set forth in the written statements or certificates upon which we have relied, nor have we undertaken
any lien, suit or judgment searches or searches of court dockets in any jurisdiction. For purposes of the opinions in paragraphs
1 and 2, we have relied exclusively upon certificates issued by a governmental authority in the relevant jurisdiction, and such
opinions are not intended to provide any conclusion or assurance beyond that conveyed by these certificates.

 

We
have assumed (i) the genuineness and authenticity of all documents examined by us and all signatures thereon, and the conformity
to originals of all copies of all documents examined by us; (ii) that the execution, delivery and/or acceptance of the Transaction
Agreements have been duly authorized by all action, corporate or otherwise, necessary by the parties to the Transaction Agreements
other than the Company (the “Other Parties”); (iii) the legal capacity of all natural persons executing the
Transaction Agreements; (iv) that each of the Other Parties has satisfied those legal requirements that are applicable to it to
the extent necessary to make the Transaction Agreements enforceable against it; (v) the Transaction Agreements constitute valid
and binding obligations of the Other Parties and are enforceable against the Other Parties in accordance with their terms; (vi)
that each of the Other Parties has complied with all legal requirements pertaining to its status as such status relates to its
rights to enforce the Transaction Agreements; (vii) that the Transaction Agreements accurately describe and contain the mutual
understandings of the parties, and that there are no oral or written statements or agreements or usages of trade or courses of
prior dealings among the parties that would modify, amend or vary any of the terms of the Transaction Agreements; (viii) that
the Other Parties will act in accordance with, and will refrain from taking any action that is forbidden by, the terms and conditions
of the Transaction Agreements; (ix) the constitutionality or validity of a relevant statute, rule, regulation or agency action
is not in issue; (x) that the Company holds requisite title and rights to property involved in the transactions contemplated by
the Transaction Agreements; (xi) all agreements, other than the Transaction Agreements, with respect to which we have provided
advice in our letter or reviewed in connection with our letter would be enforced as written; (xii) that there has not been any
mutual mistake of fact or misunderstanding, fraud, duress or undue influence; and (xiii) that each of the Parties and any agent
acting for it in connection with the Transaction Agreements have acted without notice of any defense against the enforcement of
any rights created by, or adverse claim to any property transferred pursuant to, the Transaction Agreements.

 

     

     

    

 

As
used in this letter with respect to any matter, the qualifying phrase “to our knowledge” or “our actual knowledge”
or such similar phrase limits the statements it qualifies to the conscious awareness of facts or other information by: (i) the
lawyer signing this opinion; or (ii) any lawyer who has had active involvement in negotiating or preparing the Transaction Agreements
or preparing this opinion. In this regard, it is noted that we have not made any special review or investigation in connection
with any statement so qualified.

 

Based
on the foregoing, and in reliance thereon, and subject to the qualifications, limitations and exceptions stated herein, we are
of the opinion, having due regard for such legal considerations as we deem relevant, that:

 

1.
The Company is a corporation validly existing and in good standing under the laws of the State of Delaware.

 

2.
The Company is qualified to transact business as a foreign corporation under the laws of the State of Virginia.

 

3.
The Company has the corporate power and authority to (i) own or lease its properties and to conduct its business as presently
conducted, and (ii) execute, deliver and perform the Transaction Agreements. All corporate action necessary for the authorization,
execution and delivery of the Transaction Agreements by the Company and the performance by the Company of the obligations to be
performed by the Company as of the date hereof under the Transaction Agreements, including the issuance of the Notes, the Warrants
and the Warrant Shares has been taken on the part of the Company’s directors and stockholders.

 

4.
The Company has duly executed and delivered each of the Transaction Agreements.

 

5.
Each of the Transaction Agreements is a valid and binding obligation of the Company, enforceable against the Company in accordance
with its respective terms.

 

6.
The execution and delivery by the Company of each of the Transaction Agreements and the performance by the Company of its obligations
thereunder and the consummation of the transaction contemplated thereby, did not, and do not (i) violate any provision of the
organizational documents of the Company, (ii) violate any law, rule or regulation of any U.S. federal, State of Delaware or State
of New York governmental authority applicable to the Company, (iii) require the Company to obtain any approval, consent or waiver
of, or make any filing with, any governmental agency or body (other than (a) approvals, consents or waivers already obtained or
filings already made, (b) filing of the Financing Statement in the DE Filing Office, and (c) approvals, consents, waivers, authorizations
or orders under state securities or blue sky laws as to which we express no opinion), (iv) require the consent or authorization
of, or approval by, or notice to, any party to any material instrument, contract or agreement of which we have knowledge to which
the Company is a party, including all agreements and instruments set forth on Schedule A (all such material instruments,
contracts and agreements, the “Reviewed Documents”), except for such consents, authorizations, approvals
or notices that (assuming the power and authority of the consenting entity and the authority and capacity of the person signing
on its behalf) have been obtained or made, (v) result in a violation of, or constitute a default (or an event which, with the
giving of notice or lapse of time or both, constitutes or would constitute a default) under, or give rise to any right of termination,
cancellation or acceleration under any of the Reviewed Documents, (vi) violate any judgment, order or decree of which we have
knowledge to which the Company is a party or by which any of its assets or properties is bound, or (vii) create any lien or security
interest under any of the Reviewed Documents on any of the properties of the Company that will have a material adverse effect
on the financial condition of the Company.

 

     

     

    

 

7.
When so issued in accordance with the terms of the Purchase Agreement, the Notes and the Warrants will be duly authorized and
validly issued. When so issued, the Notes, Warrants and Warrant Shares will be free of any and all liens and charges and preemptive
rights contained in the Company’s certificate of incorporation or bylaws or any of the Reviewed Documents. The Warrant Shares
to be issued to the Buyers upon the exercise of the Warrants will be duly authorized and validly issued and fully paid and non-assessable
upon exercise of the Warrants and payment of the exercise price therefor, as applicable, to the Company. There are no securities
or instruments of the Company containing anti-dilution or similar provisions that will be triggered by the issuance of the Warrants
or the Warrant Shares. There are, to our knowledge, no options or warrants to purchase, or preemptive or similar rights with respect
to, any of the capital stock of the Company, or any written agreements providing for the purchase, issuance or sale of any shares
of the capital stock of the Company, except for the Purchase Agreement and the Securities Purchase Agreement for the issuance
of common stock dated March 24, 2021. The Warrant Shares have been duly and validly authorized and reserved for issuance by all
proper corporate action.

 

8.
Assuming the accuracy of the representations and warranties of the Buyers set forth in the Purchase Agreement, the offer, issuance,
sale and delivery of the Notes and Warrants pursuant to, and in the manner contemplated by, the Purchase Agreement and the issuance
and delivery of the Warrant Shares in accordance with the terms of the Purchase Agreement and the Warrant, do not require registration
under the Securities Act of 1933, as amended (the “Securities Act”).

 

9.
Reserved.

 

10.
The Company is not, and after giving effect to the offering and sale of the Notes and the Warrants, and the application of the
proceeds thereof as described in the Purchase Agreement will not be, required to register as an Investment Company under the Investment
Company Act of 1940, as amended.

 

11.
The sale of the Notes, the application of the proceeds thereof as described in the Purchase Agreement and other transactions contemplated
thereby or by the other Transaction Agreements, do not violate or be inconsistent with the provisions of Regulation T, U or X
of the Board of Governors of the Federal Reserve System of the United States.

 

12.
The Financing Statement is in appropriate form for filing in the DE Filing Office. Upon the proper filing of the Financing Statement
in the DE Filing Office, the security interest in favor of the Collateral Agent in the Company’s rights in the UCC Collateral
described in the Financing Statement will be perfected.

 

13.
The Pledge and Security Agreement creates in favor of the Buyers a valid security interest under the NY UCC in the UCC Collateral.

 

14.
The security interest in that portion of the UCC Collateral consisting of shares of stock represented by the certificates described
on Schedule VIII to the Pledge and Security Agreement (the “Pledged Securities”) will be perfected
upon the later of the attachment of the security interest and the delivery of such certificates to the Collateral Agent in, and
while located in, the State of New York pursuant to the Pledge and Security Agreement, together with undated stock powers duly
endorsed in blank with respect thereto by an effective endorsement. Assuming that the Collateral Agent acquires its interest in
the Pledged Securities without notice of any adverse claim within the meaning of the NY UCC and that each of the Pledged Securities
is either in bearer or registered form, issued or duly endorsed in the name of the Collateral Agent or in blank (and accompanied
by an appropriate document of assignment duly executed in favor of the Collateral Agent or in blank), the Collateral Agent will
acquire its security interest in the Pledged Securities free of any adverse claim within the meaning of the NY UCC.

 

     

     

    

 

15.
The security interest in each Deposit Account will be perfected upon the execution and delivery of a Control Agreement with respect
thereto by the Company, the Collateral Agent and the depository institution that maintains such Deposit Account, assuming that
(a) the Control Agreement has been duly authorized, executed and delivered by each of the parties thereto (other than the Company)
and is the legally valid and binding obligation of such parties, (b) such depositary institution’s jurisdiction (determined
in accordance with Section 9-304(b) of the NY UCC) is the State of New York and (c) such Deposit Account constitutes a “deposit
account” (as defined in Section 9-102(a)(29) of the NY UCC.

 

Except
as expressly set forth in paragraphs 12, 13, 14 and 15, we express no opinion with respect to the creation, validity, attachment,
perfection or priority of any security interest or lien or the effectiveness of any sale or other conveyance or transfer of real
or personal property.

 

Our
opinions as herein expressed are subject to the following qualifications and limitations:

 

1.
Our opinions are subject to the effect of federal and state bankruptcy, insolvency, reorganization, arrangement, moratorium, fraudulent
conveyance and other laws relating to or affecting the rights of secured or unsecured creditors generally (or affecting the rights
of only creditors of specific types of debtors), with respect to which we express no opinion.

 

2.
Our opinions are subject to limitations imposed by general principles of equity or public policy upon the enforceability of any
of the remedies, covenants or other provisions of the Transaction Agreements, including, without limitation, concepts of materiality,
good faith and fair dealing and upon the availability of injunctive relief or other equitable remedies, and the application of
principles of equity (regardless of whether enforcement is considered in proceedings at law or in equity).

 

3.
Our opinions are subject to the invalidity under certain circumstances under law or court decisions of provisions for the indemnification
or exculpation of or contribution to a party with respect to a liability where such indemnification, exculpation or contribution
is contrary to public policy; and

 

4.
We express no opinion with respect to (i) consents to, or restrictions upon, governing law, jurisdiction, venue or arbitration;
(ii) advance consent to the availability of, or restrictions upon, remedies or judicial relief; (iii) advance waivers of claims,
defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitation, trial by
jury or at law, or other procedural rights; (iv) waivers of broadly or vaguely stated rights; (v) waivers of the obligations of
good faith, fair dealing, diligence and reasonableness and waivers of unknown future defenses; (vi) provisions for exclusivity,
election or cumulation of rights or remedies; (vii) provisions authorizing or validating conclusive or discretionary determinations;
(viii) grants of setoff rights; (ix) provisions for the payment of attorneys’ fees where such payment is contrary to law
or public policy; (x) proxies, stock or bond powers and trusts; (xi) provisions for liquidated damages, default interest, late
charges, monetary penalties, prepayment or make-whole premiums or other economic remedies to the extent such provisions are deemed
to constitute a penalty; (xii) provisions permitting, upon acceleration of any indebtedness, collection of that portion of the
stated principal amount thereof which might be determined to constitute unearned interest thereon; (xiii) the severability, if
invalid, of provisions to the foregoing effect; (xiv) provisions that limit the enforceability of provisions releasing, exculpating
or exempting a party from, or requiring indemnification of a party for, liability for its own action or inaction, to the extent
the action or inaction involves gross negligence, recklessness, willful misconduct, unlawful conduct, or violations of federal
or state securities laws or regulations or public policy; (xv) provisions that may permit a party that has materially failed to
render or offer performance required by the contract to cure that failure unless (i) permitting a cure would unreasonably hinder
the aggrieved party from making substitute arrangements for performance, or (ii) it was important in the circumstances to the
aggrieved party that performance occur by the date stated in the contract; and (xvi) provisions that limit enforcement of time
is of-the-essence clauses.

 

     

     

    

 

Our
opinions in paragraphs 12 ,13 and 15 above are limited to Article 9 of the Applicable UCC, and our opinions in paragraph 14 are
limited to Articles 8 and 9 of the Applicable UCC and therefore those opinion paragraphs, among other things, do not address collateral
of a type not subject to, or excluded from the coverage of, Articles 8 and 9, as the case may be, of the Applicable UCC. Additionally,

 

(i)
We express no opinion with respect to the priority of any security interest or lien, and we express no opinion as to the priority
of the security interest as against any lien creditor to the extent that such security interest purports to secure any advances
or other obligations other than those that are made without knowledge of the lien or pursuant to a commitment entered into without
knowledge of the lien.

 

(ii)
We express no opinion with respect to any agricultural lien or any collateral that consists of letter-of-credit rights, commercial
tort claims, goods covered by a certificate of title, claims against any government or governmental agency, consumer goods, crops
growing or to be grown, timber to be cut, goods which are or are to become fixtures, as-extracted collateral or cooperative interests.

 

(iii)
We assume the descriptions of collateral contained in, or attached as schedules to, the Transaction Agreements and the Financing
Statement accurately and sufficiently describe the collateral intended to be covered by the Transaction Agreements or such Financing
Statement. Additionally, we express no opinion as to whether the phrases “all personal property” or “all assets”
or similarly general phrases would be sufficient to create a valid security interest in the collateral or particular item or items
of collateral; however, we note that pursuant to Section 9-504 of the DE UCC the phrases “all assets” or “all
personal property” can be a sufficient description of collateral for purposes of perfection by the filing of a financing
statement.

 

(iv)
We have assumed that the Company has, or with respect to after-acquired property will have, rights in the collateral or the power
to transfer rights in the collateral, and that value (as defined in NY UCC §1-204) has been given. We express no opinion
as to the nature or extent of the Company’s rights in any of the collateral and we note that with respect to any after-acquired
property, the security interest will not attach until the Company acquires such rights or power.

 

(v)
We call to your attention the fact that the perfection of a security interest in “proceeds” (as defined in the NY
UCC) of collateral is governed and restricted by Section 9-315 of the Applicable UCC. In addition, we call to your attention that
with respect to certain types of proceeds, other parties such as holders in due course, protected purchasers of securities, persons
who obtain control over securities entitlements and buyers in the ordinary course of business may acquire a superior interest
or may take their interest free of the security interest of a secured party.

 

     

     

    

 

(vi)
We have assumed the accuracy of the factual information set forth on the Financing Statement (other than the name of the Company).

 

(vii)
Section 552 of the Federal Bankruptcy Code limits the extent to which property acquired by a debtor after the commencement of
a case under the Federal Bankruptcy Code may be subject to a security interest arising from a security agreement entered into
by the debtor before the commencement of such case.

 

(viii)
We express no opinion with respect to any property subject to a statute, regulation or treaty of the United States whose requirements
for a security interest’s obtaining priority over the rights of a lien creditor with respect to the property preempt Section
9-310(a) of the Applicable UCC.

 

(ix)
We express no opinion with respect to any goods which are accessions to, or commingled or processed with, other goods to the extent
that the security interest is limited by Section 9-335 or 9-336 of the Applicable UCC.

 

(x)
We call to your attention that a security interest may not attach or become enforceable or be perfected as to contracts, licenses,
permits, equity interests or other rights or benefits which are not assignable under applicable law, or are not assignable by
their terms, or which are assignable only with the consent of governmental entities or officers, except to the extent provided
in Sections 9-406, 9-407, 9-408 or 9-409 of the DE UCC, as applicable; and we call to your attention that your rights under the
Transaction Agreements as secured parties may be subject to the provisions of the organizational documents of any entity in which
any equity interests (or other rights of equity holders or investors) are pledged and the provisions of the applicable laws under
which any such entity is organized.

 

(xi)
We express no opinion regarding any security interest in any copyrights, patents, trademarks, service marks or other intellectual
property, or any license or sublicense thereof or the proceeds of any of the foregoing except to the extent Article 9 of the NY
UCC may be applicable to the foregoing and, without limiting the generality of the foregoing, we express no opinion as to the
effect of any federal laws relating to copyrights, patents, trademarks, service marks or other intellectual property on the opinions
expressed herein. In addition, we express no opinion as to any security interest in any license or sublicense of copyrights, patents,
trademarks or other intellectual property except to the extent that such license or sublicense affirmatively permits the creation,
perfection and enforcement of a security interest therein. Without limiting the generality of the preceding sentence, we express
no opinion as to any license, sublicense or mortgage, or exercise of lender remedies or disclosure of information with respect
thereto, that is subject to any restriction or prohibition on assignment regardless of whether any such prohibitions or restrictions
may be rendered ineffective under the NY UCC.

 

Except
as expressly set forth herein, we express no opinion as to federal or state securities laws, tax laws, antitrust or trade regulation
laws, insolvency or fraudulent transfer laws, antifraud laws, compliance with fiduciary duty requirements, pension or employee
benefit laws, usury laws, environmental laws, margin regulations, FINRA rules or stock exchange rules (without limiting other
laws excluded by customary practice).

 

The
opinions set forth above are also subject to (i) the unenforceability of contractual provisions waiving or varying the rules listed
in Section 9-602 of the NY UCC, (ii) the unenforceability under certain circumstances of contractual provisions respecting self-help
or summary remedies without notice of or opportunity for hearing or correction, (iii) the effect of provisions of the NY UCC and
other general legal principles that impose a duty to act in good faith and in a commercially reasonable manner, and (iv) the effect
of Sections 9-406, 9-407, 9-408 and 9-409 of the NY UCC on any provision of any Transaction Agreement that purports to prohibit,
restrict, require consent for or otherwise condition the assignment of rights under such Transaction Agreement.

 

     

     

    

 

Insofar
as our opinions require interpretation of the Reviewed Documents, (i) we have assumed that all courts of competent jurisdiction
would enforce such agreements in accordance with their plain meaning, (ii) to the extent that any questions of legality or legal
construction have arisen in connection with our review, we have applied the laws of the State of New York in resolving such questions,
although certain of the Reviewed Documents may be governed by other laws which differ from New York law, (iii) we express no opinion
with respect to a breach or default under any Reviewed Document that would occur only upon the happening of a contingency, and
(iv) we express no opinion with respect to any matters which require the performance of a mathematical calculation or the making
of a financial or accounting determination.

 

This
opinion is rendered on the date hereof, and we have no continuing obligation hereunder to inform you of changes of law or fact
subsequent to the date hereof or facts of which we have become aware after the date hereof.

 

This
opinion is solely for your benefit and may not be furnished to, or relied upon by, any other person or entity without the express
prior written consent of the undersigned. This opinion is limited to the matters set forth herein; no opinion may be inferred
or implied beyond the matters expressly stated in this letter.

 

	 	Very truly yours,
	 	 
	 	DRAFT

 

     

     

    

 

Schedule
A

 

1.
License Agreement with Skinvisible.

 

2.
Notes and Warrants issued in the Offering

 

3.
Polytherapeutics Agreement

 

4.
Agreement with Therapeutics, Inc. dated November 3rd, 2020.

 

5.
Securities Purchase Agreement for the issuance of common stock and warrants to be entered into concurrently with the Agreement
(“Primary SPA”)

 

6.
The Agreement;

 

7.
Warrants issued under the Agreement;

 

8.
Security Agreement in connection with Agreement.

 

9.
Employment Agreement, dated March 9, 2018, with Michael Myers

 

10.
Employment Agreement, dated March 9, 2018, with Denise Carter

 

11.
TopChem Pharmaceuticals Limited provides contract manufacturing services to Quoin, pursuant to a written agreement dated January
13, 2021 (the “TopChem Agreement”).

 

12.
In-Site Communications, Inc. provides investor relations services to Quoin, pursuant to a written agreement dated November 17,
2017.

 

13.
Axella Research, LLC provides regulatory and pre-clinical/clinical consulting services, pursuant to written agreements dated October
29, 2019 and January 11, 2020.

 

14.
Real Regulatory Limited provides regulatory consulting services, pursuant to a written agreement dated December 15, 2020.

 

15.
Amy Paller provides strategic consulting services, pursuant to a written agreement dated April 17, 2020.

 

16.
Dr. Leonard Milstone provides clinical and medical consulting services, pursuant to a written agreement dated February 15, 2018.

 

17.
ADI Dermatology provides strategic consulting services, pursuant to a written agreement dated May 6, 2020.

 

     

     

    

 

EXHIBIT
G

 

Form
of Secretary’s Certificate

 

Quoin
Pharmaceuticals, Inc.

 

SECRETARY’S CERTIFICATE

 

March
[__], 2021

 

The
undersigned hereby certifies that [he][she] is the duly elected, qualified and acting Secretary of Quoin Pharmaceuticals, Inc.,
a Delaware corporation (the “Company”), and that as such [he][she] is authorized to execute and deliver this
certificate in the name and on behalf of the Company and in connection with the Securities Purchase Agreement, dated as of March
23, 2021, by and among the Company and the investors listed on the Schedule of Buyers attached thereto (the “Securities
Purchase Agreement”), and further certifies in [his][her] official capacity, in the name and on behalf of the Company,
the items set forth below. Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Securities
Purchase Agreement.

 

		(i)	Attached
                                         hereto as Exhibit A is a true, correct and complete copy of the unanimous written
                                         consent of the Board of Directors of the Company, dated March [●], 2021. The resolutions
                                         contained in Exhibit A have not in any way been amended, modified, revoked or
                                         rescinded, have been in full force and effect since their adoption to and including the
                                         date hereof and are now in full force and effect.

 

		(ii)	Attached
                                         hereto as Exhibit B is a true, correct and complete copy of the Certificate of
                                         Incorporation of the Company, together with any and all amendments thereto, and no action
                                         has been taken to further amend, modify or repeal such Certificate of Incorporation,
                                         the same being in full force and effect in the attached form as of the date hereof.

 

		(iii)	Attached
                                         hereto as Exhibit C is a true, correct and complete copy of the Bylaws of the
                                         Company, together with any and all amendments thereto, and no action has been taken to
                                         further amend, modify or repeal such Bylaws, the same being in full force and effect
                                         in the attached form as of the date hereof.

 

		(iv)	Attached
                                         hereto as Exhibit D is a true, correct and complete copy of the organizational
                                         documents of any Subsidiaries of the Company, together with any and all amendments thereto,
                                         and, no action has been taken to further amend, modify or repeal such organizational
                                         documents, the same being in full force and effect in the attached form as of the date
                                         hereof.

 

		(v)	Each
                                         person listed below has been duly elected or appointed to the position(s) indicated opposite
                                         his name and is duly authorized to sign the Securities Purchase Agreement and each of
                                         the Transaction Documents on behalf of the Company, and the signature appearing opposite
                                         such person’s name below is such person’s genuine signature.

 

	

        Name
	Position	Signature

	 	 	 
	 	 	_________________________

 

     

     

    

 

IN
WITNESS WHEREOF, the undersigned has hereunto set his hand as of the date first written above.

 

	 	 
	 	[Name]
	 	Secretary

 

I,
[Name], [Title], hereby certify that [Name] is the duly elected and is now qualified and holds the office of acting Secretary
of the Company and that the signature set forth above is his true signature.

 

	 	 
	 	[Name]
	 	[Title]

 

     

     

    

 

EXHIBIT
H

 

Form
of Officer’s Certificate

 

Quoin
Pharmaceuticals, Inc.

 

22.
OFFICER’S CERTIFICATE

 

March
[__], 2021

 

The
undersigned Chief Executive Officer of Quoin Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
is duly authorized to execute and deliver this certificate on behalf of the Company in connection with the transactions contemplated
by the Agreement (as defined below), and, as such, hereby represents, warrants and certifies to the Buyers (as defined below),
pursuant to Section 7(vii) of the Agreement, as follows:

 

		1.	The
                                         representations and warranties of the Company set forth in (i) Section 3 of the Securities
                                         Purchase Agreement, dated as of March 23 (the “Agreement”), by and
                                         among the Company and the investors identified on the Schedule of Buyers attached to
                                         the Agreement (the “Buyers”), are true and correct as of the date
                                         when made and as of the date hereof (except for representations and warranties that speak
                                         as of a specific date, which are true and correct as of such specified date) and (ii)
                                         the Merger Agreement are true and correct as of the date when made and as of the date
                                         hereof (except for representations and warranties that speak as of a specific date, which
                                         are true and correct as of such specified date).

 

		2.	The
                                         Company has no reason to believe that the Closing (as defined in the Merger Agreement)
                                         will not occur.

 

		3.	The
                                         Company has performed, satisfied and complied in all respects with the covenants, agreements
                                         and conditions required by the Transaction Documents to be performed, satisfied and complied
                                         with by the Company as of the date hereof.

 

Capitalized
terms used but not otherwise defined herein shall have the meaning set forth in the Agreement.

 

[Signature
Page Follows]

 

     

     

    

 

IN
WITNESS WHEREOF, the undersigned has executed this certificate as of the date first written above.

 

	 	 
	 	Name: Michael Meyers
	 	Title:  Chief Executive OfficerExhibit
4.13

 

Description
of the Registrant’s Securities Registered Pursuant

to Section 12 of the Securities Exchange Act of 1934

 

Sigma
Labs, Inc. (“Sigma,” “we,” “our,” and “us”) has two classes of securities registered
under Section 12 of the Securities Exchange Act of 1934, as amended: (1) our common stock, par value $0.001 per share (the “common
stock”), and (2) warrants to purchase common stock at an exercise price of $40.00 per share (the “Public Warrants”).

 

The
following description of our common stock, and preferred stock is a summary and does not purport to be complete. It is subject
to and qualified in its entirety by reference to (1) our Amended and Restated Articles of Incorporation filed as an Exhibit to
our Form 10-K, (2) our Certificate of Correction to Amended and Restated Articles of Incorporation filed as an Exhibit to our
Current Report on Form 8-K on June 1, 2011, (3) our Amended and Restated Bylaws filed as an Exhibit to our Form 10-K, (4)
Certificate of Designations of Rights Preferences and Privileges of our Series D Convertible Preferred Stock filed as an Exhibit
to our Current Report on Form 8-K filed January 30, 2020, and (5) Certificate of Designations of Rights Preferences and Privileges
of our Series E Convertible Preferred Stock filed as an Exhibit to our Current Report on Form 8-K on January 30, 2020, each of
which is filed as an exhibit to our Annual Report on Form 10-K of which this Exhibit 4.13 is a part. We encourage you to
read the Articles of Incorporation, the Bylaws, and the Certificates of Designations, as well as the applicable provisions
of the Nevada Revised Statutes (the “NRS”), for additional information.

 

Authorized
Capital Stock

 

We are presently authorized
to issue 12,000,000 shares of common stock, $0.001 par value per share, of which ,970,303 shares were outstanding
as of March 24, 2021. We are presently authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which
1,610,000 shares have been designated “Series A Preferred Stock,” 1,000 shares have been designated “Series
B Convertible Preferred Stock,” 1,500 shares have been designated “Series C Convertible Preferred Stock,” 7,796
shares have been designated as “Series D Convertible Stock” and 500 shares have been designated as “Series E
Convertible Stock.” As of the date of this Form 10-K, we had no shares of Series A Preferred Stock, Series B Convertible
Preferred Stock and Series C Convertible Stock issued and outstanding, 132 shares of Series D Convertible Preferred Stock
issued and outstanding and 333 shares of Series E Convertible Preferred Stock issued and outstanding.

 

Common
Stock

 

We
have one class of common stock. Holders of our common stock are entitled to one vote per share on all matters to be voted upon
by stockholders and do not have cumulative voting rights in the election of directors. Holders of shares of common stock are entitled
to receive on a pro rata basis such dividends, if any, as may be declared from time to time by our board of directors in its discretion
from funds legally available for that use, subject to any preferential dividend rights of outstanding preferred stock. They are
also entitled to share on a pro rata basis in any distribution to our common stockholders upon our liquidation, dissolution or
winding up, subject to the prior rights of any outstanding preferred stock. Common stockholders do not have preemptive rights
to subscribe to any additional stock issuances by us, and they do not have the right to require the redemption of their shares
or the conversion of their shares into any other class of our stock. The rights, preferences and privileges of holders of common
stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock that we may
designate and issue in the future.

 

    	1

     

    

 

Public
Warrants

 

The
Public Warrants are exercisable at an exercise price of $40.00 per share, subject to certain adjustments. The Public Warrants
expire on February 21, 2022. Each Public Warrant will have a cashless exercise right in the event that shares of common stock
underlying such Warrants are not covered by an effective registration statement. As of December 31, 2020, we had 162,150
Public Warrants outstanding.

 

Preferred
Stock

 

Under
our articles of incorporation, our board of directors has the authority, without further action by stockholders, to designate
one or more series of preferred stock and to fix the voting powers, designations, preferences, limitations, restrictions and relative
rights granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and
terms of redemption, liquidation preference and sinking fund terms, any or all of which may be preferential to or greater than
the rights of the common stock.

 

Our
board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility
in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and
other rights of the holders of common stock.

 

In connection with our
underwritten public offering of equity securities on February 21, 2017, we created a series of Preferred Stock called “Series
A Preferred Stock.” None of such shares were issued in such offering. In our April 6, 2018 private placement, we issued
1,000 shares of Series B Preferred Stock (“Series B Preferred”), which were convertible into 100,000 shares of common
stock. All shares of our Series B Preferred have been converted and 50,000 shares of common stock issued upon conversion of such
shares are currently beneficially owned by an affiliate of a selling stockholder. In our June 26, 2018 public offering of equity
securities, we issued 350 shares of Series C Preferred Stock which were initially convertible into 35,000 shares of common stock.
Accordingly, as of the date of this Form 10-K, all shares of such preferred stock have been fully converted. In connection with
the private placements occurring on January 27, 2020, we created two new series of Preferred Stock: Series D Preferred Stock and
Series E Preferred Stock. As of the date of this Form 10-K, 132 shares of Series D Preferred Stock and 333.33 shares of
Series E Preferred Stock are issued and outstanding.

 

Under
the Certificate of Designations for the Series D Preferred Stock, the Series D Preferred Stock has an initial stated value of
$1,000 per share (the “Stated Value”). Dividends accrue at a dividend rate of 9% per annum (subject to increase upon
the occurrence (and during the continuance) of certain triggering events described therein) will accrue and, on a monthly basis,
shall be payable in kind by the increase of the Stated Value of the Series D Preferred Shares by said amount. The holders of the
Series D Preferred Shares have the right at any time to convert all or a portion of the Series D Preferred Shares (including,
without limitation, accrued and unpaid dividends and make-whole dividends through the third anniversary of the closing date) into
shares of the Company’s Common Stock at the conversion price then in effect, which is $2.50 (subject to adjustment
for stock splits, dividends, recapitalizations and similar events and full ratchet price protection). In addition, a holder may
at any time, alternatively, convert all, or any part, of its Series D Preferred Shares at an alternative conversion price, which
equals the lower of the applicable conversion price then in effect, and the greater of (x) $1.80 and (y) 85% of the average volume
weighted average price (“VWAP”) of the Common Stock for a five (5) trading day period prior to such conversion. Upon
the occurrence of certain triggering events, described in the Certificate of Designations, including, but not limited to payment
defaults, breaches of transaction documents, failure to maintain listing on the Nasdaq Capital Market, and other defaults set
forth therein, the Series D Preferred Shares would become subject to redemption, at the option of a holder, at a 125% premium
to the underlying value of the Series D Preferred Shares being redeemed.

 

    	2

     

    

  

Under
the Certificate of Designations for the Series E Preferred Stock, the Series E Preferred Shares have an initial stated value of
$1,500 per share (the “Stated Value”). Dividends at the initial rate of 9% per annum will accrue and, on a monthly
basis, shall be payable in kind by the increase of the Stated Value of the Series E Preferred Stock by said amount. The holders
of the Series E Preferred Shares have the right at any time to convert all or a portion of the Preferred Shares (including, without
limitation, accrued and unpaid dividends and make-whole dividends through the third anniversary of the closing date) into shares
of the Company’s Common Stock at an initial conversion rate determined by dividing the Conversion Amount by the Conversion
Price ($0.13 above the consolidated closing bid price for the trading day prior to the execution of the Securities Purchase Agreement,
dated January 27, 2020, between and the purchasers referenced therein). The Conversion Amount is the sum of the Stated Value of
the Series E Preferred Shares then being converted plus any other unpaid amounts payable with respect to the Series E Preferred
Shares being converted plus the “Make Whole Amount” (the amount of any dividends that, but for the conversion, would
have accrued at the dividend rate for the period through the third anniversary of the initial issuance date). The Conversion Rate
is also subject to adjustment for stock splits, dividends recapitalizations and similar events.

 

Transfer
Agent

 

The
transfer agent and registrar of our common stock is Issuer Direct Corporation. The address of our transfer agent and registrar
is 1981 Murray Holladay Road, Suite 100 Salt Lake City, Utah 84117, and its telephone number is (801) 272-9294.

 

Anti-Takeover
Effects of Certain Provisions of Our Charter Documents

 

Our
articles of incorporation and bylaws contain provisions that could delay or prevent changes in control or changes in our management
without the consent of our board of directors. These provisions include the following:

 

	 	●	a
    classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership
    of a majority of our board of directors; 
	 	 	 
	 	●	no
    cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

 

    	3

     

    

 

	 	●	the
    exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors
    or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board
    of directors; 
	 	 	 
	 	●	the
    ability of our board of directors to authorize the issuance of additional shares of preferred stock and to determine the terms
    of those shares, including preferences and voting rights, without stockholder approval, which could adversely affect the rights
    of our common stockholders or be used to deter a possible acquisition of our company; 
	 	 	 
	 	●	the
    ability of our board of directors to alter our bylaws without obtaining stockholder approval; 
	 	 	 
	 	●	the
    required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt,
    amend or repeal our bylaws or repeal the provisions of our articles of incorporation and bylaws regarding the election and
    removal of directors; 
	 	 	 
	 	●	a
    prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special
    meeting of our stockholders; 
	 	 	 
	 	●	the
    requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief
    executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration
    of a proposal or to take action, including the removal of directors; and 
	 	 	 
	 	●	advance
    notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose
    matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting
    a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of
    us.

 

These
provisions could inhibit or prevent possible transactions that some stockholders may consider attractive.

 

NASDAQ
Capital Market

 

Our
Common Stock and Public Warrants are currently traded on the NASDAQ Capital Market under the symbols “SGLB” and “SGLBW”
respectively.

 

Nevada
Anti-Takeover Law and Charter and Bylaws Provisions

 

NRS
sections 78.378 to 78.3793 provide state regulation over the acquisition of controlling interest in certain Nevada corporations
unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do not apply.
This statute currently does not apply to our company because in order to be applicable, we would need to have a specified number
of Nevada residents as shareholders, and we would have to do business in Nevada directly or through an affiliate.

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]